0001757898-22-000011 | 10-K | XBRL Viewer

Print Document View Excel Document

Cover - USD ($)	12 Months Ended
Cover - USD ($)	Mar. 31, 2022	May 25, 2022	Sep. 30, 2021
Entity Information [Line Items]
Document Annual Report	true
Document Transition Report	false
Entity Central Index Key	0001757898
Document Period End Date	Mar. 31, 2022
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		100,080,052
Entity Address, Address Line One	70 Sir John Rogerson's Quay,
Entity Address, City or Town	Dublin 2,
Entity Address, Country	IE
Entity Address, Postal Zip Code	D02 R296
ICFR Auditor Attestation Flag	true
Current Fiscal Year End Date	--03-31
Local Phone Number	232 2000
City Area Code	1
Country Region	353
Entity Shell Company	false
Entity Public Float			$ 20,355,000,000
Entity Registrant Name	STERIS plc
Document Type	10-K
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity File Number	001-38848
Entity Incorporation, State or Country Code	L2
Entity Tax Identification Number	98-1455064
Ordinary Shares
Entity Information [Line Items]
Title of 12(b) Security	Ordinary Shares, $0.001 par value
Trading Symbol	STE
Security Exchange Name	NYSE
STE Two700 Senior Notes Due2031 Member
Entity Information [Line Items]
Title of 12(b) Security	2.700% Senior Notes due 2031
Trading Symbol	STE/31
Security Exchange Name	NYSE
Two700 Senior Notes Due2051 Member
Entity Information [Line Items]
Title of 12(b) Security	3.750% Senior Notes due 2051
Trading Symbol	STE/51
Security Exchange Name	NYSE

Audit Information	12 Months Ended
Audit Information	Mar. 31, 2022
Audit Information [Abstract]
Auditor Firm ID	42
Auditor Name	Ernst & Young LLP
Auditor Location	Cleveland, Ohio

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Mar. 31, 2022	Jun. 02, 2021	Mar. 31, 2021
Statement of Financial Position [Abstract]
Accounts Receivable, Allowance for Credit Loss, Current	$ 24,371		$ 11,355
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000
Common shares issued	100,067		85,353
Common shares outstanding	100,067		85,353

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Current assets:
Cash and cash equivalents	$ 348,320	$ 220,531
Accounts receivable (net of allowances of $24,371 and $11,355, respectively)	799,041	609,406
Inventories, net	574,999	315,067
Prepaid expenses and other current assets	156,637	66,750
Total current assets	1,878,997	1,211,754
Property, plant, and equipment, net	1,552,576	1,235,400
Operating Lease, Right-of-Use Asset	188,480	150,142
Goodwill	4,404,343	3,026,049
Intangible Assets, Net (Excluding Goodwill)	3,328,537	898,406
Other assets	70,661	52,720
Assets	11,423,594	6,574,471
Current liabilities:
Accounts payable	225,737	156,950
Accrued Income Taxes, Current	26,873	27,561
Accrued payroll and other related liabilities	183,721	150,078
Capital Lease Obligations, Current	36,472	22,774
Accrued expenses and other	306,544	220,557
Short-term Debt	142,875	0
Total current liabilities	922,222	577,920
Long-term indebtedness	2,945,481	1,650,540
Deferred income taxes, net	780,619	236,860
Capital Lease Obligations, Noncurrent	155,056	129,673
Other Liabilities, Noncurrent	75,579	88,010
Total liabilities	4,878,957	2,683,003
Commitments and contingencies (see note 10)
Ordinary shares, with $0.001 par value; 500,000 shares authorized; 100,067 and 85,353 ordinary shares issued and outstanding, respectively	4,742,920	2,002,825
Retained earnings	1,999,244	1,939,408
Accumulated other comprehensive income	(209,808)	(61,243)
Total shareholders' equity	6,532,356	3,880,990
Noncontrolling interest	12,281	10,478
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	6,544,637	3,891,468
Total liabilities and equity	$ 11,423,594	$ 6,574,471

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Revenues:
Total revenues	$ 4,585,064	$ 3,107,519	$ 3,030,895
Cost of revenues:
Cost of Goods and Services Sold	2,568,702	1,764,419	1,710,899
Gross Profit	2,016,362	1,343,100	1,319,996
Operating expenses:
Selling, general, and administrative	1,502,752	731,320	716,731
Research and development	87,944	66,326	65,546
Restructuring Costs	48	(2,914)	673
Total operating expenses	1,590,744	794,732	782,950
Income (loss) from operations	425,618	548,368	537,046
Non-operating expenses, net:
Interest expense	89,593	37,180	40,279
Fair value adjustment related to convertible debt liability	27,806	0	0
Interest income and miscellaneous expense	(6,284)	(6,345)	(1,987)
Total non-operating expenses, net	111,115	30,835	38,292
Income (loss) before income tax expense (benefit)	314,503	517,533	498,754
Income tax expense (benefit)	71,633	120,663	90,895
Net income	242,870	396,870	407,859
Less: Net (loss) income attributable to noncontrolling interests	(1,018)	(530)	200
Net income attributable to shareholders	$ 243,888	$ 397,400	$ 407,659
Net income (loss) per common share
Basic	$ 2.50	$ 4.66	$ 4.81
Diluted	2.48	4.63	4.76
Cash dividends declared per common share outstanding	$ 1.69	$ 1.57	$ 1.45
Product [Member]
Revenues:
Total revenues	$ 2,556,281	$ 1,443,540	$ 1,402,788
Cost of revenues:
Cost of Goods and Services Sold	1,419,925	765,076	750,129
Service [Member]
Revenues:
Total revenues	2,028,783	1,663,979	1,628,107
Cost of revenues:
Cost of Goods and Services Sold	$ 1,148,777	$ 999,343	$ 960,770

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Consolidated Statements of Comprehensive Income [Abstract]
Net income	$ 242,870	$ 396,870	$ 407,859
Less: Net (loss) income attributable to noncontrolling interests	(1,018)	(530)	200
Net income attributable to shareholders	243,888	397,400	407,659
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, after Tax	6,795	1,294	(2,609)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	(155,360)	172,926	(73,076)
Total other comprehensive (loss) income attributable to shareholders	(148,565)	174,220	(75,685)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$ 95,323	$ 571,620	$ 331,974

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 23: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 31: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

+ Details

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Statement of Comprehensive Income [Abstract]
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Tax	$ 507	$ 667	$ 295

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Statement of Cash Flows [Abstract]
Net income	$ 242,870	$ 396,870	$ 407,859
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation, depletion, and amortization	553,104	219,237	197,235
Deferred income taxes	(106,620)	4,240	9,442
Share-based compensation	57,660	25,966	23,811
Loss on the disposal of property, plant, equipment, and intangibles, net	15,117	(1,982)	(174)
Loss (Gain) on Disposition of Business	(874)	2,030	1,770
Fair value adjustment related to convertible debt liability	27,806	0	0
Amortization of inventory fair value adjustments	66,663	0	0
Other items	(21,639)	24,273	426
Changes in operating assets and liabilities:
Accounts receivable, net	(51,969)	12,076	(17,866)
Inventories, net	(102,922)	3,769	(39,140)
Other current assets	7,126	458	3,784
Accounts payable	14,887	(7,213)	(2,779)
Accruals and other, net	(16,398)	9,916	6,191
Net cash provided by operating activities	684,811	689,640	590,559
Investing activities:
Purchases of property, plant, equipment, and intangibles, net	(287,563)	(239,262)	(214,516)
Proceeds from the sale of property, plant, equipment, and intangibles	1,741	569	4,156
Proceeds from Divestiture of Businesses	169,712	518	439
Payments to Acquire Investments	0	(4,400)	0
Investments in businesses, net of cash acquired	(550,449)	(909,192)	(109,814)
Payments for (Proceeds from) Other Investing Activities	0	(2,392)	0
Net cash used in investing activities	(666,559)	(1,154,159)	(319,735)
Financing activities:
Proceeds from Issuance of Senior Long-term Debt	1,350,000	0	0
Proceeds from Issuance of Debt	650,000	550,000	0
Repayments of Secured Debt	(345,000)	0	0
Repayments of Long-term Debt	(721,284)	(35,000)	0
Repayments of Convertible Debt	(371,361)	0	0
Proceeds Under Credit Facility, net	(190,174)	(30,461)	(26,500)
Amortization of Financing Costs	(17,472)	(12,846)	(1,281)
Payments of Merger Related Costs, Financing Activities	(32,679)	(2,395)	(626)
Repurchases of ordinary shares	(55,777)	(14,646)	(51,241)
Cash dividends paid to common shareholders	(163,169)	(133,837)	(123,034)
Payments to Noncontrolling Interests	(997)	(4,179)	(1,245)
Proceeds from Noncontrolling Interests	3,672	2,258	6,050
Proceeds from (Payments for) Other Financing Activities	10,071	26,726	34,731
Net cash (used in) provided by financing activities	115,830	345,620	(163,146)
Effect of exchange rate changes on cash and cash equivalents	(6,293)	19,849	(8,730)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	127,789	(99,050)	98,948
Cash and cash equivalents at beginning of period	220,531	319,581	220,633
Cash and cash equivalents at end of period	$ 348,320	$ 220,531	$ 319,581

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Previously Reported	Ordinary Shares	Ordinary Shares Previously Reported	Retained Earnings [Member]	Retained Earnings [Member] Previously Reported	Accumulated Other Comprehensive Income (Loss)	Accumulated Other Comprehensive Income (Loss) Previously Reported	Noncontrolling Interest	Noncontrolling Interest Previously Reported
Common shares outstanding			84,517
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest		$ 3,197,230		$ 1,998,564		$ 1,350,456		$ (159,778)		$ 7,988
Net income	$ 407,859				$ 407,659
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest	(75,685)						$ (75,685)
Stock Repurchased and Retired During Period, Shares			(396)
Stock Repurchased and Retired During Period, Value	(51,241)		$ (74,821)		23,580
Stock Issued During Period, Shares, Employee Stock Purchase Plans			803
Stock Issued During Period, Value, Employee Stock Purchase Plan	58,421		$ 58,421
Dividends, Common Stock, Cash	(123,034)				(123,034)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	(1,245)								$ (1,245)
Noncontrolling Interest, Increase from Contributions to Noncontrolling Interest Holders	6,050								6,050
Changes In Noncontrolling Interests, Other	(145)								(145)
Less: Net (loss) income attributable to noncontrolling interests	200								200
Common shares outstanding			84,924
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	3,418,210		$ 1,982,164		1,658,661		(235,463)		12,848
Net income	396,870				397,400
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest	174,220						174,220
Stock Repurchased and Retired During Period, Shares			(127)
Stock Repurchased and Retired During Period, Value	(14,646)		$ (31,830)		17,184
Stock Issued During Period, Shares, Employee Stock Purchase Plans			556
Stock Issued During Period, Value, Employee Stock Purchase Plan	52,491		$ 52,491
Dividends, Common Stock, Cash	(133,837)				(133,837)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	(4,179)								(4,179)
Noncontrolling Interest, Increase from Contributions to Noncontrolling Interest Holders	2,258								2,258
Changes In Noncontrolling Interests, Other	81								81
Less: Net (loss) income attributable to noncontrolling interests	$ (530)								(530)
Common shares outstanding	85,353		85,353
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 3,891,468		$ 2,002,825		1,939,408		(61,243)		10,478
Net income	242,870				243,888
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest	(148,565)						(148,565)
Stock Repurchased and Retired During Period, Shares			(353)
Stock Repurchased and Retired During Period, Value	(55,777)		$ (34,894)		(20,883)
Stock Issued During Period, Shares, Employee Stock Purchase Plans			770
Stock Issued During Period, Value, Employee Stock Purchase Plan	67,499		$ 67,499
Dividends, Common Stock, Cash	(163,169)				(163,169)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders	(997)								(997)
Noncontrolling Interest, Increase from Contributions to Noncontrolling Interest Holders	3,672								3,672
Changes In Noncontrolling Interests, Other	146								146
Less: Net (loss) income attributable to noncontrolling interests	(1,018)								(1,018)
Noncontrolling Interest, Increase from Business Combination			14,297
Stock Issued During Period, Value, Acquisitions	2,689,317		$ 2,689,317
Consideration related to equity component of Cantel Convertible Debt	175,555		175,555
Consideration Related to Cantel Equity Compensation Programs	18,173		18,173
Reclassification to Cantel convertible debt, premium liability	$ (175,555)		$ (175,555)
Common shares outstanding	100,067		100,067
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest	$ 6,544,637		$ 4,742,920		$ 1,999,244		$ (209,808)		$ 12,281

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Parenthetical) - $ / shares	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Statement of Stockholders' Equity [Abstract]
Ordinary Shares, Dividends, Per Share, Cash Paid	$ 1.69	$ 1.57	$ 1.45

Nature of Operations and Summary of Significant Accounting Policies

12 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Nature of Operations

1. NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations. STERIS is a leading global provider of products and services that support patient care with an emphasis on infection prevention. WE HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare, life sciences and dental products and services. We offer our Customers a unique mix of innovative consumable products, such as detergents, gastrointestinal (“GI”) endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, dental instruments and tools, instrument and scope repair, laboratory testing services, outsourced reprocessing, and capital equipment products, such as sterilizers and surgical tables, automated endoscope reprocessors, and connectivity solutions such as operating room (“OR”) integration.

We operate and report in four reportable business segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. We describe our business segments in Note 11 to our consolidated financial statements titled, "Business Segment Information."

Our fiscal year ends on March 31. References in this Annual Report to a particular "year," "fiscal," "fiscal year," or "year-end" mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below.

Principles of Consolidation. We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.

Use of Estimates. We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available.

Cash Equivalents and Supplemental Cash Flow Information. Cash equivalents are all highly liquid investments with a maturity of three months or less when purchased. We invest our excess cash in short-term instruments including money market funds and time deposits with major banks and financial institutions. We select investments in accordance with the criteria established in our investment policy. Our investment policy specifies, among other things, maturity, credit quality and concentration restrictions with the objective of preserving capital and maintaining adequate liquidity.

Information supplementing our Consolidated Statements of Cash Flows is as follows:


Years Ended March 31,	2022		2021		2020
Cash paid during the year for:
Interest	$	84,696	$	36,257	$	38,021
Income taxes	138,382		109,646		92,462
Cash received during the year for income tax refunds	4,605		4,631		4,378

Revenue Recognition and Associated Liabilities. We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018. At the time of adoption, certain of our capital equipment contracts were comprised of a single integrated performance obligation, which resulted in the deferral of the corresponding capital equipment revenue and cost of revenues until installation was complete. Since the adoption of the standard, there have been changes made in our selling philosophy, product architecture, and manufacturing processes with respect to this product line, that impact whether the promises to transfer the individual goods or services to the Customer are separately identifiable from other promises in the contract. After review of these changes, we have concluded that these contracts consist of multiple performance obligations that are capable of being distinct and meet the criteria for revenue to be recognized when the Customer obtains control of the asset, which is upon delivery of each performance obligation. Revenues and costs of revenues related to these contracts totaling $14,609 and $7,560, respectively, that had previously been deferred were recognized in our fiscal 2021 first quarter.

Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers.

We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets.

In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately.

Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year.

We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less.

Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At March 31, 2022, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements.

Refer to Note 11, titled "Business Segment Information" for disaggregation of revenue.

Product Revenues

Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation.

Service Revenues

Within our Healthcare and Life Sciences segments, service revenues include revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair.

We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancellable

without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure.

Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service.

Contract Liabilities

Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During fiscal 2022, we recognized revenue of $46,760 that was included in our contract liability balance at the beginning of the period. During fiscal 2021, we recognized revenue of $42,618 that was included in our contract liability balance at the beginning of the period.

Refer to Note 7, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances.

Service Liabilities

Payments received in advance of performance for cancellable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract.

Refer to Note 7, titled "Additional Consolidated Balance Sheet Information" for Service liability balances.

Remaining Performance Obligations

Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase, and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of March 31, 2022, the transaction price allocated to remaining performance obligations was approximately $1,546,000. We expect to recognize approximately 54% of the transaction price within one year and approximately 37% beyond one year. The remainder has yet to be scheduled for delivery.

Accounts Receivable. Accounts receivable are presented at their face amount, less allowances for sales returns and uncollectible accounts. Accounts receivable consist of amounts billed and currently due from Customers and amounts earned but unbilled. We generally obtain and perfect security interest in products sold in the United States when we have a concern with the Customer's risk profile.

We maintain an allowance for uncollectible accounts receivable for estimated losses in the collection of amounts owed by Customers. We estimate the allowance based on analyzing a number of factors, including amounts written off historically, Customer payment practices, and general economic conditions. We also analyze significant Customer accounts on a regular basis and record a specific allowance when we become aware of a specific Customer’s inability to pay. As a result, the related accounts receivable are reduced to an amount that we reasonably believe is collectible.

We maintain an allowance for sales returns based upon known returns and estimated returns for both capital equipment and consumables. We estimate returns of capital equipment and consumables based upon recent historical experience.

Inventories, net. Inventories are stated at the lower of their cost and net realizable value determined by the first-in, first-out (“FIFO”) cost method. Inventory costs include material, labor, and overhead.

We review inventory on an ongoing basis, considering factors such as deterioration, obsolescence, and other items. We record an allowance for estimated losses when the facts and circumstances indicate that particular inventories will not be usable. If future market conditions vary from those projected, and our estimates prove to be inaccurate, we may be required to write-down inventory values and record an adjustment to cost of revenues.

Property, Plant, and Equipment. Our property, plant, and equipment consists of land and land improvements, buildings and leasehold improvements, machinery and equipment, information systems, radioisotope (cobalt-60), and construction in progress. Property, plant, and equipment are presented at cost less accumulated depreciation and depletion. We capitalize additions and improvements. Repairs and maintenance are charged to expense as they are incurred.

Land is not depreciated and construction in progress is not depreciated until placed in service. Depreciation of most assets is computed on the cost less the estimated salvage value by using the straight-line method over the estimated remaining useful lives. Depletion of radioisotope is computed using the annual decay factor of the material, which is similar to the sum-of-the-years-digits method.

We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table:


Asset Type						Useful Life (years)
Land improvements						3-40
Buildings and leasehold improvements						2-50
Machinery and equipment						2-20
Information Systems						2-20
Radioisotope (cobalt-60)						20

When we sell, retire, or dispose of property, plant, and equipment, we remove the asset’s cost and accumulated depreciation from our Consolidated Balance Sheet. We recognize the net gain or loss on the sale or disposition in the Consolidated Statements of Income in the period when the transaction occurs.

Interest. We capitalize interest costs incurred during the construction of long-lived assets. We capitalized interest costs of $3,886 and $1,998 for the years ended March 31, 2022 and 2021, respectively. Total interest expense for the years ended March 31, 2022, 2021, and 2020 was $89,593, $37,180, and $40,279, respectively.

Identifiable Intangible Assets. Our identifiable intangible assets include product technology rights, trademarks, licenses, non-compete agreements, and Customer and vendor relationships. We record these assets at cost, or when acquired as part of a business acquisition, at estimated fair value. Determining the fair value of identifiable intangible requires management’s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to forecasted revenue growth rates, forecasted profit margins, and Customer attrition rates, among other items. We generally amortize identifiable intangible assets over periods ranging from 5 to 20 years using the straight-line method. Our intangible assets also include indefinite lived assets including certain trademarks and tradenames that were acquired in connection with business combinations. These assets are tested at least annually for impairment.

Investments. Investments in marketable securities are stated at fair value and are included in "Other assets" on the Consolidated Balance Sheets. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income.

Asset Impairment Losses. Property, plant, equipment, and identifiable intangible assets are reviewed for impairment when indicators of impairment exist and circumstances indicate that the carrying value of such assets may not be recoverable. Impaired assets are recorded at the lower of carrying value or estimated fair value. We monitor for such indicators on an ongoing basis and if an impairment exists, we record the loss in the Consolidated Statements of Income during that period.

Asset Retirement Obligations. We incur retirement obligations for certain assets. We record initial liabilities for the asset retirement obligations ("ARO") at fair value. Recognition of ARO includes: estimating the present value of a liability and offsetting asset, the subsequent accretion of that liability and depletion of the asset, and a periodic review of the ARO liability estimates and discount rates used in the analysis. We provide additional information about our asset retirement obligations in Note 5 to our consolidated financial statements titled, “Property, Plant and Equipment.”

Acquisitions of Business. Assets acquired and liabilities assumed in a business combination are accounted for at fair value on the date of acquisition. Costs related to the acquisition are expensed as incurred.

Goodwill. We perform our annual impairment test for goodwill in the third quarter of each year. We may consider qualitative indicators of the fair value of a reporting unit when it is unlikely that a reporting unit has impaired goodwill. We may also utilize a discounted cash flow analysis that requires certain assumptions and estimates be made regarding market conditions and our future profitability. We review the book value compared to the fair value at the reporting unit level. We calculate the fair value of our reporting units based on the present value of estimated future cash flows. Management's judgment is necessary to evaluate the impact of operating and macroeconomic changes and to estimate future cash flows to measure fair value. Assumptions used in our impairment evaluations, such as forecasted growth rates and cost of capital, are consistent with internal projections, strategic plans, and operating plans. We believe such assumptions and estimates are also comparable to those that would be used by other market place participants.

Self-Insurance Liabilities. We record a liability for self-insured risks that we retain for general and product liabilities, workers’ compensation, and automobile liabilities based on actuarial calculations. We use our historical loss experience and actuarial methods to calculate the liability. This liability includes estimates for both losses and incurred but not reported claims. We review the assumptions used to calculate the estimated liability at least annually to evaluate the adequacy of the amount recorded. We maintain insurance policies to cover losses greater than our estimated liability, which are subject to the terms and conditions of those policies. We are also self-insured for certain employee medical claims. We estimate a liability for incurred but not reported claims based upon recent claims experience.

Benefit Plans. We sponsor defined benefit pension plans. We also sponsor a post-retirement benefits plan for certain former employees. We determine our costs and obligations related to these plans by evaluating input from third-party professional advisers. These costs and obligations are affected by assumptions including the discount rate, expected long-term rate of return on plan assets, the annual rate of change in compensation for eligible employees, estimated changes in costs of healthcare benefits, and other factors. We review the assumptions used on an annual basis.

We recognize an asset for the overfunded status or a liability for the underfunded status of defined benefit pension and post-retirement benefits plans in our consolidated balance sheets. This amount is measured as the difference between the fair value of plan assets and the benefit obligation (the projected benefit obligation for pension plans and the accumulated post-retirement benefit obligation for other post-retirement benefit plans). Changes in the funded status of the plans are recorded in other comprehensive income in the year they occur. We measure plan assets and obligations as of the balance sheet date. We provide additional information about our pension and other post-retirement benefits plans in Note 9 to our consolidated financial statements titled, “Benefit Plans.”

Fair Value of Financial Instruments. Except for long-term debt, our financial instruments are highly liquid or have short-term maturities. We provide additional information about the fair value of our financial instruments in Note 17 titled, “Fair Value Measurements.”

Foreign Currency Translation. Most of our operations use their local currency as their functional currency. Financial statements of subsidiaries are translated into U.S. dollars using the exchange rate at each balance sheet date for assets and liabilities and a weighted average exchange rate for each period for revenues, expenses, gains and losses. Translation adjustments for subsidiaries whose local currency is their functional currency are recorded as a component of accumulated other comprehensive income (loss) within equity. Transaction gains and losses resulting from fluctuations in currency exchange rates on transactions denominated in currencies other than the functional currency are recognized as incurred in the accompanying Consolidated Statement of Income, except for certain inter-company balances designated as long-term in nature.

Forward and Swap Contracts. We enter into foreign currency forward contracts to hedge assets and liabilities denominated in foreign currencies, including inter-company transactions.We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. We may also hold forward foreign exchange contracts to hedge a portion of our expected non-U.S. dollar denominated earnings against our reporting currency, the U.S. dollar. We do not use derivative financial instruments for speculative purposes. These contracts are marked to market, with gains and losses recognized within “Selling, general, and administrative expenses” or "Cost of revenues" in the accompanying Consolidated Statements of Income.

Warranty. Warranties are provided on the sale of certain of our products and services and an accrual for estimated future claims is recorded at the time revenue is recognized. We estimate warranty expense based primarily on historical warranty claim experience.

Shipping and Handling. We record shipping and handling costs in costs of revenues. Shipping and handling costs charged to Customers are recorded as revenues in the period the product revenues are recognized.

Advertising Expenses. Costs incurred for communicating, advertising and promoting our products are generally expensed when incurred as a component of Selling, General and Administrative Expense. We incurred $15,599, $6,795, and $12,652 of advertising costs during the years ended March 31, 2022, 2021, and 2020, respectively.

Research and Development. We incur research and development costs associated with commercial products and expense these costs as incurred. If a Customer reimburses us for research and development costs, the costs are charged to the related contracts as costs of revenues.

Income Taxes. We defer income taxes for all temporary differences between pre-tax financial and taxable income and between the book and tax basis of assets and liabilities. We record valuation allowances to reduce net deferred tax assets to an amount that we expect will more-likely-than-not be realized. In making such a determination, we consider all available information, including scheduled reversals of deferred tax liabilities, projected future taxable income, tax planning strategies, and if applicable, any carryback claims that can be filed. In the event we were to determine that we would be able to realize our deferred income tax assets in the future in excess of their net recorded amount, we would make an adjustment to the valuation allowance which would reduce the provision for income taxes and the effective tax rate.

We evaluate uncertain tax positions in accordance with a two-step process. The first step is recognition: The determination of whether or not it is more-likely-than-not that a tax position will be sustained upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position. In evaluating whether a tax position has met the more-likely-than-not recognition threshold, we presume that the position will be examined by the appropriate tax authority and that the tax authority will have full knowledge of all relevant information. The second step is measurement: A tax position that meets the more-likely-than-not threshold is measured to determine the amount of benefit to recognize in the financial statements. The measurement process requires the determination of the range of possible settlement amounts and the probability of achieving each of the possible settlements. The tax position is measured at the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. No tax benefits are recognized for positions that do not meet the more-likely-than-not threshold. Tax positions that previously failed to meet the more-likely-than-not threshold are recognized in the first subsequent financial reporting period in which that threshold is met. Previously recognized tax positions that no longer meet the more-likely-than-not recognition threshold are derecognized in the first subsequent financial reporting period in which the threshold is no longer met. We describe income taxes further in Note 8 to our consolidated financial statements titled, “Income Taxes.”

Share-Based Compensation. We describe share-based compensation in Note 14 to our consolidated financial statements titled, “Share-Based Compensation.” We measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. We record liability awards at fair value each reporting period and the change in fair value is reflected as share-based compensation expense in our Consolidated Statements of Income. The expense is classified as cost of goods sold, selling, general and administrative expenses or research and development expenses in a manner consistent with the employee’s compensation and benefits. These costs are recognized in the Consolidated Statement of Income over the period during which an employee is required to provide service in exchange for the award.

Restructuring. We recognize restructuring expenses as incurred. Asset impairment and accelerated depreciation expenses primarily relate to inventory write-downs for rationalized products and adjustments in the carrying value of the related facilities and machinery and equipment to their estimated fair value. In addition, the remaining useful lives of other property, plant, and equipment associated with the related operations are reevaluated based on the respective restructuring plan, which may result in the acceleration of depreciation and amortization of certain assets.

Recently Issued Accounting Standards Impacting the Company

Recently Issued Accounting Standards Impacting the Company are presented in the following table:

Standard

Date of Issuance

Description

Date of Adoption

Effect on the financial statements or other significant matters

Standards that have been adopted in fiscal 2022

ASU 2019-12 "Income Taxes (Topic 740)"

December 2019

The standard provides final guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance simplifies accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill.

First Quarter Fiscal 2022

We adopted this standard effective April 1, 2021 with no material impact to our consolidated financial statements.

ASU 2020-06 "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)"

August 2020

This standard simplifies the accounting for convertible instruments and its application of the derivatives scope exception for contracts in an entity’s own equity. The standard reduces the number of accounting models that require separating embedded conversion features from convertible instruments. As a result, only conversion features accounted for under the substantial premium model and those that require bifurcation will be accounted for separately. For contracts in an entity’s own equity, the new standard eliminates some of the current requirements for equity classification. The standard also addresses how convertible instruments are accounted for in the diluted earnings per share calculation and requires enhanced disclosures about the terms of convertible instruments and contracts in an entity’s own equity.

First Quarter Fiscal 2022

We adopted this standard effective April 1, 2021 and applied it to our accounting for the convertible debt assumed in the acquisition of Cantel Medical LLC ("Cantel").

Standards that have not yet been adopted.

ASU 2021-08 "Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.

October 2021

The standard provides guidance to improve the accounting for acquired revenue contracts with Customers in a business combination by addressing diversity in practice and inconsistency related to the recognition of an acquired contract liability and payment terms and their effect on subsequent revenue recognized by the acquirer. The standard is effective for annual periods beginning after December 15, 2022 including interim periods within that year and early adoption is permitted.

We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Notes)

12 Months Ended

Mar. 31, 2022

Business Combinations and Divestitures [Abstract]

Business Combination Disclosure [Text Block]

Fiscal 2022 Acquisition of Cantel Medical LLC

On June 2, 2021, we acquired all outstanding equity interests in Cantel Medical LLC ("Cantel") through a U.S. subsidiary. Cantel, formerly headquartered in Little Falls, New Jersey, with approximately 3,700 employees, is a global provider of infection prevention products and services primarily to endoscopy and dental Customers.

We believe that the acquisition will strengthen STERIS’s leadership in infection prevention by bringing together two complementary businesses able to offer a broader set of Customers a more diversified selection of infection prevention, endoscopy and sterilization products and services. Cantel’s Dental business extends our business into a new Customer segment where there is an increasing focus on infection prevention protocols and processes. This business is reported as the Dental segment. The rest of Cantel was integrated into our existing Healthcare and Life Sciences segments. Additionally, the acquisition is expected to result in cost savings from optimizing global back-office infrastructure, leveraging best-demonstrated practices across locations and eliminating redundant public company costs.

Total Purchase Consideration

The total consideration for Cantel Common Stock and stock equivalents was $3,599,471. The consideration was comprised of the following:


(shares in thousands)
Cash consideration $16.93 per Cantel share (42,816 shares)	$	716,412
Cash consideration for fractional shares	14
STERIS plc ordinary shares 14,297 shares at ($188.07 per share)	2,689,317
Consideration related to Cantel equity compensation programs	18,173

Consideration related to equity component of Cantel convertible debt	175,555
Total purchase consideration	$	3,599,471

In addition, STERIS assumed and repaid $721,284 of existing Cantel debt obligations and assumed Cantel's obligations associated with convertible senior notes issued on May 15, 2020, which is described in Note 6 titled, "Debt."

We funded the cash portion of the transaction consideration and repayment of a significant amount of Cantel’s existing debt obligations with a portion of the proceeds from new debt, which is described in Note 6 titled, "Debt".

Fair Value of Assets Acquired and Liabilities Assumed

The acquisition of Cantel has been accounted for using the acquisition method of accounting which requires, among other things, the assets acquired and liabilities assumed be recognized at their respective fair values as of the acquisition date. Acquisition accounting is dependent upon certain valuations and other studies. The process for estimating the fair values of identifiable intangible assets and certain tangible assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates.

The purchase price has been allocated based on the latest draft valuations and remains preliminary. As we finalize the fair value of assets acquired and liabilities assumed, additional purchase price adjustments and associated deferred taxes will be recorded during the remaining measurement period. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact our results of operations. The finalization of the purchase accounting assessment in the first quarter of fiscal 2023 may result in additional changes in the valuation of assets acquired and liabilities assumed and that may impact our results of operations and financial position. Goodwill has been allocated to the Healthcare, Dental and Life Sciences segments. Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. Goodwill recognized as a result of the acquisition is not deductible for tax purposes.

The table below presents the preliminary estimated fair values of assets acquired and liabilities assumed on the acquisition date. These preliminary estimates will be revised during the measurement period as third-party valuations are finalized, additional information becomes available and as additional analyses are performed, and these differences could have a material impact on our results of operations and financial position.


	Cantel (1)
Cash	$	169,073
Accounts receivable	172,226
Inventory	249,221
Property, plant and equipment	267,360
Lease right-of-use assets	59,720
Other assets	72,864
Intangible assets	2,942,000
Goodwill	1,522,381
Total assets acquired	5,454,845
Convertible debt, par value	168,000
Other current liabilities	247,549
Long-term lease obligations	47,856
Deferred income taxes, net	670,685
Long-term indebtedness	721,284
Total liabilities assumed	1,855,374
Net assets acquired	$	3,599,471

(1) Purchase price allocation is preliminary as of March 31, 2022, as valuations have not been finalized.

Cantel Other Intangible Assets

The estimated fair values of identifiable intangible assets were prepared using income valuation methodologies, which require a forecast of expected future cash flows using either the relief-from-royalty method or the multi-period excess earnings method. The estimated useful lives are based on the historical experience of STERIS, available similar industry data and assumptions made by management.Values and useful lives are presented in the table below.

Total

Useful Life

Customer relationships

2,278,000

9-10 years

Trade names

422,000

11 years

Developed technology

222,000

9 years

Non-compete agreements

20,000

2 years

Total intangible assets acquired

2,942,000

Contingent liabilities assumed totaled $25,000 and were related to contingent consideration associated with a prior acquisition completed by Cantel. Payment was made in June 2021.

Actual and Pro Forma Impact

Our consolidated financial statements include Cantel's results of operations from the date of acquisition on June 2, 2021 through March 31, 2022. Net sales and operating income attributable to Cantel from the date of acquisition and included in our consolidated financial statements for the fiscal year ended March 31, 2022 total $974,408 and $41,757, respectively.

The following unaudited pro forma information gives effect to our acquisition of Cantel as if the acquisition had occurred on April 1, 2020 and Cantel had been included in our consolidated results of operations for the fiscal years ended March 31, 2022 and 2021.


	Fiscal Year Ended March 31,
	(unaudited)
	2022		2021
Net revenues	$	4,790,161	$	4,190,244
Net income from continuing operations	449,382		5,849

The historical consolidated financial information of STERIS and Cantel has been adjusted in the pro forma information to give effect to pro forma events that are directly attributable to the transaction and factually supportable. The unaudited pro forma results include adjustments to reflect the amortization of the inventory step-up and the incremental depreciation and amortization to be reported based on the latest draft of valuations of assets acquired. Adjustments to financing costs and income tax expense also were made to reflect the capital structure and anticipated effective tax rate of the combined entity. These pro forma amounts are not necessarily indicative of the results that would have been obtained if the acquisition had occurred as of the beginning of the period presented or that may occur in the future, and does not reflect future synergies, integration costs, or other such costs or savings.

Other Fiscal 2022 Acquisitions

In addition to the acquisition of Cantel, we completed three other tuck-in acquisitions during fiscal 2022, which continued to expand our product and service offerings in the Healthcare segment. Total aggregate consideration for these transactions was approximately $3,146, net of cash acquired and including deferred consideration of $50.

Fiscal 2021 Acquisitions

On January 4, 2021, we purchased the remaining outstanding shares of an entity in which we had initially made an equity investment in fiscal 2019. Total consideration was approximately $78,045, net of cash acquired and subject to any working capital adjustments. Total non-cash consideration for this transaction was $41,771, which consisted of the settlement of outstanding principal and interest on a loan receivable, the initial equity investment, and receivables related to capital equipment purchases that existed at the acquisition date. The business has been integrated into our Applied Sterilization Technologies business segment and we funded the transaction through a combination of cash on hand and credit facility borrowings.

On November 18, 2020, we acquired all of the outstanding units and equity of Key Surgical, LLC ("Key Surgical"). Key Surgical is a global provider of sterile processing, operating room and endoscopy consumable products serving hospitals and surgical facilities. Key Surgical has been integrated into our Healthcare segment. The total purchase price of the acquisition was $853,203, net of cash acquired and remains subject to customary working capital adjustments. The purchase price for the acquisition was financed with a combination of cash on hand, credit facility borrowings and proceeds from borrowings under a then new Term loan agreement. Please refer to Note 6 titled, "Debt" for more information.

We also completed two other tuck-in acquisitions during fiscal 2021, which continued to expand our product and service offerings in the Healthcare segment. Total aggregate consideration for these transactions was approximately $20,909, net of cash acquired and including deferred consideration of approximately $1,194.

Fiscal 2020 Acquisitions

During fiscal 2020, we completed several tuck-in acquisitions which continued to expand our product and service offerings in the Healthcare, Applied Sterilization Technologies and Life Sciences segments. The aggregate purchase price associated with these transactions was approximately $128,860, net of cash acquired and including contingent and deferred consideration.

Fair Value of Assets Acquired and Liabilities Assumed

The table below summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition dates for our fiscal 2022, 2021 and 2020 acquisitions.


	Fiscal Year 2022(1)		Fiscal Year 2021				Fiscal Year 2020
(dollars in thousands)	Other Acquisitions (Excluding Cantel)		Key Surgical		Other Acquisitions		All Acquisitions
Cash	$	—	$	12,615	$	9,159	$	8,811
Accounts receivable	—		13,967		9,621		10,331
Inventory	—		21,414		22,123		8,999
Property, plant and equipment	—		6,030		26,363		9,241
Lease right-of-use assets, net	—		4,907		4,420		4,462
Other assets	—		6,680		3,378		1,133
Intangible assets (2)	1,578		356,999		28,188		36,500
Goodwill	1,602		527,675		42,808		74,531
Total assets	3,180		950,287		146,060		154,008
Current liabilities	(34)		(21,599)		(28,245)		(20,659)
Non-current liabilities	—		(62,870)		(9,704)		(4,000)
Total liabilities	(34)		(84,469)		(37,949)		(24,659)
Net assets	$	3,146	$	865,818	$	108,111	$	129,349

(1) Purchase price allocation is still preliminary as of March 31, 2022, as valuations have not been finalized, pending further analyses of the significant drivers of fair value.

(2) Includes $315,575, related to the fair value of the Customer relationships intangible asset, obtained in the acquisition of Key Surgical. The estimation of fair value was determined under an income approach using discounted cash flows. The estimate requires assumptions including forecasted revenue growth rates, forecasted profit margins, and Customer attrition rates.

Goodwill is the excess of the consideration transferred over the net assets recognized and represents the expected revenue and cost synergies of the combined company and assembled workforce. The deductible portion of goodwill for tax purposes recognized as a result of the fiscal 2022 and fiscal 2021 acquisitions was $427,035 and $197,344, respectively.

Acquisition related transaction and integration costs totaled $205,788, $35,634, and $8,225 for the fiscal years ended March 31, 2022, 2021, and 2020, respectively. Fiscal 2022 acquisition and integration expenses were primarily related to the acquisition of Cantel. Fiscal 2021 acquisition and integration expenses were primarily related to the acquisitions of Key Surgical LLC and Cantel. These costs are included in Selling, general, and administrative expenses in the Consolidated Statements of Income.

Divestitures

Fiscal 2022

Divestitures. In December 2021, we entered into an Asset Purchase Agreement to sell our Renal Care business to Evoqua Water Technologies Corp., for cash consideration of approximately $196,000, subject to certain potential adjustments, including a customary working capital adjustment and contingent consideration of $12,300. We recognized a gain on the sale of $950. The transaction closed on January 3, 2022. We acquired the Renal Care business as part of the Cantel transaction, which closed on June 2, 2021, and had been integrated into STERIS's Healthcare segment. The Renal Care business generated annual revenues of approximately $180,000. The proceeds from the sale received at closing were used to repay outstanding debt.

Fiscal 2021

During fiscal 2021, we sold an Applied Sterilization Technologies laboratory that was located in the Netherlands. We recorded proceeds of $518, net of cash divested, and recognized a pre-tax loss on the sale of $2,024 in the selling, general and administrative expense line of the Consolidated Statements of Income. The business generated annual revenues of approximately $6,000.

Fiscal 2020

During fiscal 2020, we sold the operations of our Healthcare services business that were located in China. We recorded proceeds of $439, net of cash divested, and recognized a pre-tax loss on the sale of $2,365 in the selling, general and administrative expense line of the Consolidated Statements of Income. The business generated annual revenues of approximately $5,000.

Loans Receivable

In connection with an equity investment of $4,955, we agreed to provide a credit facility of up to approximately $11,606 for a term of up to seven years ending in 2025. The loan carried an interest rate of 4% compounded daily and interest was payable annually. Outstanding borrowings under the agreement totaled $7,084 at March 31, 2020. During fiscal 2021, we purchased the remaining shares of the equity investment. In addition to the purchase price, the acquisition agreement included the capitalization of the outstanding principal and accumulated interest under this credit facility in the amount of $11,708.

In connection with the fiscal 2017 divestiture of Synergy Health Netherlands Linen Management Services, we entered into a loan agreement to provide financing of up to €15,000 for a term of up to 15 years. The loan carried an interest rate of 4% for the first four years and 12% thereafter. The loan was renegotiated during the third quarter of fiscal 2020. According to the new terms of the loan agreement, the outstanding balance at October 31, 2019, of €7,300, will be repaid in six equal annual installments beginning on October 18, 2022. The loan carries an interest rate of 4% for the first four years and 8% thereafter. Outstanding principal borrowings under the agreement totaled $8,129 (or €7,300) at March 31, 2022, and $8,568 (or €7,300) at March 31, 2021.

Amounts for loan receivables as noted above are recorded in the "Other assets" line of our Consolidated balance sheets. Interest income is not material.

Goodwill and Intangible Assets

12 Months Ended

Mar. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill

3. GOODWILL AND INTANGIBLE ASSETS

Changes to the carrying amount of goodwill for the years ended March 31, 2022 and 2021 were as follows:


	Healthcare Segment		Applied Sterilization Technologies Segment		Life Sciences Segment		Dental		Total
Balance at March 31, 2020	827,266		1,380,262		148,557		—		2,356,085
Goodwill acquired or allocated	536,713		33,770		—		—		570,483

Foreign currency translation adjustments and other	20,784		78,207		490		—		99,481
Balance at March 31, 2021	$	1,384,763	$	1,492,239	$	149,047	$	—	$	3,026,049
Cantel goodwill acquired (1)	1,019,332		—		30,356		472,693		1,522,381
Measurement period adjustments to acquired goodwill	(6,533)		(9,286)		—		—		(15,819)

Divestitures	(7,000)		—		—		—		(7,000)
Foreign currency translation adjustments and other	(63,732)		(50,095)		(115)		(7,326)		(121,268)
Balance at March 31, 2022	$	2,326,830	$	1,432,858	$	179,288	$	465,367	$	4,404,343

(1) Amounts are still preliminary, as Cantel acquisition valuations have not been finalized.

See Note 2, titled "Business Acquisitions and Divestitures", for additional information regarding our recent business acquisitions and divestitures.

We evaluate the recoverability of recorded goodwill amounts annually during the third fiscal quarter, or when evidence of potential impairment exists. As a result of our annual impairment review of goodwill for fiscal years 2022, 2021 and 2020, no indicators of impairment were identified.

Information regarding our intangible assets is as follows:


	2022				2021
March 31,	Gross Carrying Amount (1)		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Customer relationships	$	3,117,314	$	539,845	$	968,040	$	291,802
Non-compete agreements	23,571		12,392		5,401		4,169
Patents and technology	518,714		211,822		318,424		171,952
Trademarks and tradenames	470,919		74,455		78,058		42,867
Supplier relationships	54,800		18,267		54,800		15,527

Total	$	4,185,318	$	856,781	$	1,424,723	$	526,317

(1) The increase in fiscal 2022 was primarily due to the Cantel acquisition. See Note 2, titled "Business Acquisitions and Divestitures", for additional information.

Certain trademarks and tradenames obtained as a result of business combinations are indefinite-lived assets. The approximate carrying value of these assets at March 31, 2022 and March 31, 2021 was $14,250. We evaluate our indefinite-lived intangible assets annually during the third quarter, or when evidence of potential impairment exists. No impairment was recognized for fiscal years 2022, 2021 or 2020.

Total amortization expense for intangible assets was $368,698, $86,512, and $74,528 for the years ended March 31, 2022, 2021, and 2020, respectively. Based upon the current amount of intangible assets subject to amortization, the amortization expense for each of the five succeeding fiscal years is estimated to be as follows:


	2023		2024		2025		2026		2027
Estimated amortization expense	$	384,258	$	370,549	$	364,488	$	355,475	$	349,116

The estimated annual amortization expense presented in the preceding table has been calculated based upon March 31, 2022 currency exchange rates.

Inventories, Net

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Inventories, Net

4. INVENTORIES, NET

Components of our inventories are presented in the following table.


March 31,	2022		2021

Raw materials	$	195,035	$	103,939
Work in process	76,021		54,283
Finished goods	334,880		176,623

Reserve for excess and obsolete inventory	(30,937)		(19,778)
Inventories, net	$	574,999	$	315,067

Property, Plant and Equipment

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Property, Plant and Equipment

Information related to the major categories of our depreciable assets is as follows:


March 31,	2022		2021
Land and land improvements (1)	$	84,015	$	69,477
Buildings and leasehold improvements	654,851		567,132
Machinery and equipment	903,649		779,044
Information systems	222,620		193,222
Radioisotope	597,641		565,681
Construction in progress (1)	356,013		211,381
Total property, plant, and equipment	2,818,789		2,385,937
Less: accumulated depreciation and depletion	(1,266,213)		(1,150,537)
Property, plant, and equipment, net	$	1,552,576	$	1,235,400

(1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Depreciation and depletion expense were $184,406, $132,725 and $122,707, for the years ended March 31, 2022, 2021, and 2020, respectively.

Asset Retirement Obligations

We provide contract sterilization services including Gamma irradiation which utilizes cobalt-60 in the form of cobalt pencils. We have incurred asset retirement obligations (ARO) associated with the future disposal of these assets once depleted. Recognition of ARO includes: the present value of a liability and offsetting asset, the subsequent accretion of that liability and depletion of the asset, and the periodic review of the ARO liability estimates and discount rates used in the analysis.

The following table summarizes the activity in the liability for asset retirement obligations.


	Asset Retirement Obligations
Balance at March 31, 2020	$	12,514
Liabilities incurred during the period	859
Liabilities settled during the period	(251)
Accretion expense and change in estimate	137
Foreign currency and other	71
Balance at March 31, 2021	$	13,330
Liabilities incurred during the period	86
Liabilities settled during the period	(3)
Accretion expense and change in estimate	146
Foreign currency and other	(16)
Balance at March 31, 2022	$	13,543

Debt

12 Months Ended

Mar. 31, 2022

Debt Disclosure [Abstract]

Debt

6. DEBT

Indebtedness as of March 31, 2022 and 2021 was as follows:


	March 31, 2022		March 31, 2021



Short-term debt
Term loan, current portion	$	27,500	$	—
Delayed draw term loan, current portion	24,375		—
Private Placement Senior Notes	91,000		—
Total short-term debt	$	142,875	$	—


Long-term debt
Private Placement Senior Notes	$	758,726	$	860,308
Revolving Credit Facility	58,908		247,423
Deferred financing costs	(25,278)		(7,191)
Term loan	177,500		550,000
Delayed draw term loan	625,625		—
Senior Public Notes	1,350,000		—
Total long-term debt	$	2,945,481	$	1,650,540
Total debt	$	3,088,356	$	1,650,540

On March 19, 2021, STERIS plc ("the Company"), STERIS Corporation, STERIS Limited (“Limited”), and STERIS Irish FinCo Unlimited Company ("FinCo", "STERIS Irish FinCo"), each as a borrower and guarantor, entered into a credit agreement with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as administrative agent (the “Revolving Credit Agreement”) providing for a $1,250,000 revolving credit facility (the “Revolver”), which replaced a prior revolving credit agreement.

The Revolver provides for revolving credit borrowings, swing line borrowings and letters of credit, with sublimits for swing line borrowings and letters of credit. The Revolver may be increased in specified circumstances by up to $625,000 in the discretion of the lenders. The Revolver matures on the date that is five years after March 19, 2021, and all unpaid borrowings, together with accrued and unpaid interest thereon, are repayable on that date. The Revolver bears interest from time to time, at either the Base Rate , Eurocurrency Rate, or the Adjusted Daily Simple RFR, as defined in and calculated under and as in effect from time to time under the Revolving Credit Agreement, plus the Applicable Margin, as defined in the Revolving Credit Agreement. The Applicable Margin is determined based on the Debt Rating of STERIS, as defined in the Credit Agreement. Interest on Base Rate Advances is payable quarterly in arrears, and interest on Eurocurrency Rate Advances is payable at the end of the relevant interest period therefor, but in no event less frequently than every three months, and interest on RFR Advances is payable monthly after the date of borrowing. Swingline borrowings bear interest at a rate to be agreed by the applicable swingline lender and the applicable borrower, subject to a cap in the case of swingline borrowings denominated in U.S. Dollars equal to the Base Rate plus the Applicable Margin for Base Rate Advances plus the Facility Fee. Advances may be extended in U.S. Dollars or in specified alternative currencies. In connection with the cessation of British Pound Sterling LIBOR and Swiss Franc LIBOR as of December 31, 2021, JPMorgan Chase Bank, N.A. as administrative agent, pursuant to authority contained in the Revolver, amended the Revolver on January 1, 2022 to make Benchmark Replacement Conforming Changes (as defined in the Revolver). The amendment concerns technical, administrative or operational changes related to borrowings in British Pounds Sterling and Swiss Francs.

As of March 31, 2022 a total of $58,908 of Credit Agreement and Swing Line Facility borrowings were outstanding under the Credit Agreement, based on currency exchange rates as of March 31, 2022.

On March 19, 2021, the Company, STERIS Corporation, Limited, and FinCo, each as a borrower and guarantor, entered into a term loan agreement with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as Administrative agent (the “Term Loan Agreement”) providing for a $550,000 term loan facility (the “Term Loan”), which replaced an existing term loan agreement, dated as of November 18, 2020 (the “Existing Term Loan Agreement”). The proceeds of the Term Loan were used to refinance the Existing Term Loan Agreement.

The Term Loan matures on the date that is five years after March 19, 2021 (the “Term Loan Closing Date”). No principal payments are due on the Term Loan for the period beginning from the first full fiscal quarter ended after the Term Loan Closing Date to and including the fourth full fiscal quarter ended after the Term Loan Closing Date. For the period beginning from the fifth full fiscal quarter ended after the Term Loan Closing Date to and including the twelfth full fiscal quarter ended after the Term Loan Closing Date, quarterly principal payments, each in the amount of 1.25% of the original principal amount of the Term Loan, are due on the last business day of each fiscal quarter. For the period beginning from the thirteenth full fiscal quarter ended after the Term Loan Closing Date through the maturity of the loan, quarterly principal payments, each in the amount of 1.875% of the original principal amount of the Term Loan, are due on the last business day of each fiscal quarter. The remaining unpaid principal is due and payable on the maturity date.

The Term Loan bears interest from time to time, at either the Base Rate or the Eurocurrency Rate, as defined in and calculated under and as in effect from time to time under the Term Loan Agreement, plus the Applicable Margin, as defined in the Term Loan Agreement. The Applicable Margin is determined based on the Debt Rating of STERIS, as defined in the Term Loan Agreement. Base Rate Advances are payable quarterly in arrears and Eurocurrency Rate Advances are payable at the end of the relevant interest period therefor, but in no event less frequently than every three months.

Also on March 19, 2021, the Company, STERIS Corporation, Limited, and FinCo, each as a borrower and guarantor, entered into a delayed draw term loan agreement with various financial institutions as lenders, and JPMorgan Chase Bank, N.A., as administrative agent (the “Delayed Draw Term Loan Agreement”) providing for a delayed draw term loan facility of up to $750,000 (the “Delayed Draw Term Loan”) in connection with STERIS’s acquisition of Cantel. During the first quarter of fiscal 2022, we borrowed $650,000 under our Delayed Draw Term Loan Agreement. The Delayed Draw Term Loan was funded by the lenders upon consummation of the Cantel acquisition (the “Acquisition Closing Date”). The proceeds of the Delayed Draw Term Loan were used, together with the proceeds from other new indebtedness, to fund the cash consideration for the acquisition, as well as for various other items.

The Delayed Draw Term Loan matures on the date that is five years after the Acquisition Closing Date. No principal payments are due on the Delayed Draw Term Loan for the period beginning from the first full fiscal quarter ended after the Acquisition Closing Date to and including the fourth full fiscal quarter ended after the Acquisition Closing Date. For the period beginning from the fifth full fiscal quarter ended after the Acquisition Closing Date to and including the twelfth full fiscal quarter ended after the Acquisition Closing Date, quarterly principal payments, each in the amount of 1.25% of the original principal amount of the Delayed Draw Term Loan, are due on the last business day of each fiscal quarter. For the period beginning from the thirteenth full fiscal quarter ended after the Acquisition Closing Date through the maturity of the loan, quarterly principal payments, each in the amount of 1.875% of the original principal amount of the Delayed Draw Term Loan, are due on the last business day of each fiscal quarter. The remaining unpaid principal is due and payable on the maturity date.

The Delayed Draw Term Loan bears interest from time to time, at either the Base Rate or the Eurocurrency Rate, as defined in and calculated under and as in effect from time to time under the Delayed Draw Term Loan Agreement, plus the Applicable Margin, as defined in the Delayed Draw Term Loan Agreement. The Applicable Margin is determined based on the Debt Rating of STERIS, as defined in the Delayed Draw Term Loan Agreement. Interest on borrowings made at the Base Rate (“Base Rate Advances”) is payable quarterly in arrears and interest on borrowings made at the Eurocurrency Rate (“Eurocurrency Rate Advances”) is payable at the end of the relevant interest period therefor, but in no event less frequently than every three months. There is no premium or penalty for prepayment of Base Rate Advances, but prepayments of Eurocurrency Rate Advances are subject to a breakage fee.

Senior Public Notes

On April 1, 2021, STERIS Irish FinCo Unlimited Company ("FinCo," "STERIS Irish FinCo," the "Issuer") completed an offering of $1,350,000 in aggregate principal amount, of its senior notes in two separate tranches: (i) $675,000 aggregate principal amount of the Issuer’s 2.70% Senior Notes due 2031 (the “2031 Notes”) and (ii) $675,000 aggregate principal amount of the Issuer’s 3.750% Senior Notes due 2051 (the “2051 Notes” and, together with the 2031 Notes, the “Senior Public Notes”). The Senior Public Notes were issued pursuant to an Indenture, dated as of April 1, 2021 (the “Base Indenture”), among FinCo, and STERIS plc, STERIS Corporation and STERIS Limited (the “Guarantors”) and U.S. Bank National Association, as trustee (the “Trustee”), as supplemented by the First Supplemental Indenture, dated as of April 1, 2021, among FinCo, the Guarantors and the Trustee (the “Supplemental Indenture” and, together with the Base Indenture, the “Indenture”). Each of the Guarantors guaranteed the Senior Public Notes jointly and severally on a senior unsecured basis (the “Guarantees”). The 2031 Notes will mature on March 15, 2031 and the 2051 Notes will mature on March 15, 2051. The Senior Public Notes will bear interest at the rates set forth above. Interest on the Senior Public Notes is payable on March 15 and September 15 of each year, beginning on September 15, 2021, until their respective maturities.

Cantel's Convertible Debt

On May 15, 2020, Cantel issued $168,000 aggregate principal amount of 3.25% convertible senior notes due 2025 (the “Notes”) in a private placement. The initial conversion price was $41.51 per share of Cantel common stock (based on an initial conversion rate of 24.0912 shares of Cantel common stock per one thousand dollars in principal amount of Notes) and was, along with the conversion rate, subject to adjustment if certain events occurred.

On June, 3, 2021, Cantel (a) delivered a notice to holders of its Notes pursuant to the indenture governing the Notes (as supplemented, the "Cantel Indenture”), notifying holders that, as a result of each of (i) the consummation of the series of mergers (the “Mergers”) contemplated by the Agreement and Plan of Merger, dated as of January 12, 2021 (as amended by Amendment to Agreement and Plan of Merger, dated as of March 1, 2021), among Cantel, STERIS plc (“Parent”), Solar New US Holding Co, LLC (now known as Solar New US Holding Corporation) (“US Holdco”), an indirect and wholly owned subsidiary of Parent, and Crystal Merger Sub 1, LLC, a direct and wholly owned subsidiary of US Holdco, and (ii) the delisting of Cantel common stock from the New York Stock Exchange (the “NYSE”), a “Fundamental Change” and a “Make-Whole Fundamental Change,” each as defined in the Cantel Indenture, had occurred effective as of June 2, 2021 and (b) commenced an offer to purchase any and all outstanding Notes as a result of the Fundamental Change.

A tender offer statement on Schedule TO (“Schedule TO”) was filed by Cantel with the U.S. Securities and Exchange Commission ("SEC") with respect to the right of each holder (each, a “Holder”) of the Notes to require Cantel to repurchase, at the Holder’s option, 100% of the principal amount of the Notes, plus accrued and unpaid interest thereon to, but excluding the settlement date of July 6, 2021 (as such date was amended by Amendment No. 1 to Schedule TO (“Amendment No. 1”), dated June 29, 2021).

The offer to purchase the Notes expired at 11:59 p.m. New York City time, on July 1, 2021 (the “Expiration Time,” as such date was amended by Amendment No. 1), and was not extended. Wells Fargo Bank, National Association, as paying agent and trustee under the Indenture (the “Cantel Trustee”), informed Cantel that as of the Expiration Time, none of the Notes had been validly tendered (and not properly withdrawn) for purchase.

Pursuant to the terms of the Cantel Indenture, in connection with the consummation of the Mergers, Cantel, Parent and the Cantel Trustee entered into a supplemental indenture providing that, following the Mergers, each holder’s right to convert each one thousand dollar principal amount of Notes into shares of Cantel common stock was changed into a right to convert such principal amount of Notes into the kind and amount of cash, stock, other securities, other property or assets, subject to settlement method election provisions of the Indenture, that a holder of Cantel common stock was entitled to receive upon consummation of the Mergers. At the consummation of the Mergers, holders of Cantel common stock received $16.93 in cash and 0.33787 ordinary shares, par value $0.001 per share, of the Parent (“Parent Shares”) for each share of Cantel common stock (each a “unit of Reference Property”).

Because each of the consummation of the Mergers and the delisting of Cantel common stock from the NYSE constituted a “Make-Whole Fundamental Change” under the Cantel Indenture, any Notes surrendered for conversion from and including June 2, 2021 until July 2, 2021 (the “Make-Whole Conversion Period”) were subject to conversion at the conversion rate of 25.0843 units of Reference Property (the “Make-Whole Conversion Rate”), which corresponded to 8.4752 Parent Shares and approximately $424.68 in cash per one thousand dollars in principal amount of Cantel Notes. The Make-Whole Conversion Rate was based on an increase in the Conversion Rate by 0.9931 Additional Shares (as defined in the Indenture) based on a Make-Whole Effective Date of June 2, 2021 and a Stock Price (each as defined in the Indenture) of $81.3520. Cantel settled all conversions of Notes in connection with the Make-Whole Fundamental Changes that constituted the Mergers and delisting of Cantel common stock from the NYSE pursuant to the Cash Settlement provisions of the Cantel Indenture.

The Cantel Trustee, acting as conversion agent, informed Cantel that holders of 100% of the outstanding Notes elected to convert their Notes during the Make-Whole Conversion Period.

The fair value of the Notes exceeded their aggregate par value of $168,000 at the date of consummation of the Mergers. The fair value was estimated utilizing the closing price of Parent Shares on June 2, 2021. A premium of approximately $175,555 in excess of the aggregate par value of the Notes represented purchase consideration and was initially classified in additional paid-in capital in accordance with ASC 2020-06, "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)."

Because all Holders elected to convert during the Make-Whole Conversion Period, the aggregate par value outstanding was reclassified to current liabilities in the balance sheet. The premium initially recorded as additional paid in capital at the effective time of the Mergers was reclassified to "Convertible debt, premium liability," also classified as a current liability, and was settled in cash.

The final total Cash Settlement value of the Notes was approximately $371,361, comprised of the aggregate par value of $168,000 and the fair value of the liability representing the premium over par of approximately $203,361.

The liability representing the premium over par value increased between the effective date of the Mergers and settlement because of the movement in trading prices of Parent Shares during the Observation Periods. The fluctuation in fair value during such Observation Periods is reported in the statement of income as a component of “Non-operating expense, net.”

Our outstanding Private Placement Senior Notes at March 31, 2022 and 2021 were as follows:


	Applicable Note Purchase Agreement	Maturity Date	U.S. Dollar Value at March 31, 2022		U.S. Dollar Value at March 31, 2021
$91,000 Senior notes at 3.20%	2012 Private Placement	December 2022	91,000		91,000
$80,000 Senior notes at 3.35%	2012 Private Placement	December 2024	80,000		80,000
$25,000 Senior notes at 3.55%	2012 Private Placement	December 2027	25,000		25,000
$125,000 Senior notes at 3.45%	2015 Private Placement	May 2025	125,000		125,000
$125,000 Senior notes at 3.55%	2015 Private Placement	May 2027	125,000		125,000
$100,000 Senior notes at 3.70%	2015 Private Placement	May 2030	100,000		100,000
$50,000 Senior notes at 3.93%	2017 Private Placement	February 2027	50,000		50,000
€60,000 Senior notes at 1.86%	2017 Private Placement	February 2027	66,815		70,426
$45,000 Senior notes at 4.03%	2017 Private Placement	February 2029	45,000		45,000
€20,000 Senior notes at 2.04%	2017 Private Placement	February 2029	22,271		23,475
£45,000 Senior notes at 3.04%	2017 Private Placement	February 2029	59,089		61,863
€19,000 Senior notes at 2.30%	2017 Private Placement	February 2032	21,158		22,302
£30,000 Senior notes at 3.17%	2017 Private Placement	February 2032	39,393		41,242
Total Senior Notes			$	849,726	$	860,308

On February 27, 2017, Limited issued and sold an aggregate principal amount of $95,000, €99,000, and £75,000, of senior notes in a private placement to certain institutional investors in an offering that was exempt from the registration requirements of the Securities Act of 1933. These notes have maturities of between 10 years and 15 years from the issue date. The agreement governing these notes contains leverage and interest coverage covenants.

On May 15, 2015, STERIS Corporation issued and sold $350,000 of senior notes, in a private placement to certain institutional investors in an offering that was exempt from the registration requirements of the Securities Act of 1933. These notes have maturities of 10 years to 15 years from the issue date. The agreement governing these notes contains leverage and interest coverage covenants.

In December 2012, and in February 2013 STERIS Corporation issued and sold $200,000 of senior notes, in a private placement to certain institutional investors in offerings that were exempt from the registration requirements of the Securities Act of 1933. The agreement governing the notes contains leverage and interest coverage covenants.

The private placement note purchase agreements specify increases to the coupon interest rates while the ratio of Consolidated Total Debt to Consolidated EBITDA, as defined in the note purchase agreements, exceeds certain thresholds. Beginning September 1, 2021 and through March 31, 2022 the coupon rates on the 2012 private placement notes were increased by 0.50%.

On March 19, 2021, STERIS Corporation as issuer, and the Company, Limited and FinCo, as guarantors, entered into (1) a First Amendment to Amended and Restated Note Purchase Agreement dated March 5, 2019 (which had amended and restated certain note purchase agreements originally dated December 4, 2012) per the 2012 and 2013 senior notes (the “2012 Amendment”), and (2) a First Amendment to Amended and Restated Note Purchase Agreement dated March 5, 2019 (which had amended and restated certain note purchase agreements originally dated March 31, 2015) for the 2015 senior notes (the “2015 Amendment”). Also on March 19, 2021, Limited, as Issuer, and the Company, STERIS Corporation and FinCo, as guarantors, entered into a First Amendment to Amended and Restated Note Purchase Agreement dated March 5, 2019 (which had amended and restated a certain note purchase agreement originally dated January 23, 2017) for the 2017 senior notes (together with the 2012 Amendment and the 2015 Amendment, the “NPA Amendments”). The NPA Amendments provided, among other things, for the waiver of certain repurchase rights of the note holders and increased the size of certain baskets to more closely align with other current credit agreement baskets.

At March 31, 2022, we were in compliance with all financial covenants associated with our indebtedness.

The combined annual aggregate amount of maturities of our outstanding debt by fiscal year is as follows:


2023	$	142,875
2024	60,000
2025	165,937
2026	341,408
2027 and thereafter	2,403,414
Total	$	3,113,634

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Additional Consolidated Balance Sheets Information

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Additional Consolidated Balance Sheets Information

7. ADDITIONAL CONSOLIDATED BALANCE SHEET INFORMATION

Additional information related to our Consolidated Balance Sheet is as follows:


March 31,	2022		2021
Accrued payroll and other related liabilities:
Compensation and related items	$	71,878	$	47,157
Accrued vacation/paid time off	13,669		12,389
Accrued bonuses	64,702		62,530
Accrued employee commissions	30,171		24,022
Other post-retirement benefits obligations-current portion	1,190		1,326
Other employee benefit plans' obligations-current portion	2,111		2,654
Total accrued payroll and other related liabilities	$	183,721	$	150,078
Accrued expenses and other:
Deferred revenues	$	110,791	$	62,492
Service liabilities	51,365		46,720
Self-insured and related risk reserves-current portion	8,995		8,095
Accrued dealer commissions	31,700		27,348
Accrued warranty	14,108		9,406
Asset retirement obligation-current portion	1,181		1,193

Other	88,404		65,303
Total accrued expenses and other	$	306,544	$	220,557
Other liabilities:
Self-insured risk reserves-long-term portion	$	19,213	$	17,295
Other post-retirement benefits obligations-long-term portion	7,335		8,690
Defined benefit pension plans obligations-long-term portion	1,772		3,748
Other employee benefit plans obligations-long-term portion	1,360		2,353
Accrued long-term income taxes	12,225		13,241
Asset retirement obligation-long-term portion	12,362		12,137
Other	21,312		30,546
Total other liabilities	$	75,579	$	88,010

Income Tax Expense

12 Months Ended

Mar. 31, 2022

Income Tax Expense [Abstract]

Income Tax Expense (Benefit)

We consider the tax expense recorded for the Tax Cuts and Jobs Act ("TCJA") to be complete at this time. However, it is possible that additional legislation, regulations, interpretations and/or guidance may be issued in the future that may result in additional adjustments to the tax expense recorded related to the TCJA. We will continue to monitor and assess the impact of any new developments.

Income from continuing operations before income taxes was as follows:


Years Ended March 31,	2022		2021		2020

United States operations	$	79,662	$	326,991	$	325,595
Ireland operations	88,078		73,442		29,543
Other locations operations	146,763		117,100		143,616
	$	314,503	$	517,533	$	498,754

The components of the provision for income taxes related to income from continuing operations consisted of the following:


Years Ended March 31,	2022		2021		2020

Current:
United States federal	$	88,158	$	57,550	$	42,032
United States state and local	21,438		16,272		9,971
Ireland	12,002		9,244		5,036
Other locations	53,354		36,699		24,600
	174,952		119,765		81,639
Deferred:
United States federal	(73,833)		7,523		10,089
United States state and local	(17,124)		(550)		2,366
Ireland	(739)		(787)		(899)
Other locations	(11,623)		(5,288)		(2,300)
	(103,319)		898		9,256
Total Provision for Income Taxes	$	71,633	$	120,663	$	90,895

The total provision for income taxes can be reconciled to the tax computed at the Ireland statutory tax rate as follows:


Years Ended March 31,	2022		2021		2020
National statutory tax rate	12.5	%	12.5	%	12.5	%
Increase (decrease) in accruals for uncertain tax positions	0.2	%	(0.1)	%	(0.3)	%
U.S. state and local taxes, net of federal income tax benefit	1.4	%	2.4	%	2.0	%
Increase in valuation allowances	0.9	%	0.3	%	0.5	%
U.S. research and development credit	(0.8)	%	(0.5)	%	(0.5)	%
U.S. foreign income tax credit	(1.1)	%	(0.3)	%	(0.6)	%
Difference in non-Ireland tax rates	12.6	%	8.3	%	6.9	%
U.S. federal audit adjustments	—	%	2.1	%	—	%
Excess tax benefit for equity compensation	(5.1)	%	(1.9)	%	(2.8)	%
Tax rate changes on deferred tax assets and liabilities	2.3	%	0.4	%	0.1	%
U.S. tax reform impact, GILTI and FDII	(0.9)	%	(0.6)	%	0.1	%

Capitalized acquisition, redomiciliation costs	1.8	%	0.6	%	0.1	%
All other, net	(1.0)	%	0.1	%	0.2	%
Total Provision for Income Taxes	22.8	%	23.3	%	18.2	%

Unrecognized Tax Benefits. We classify uncertain tax positions and related interest and penalties as long-term liabilities within “Other liabilities” in our accompanying Consolidated Balance Sheets, unless they are expected to be paid within 12 months, in which case, the uncertain tax positions would be classified as current liabilities within “Accrued income taxes.” We recognize interest and penalties related to unrecognized tax benefits within “Income tax expense” in our accompanying Consolidated Statements of Income.

A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits is as follows:


	2022		2021
Unrecognized Tax Benefits Balance at April 1	$	2,295	$	875
Increases for tax provisions of current year	—		655
Decreases for tax provisions of prior year	(135)		(896)
Balances related to acquired/disposed businesses	746		1,640
Other, including currency translation	—		21


Unrecognized Tax Benefits Balance at March 31	$	2,906	$	2,295

We recognized interest and penalties related to uncertain tax positions in the provision for income taxes. As of March 31, 2022 and 2021, we had $152 and $106 accrued for interest and penalties, respectively. If all unrecognized tax benefits were recognized, the net impact on the provision for income tax expense would be $3,058. The increase in unrecognized tax benefits from prior year is due to the additions of new positions. It is reasonably possible that during the next 12 months, there will be no material reductions in unrecognized tax benefits as a result of the expiration of various statutes of limitations or other matters.

We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2018 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2016. We remain subject to tax authority audits in various jurisdictions wherever we do business.

In the fourth quarter of fiscal 2021, we completed an appeals process with the U.S. Internal Revenue Service (the “IRS”) regarding proposed audit adjustments related to deductibility of interest paid on intercompany debt for fiscal years 2016 through 2017. An agreement was reached on final interest rates, which also impacts subsequent years through 2020. We estimate the total federal, state, and local tax impact of the settlement to be approximately $12,000, for the fiscal years 2016 through 2020, of which approximately $7,300 has been paid through March 31, 2022.

In May 2021, we received two notices of proposed tax adjustment from the IRS regarding deemed dividend inclusions and associated withholding tax. The notices relate to the fiscal and calendar year 2018. The IRS adjustments would result in a cumulative tax liability of approximately $50,000. We are contesting the IRS’s assertions and intend to pursue available remedies such as appeals and litigation, if necessary. We have not established reserves related to these notices. An unfavorable outcome is not expected to have a material adverse impact on our consolidated financial position but could be material to our consolidated results of operations and cash flows for any one period.

We estimate that the tax benefit from our Costa Rican Tax Holiday is $2,600 (or $0.03 per fully diluted share), annually. The Tax Holiday runs fully exempt, from income tax, through 2025 and partially exempt through 2029.

Deferred Taxes. The significant components of the deferred tax assets and liabilities recorded in our accompanying balance sheets at March 31, 2022 and 2021 were as follows:


March 31,	2022		2021

Deferred Tax Assets:
Post-retirement benefit accrual	$	2,086	$	2,422
Compensation	14,340		13,208
Net operating loss carryforwards	25,550		15,151
Accrued expenses	12,092		6,360
Insurance	2,561		3,348
Deferred income	20,688		10,281
Bad debt	2,187		1,661
Pension	—		1,574
Operating leases (1)	44,401		34,020
Foreign tax credit carryforwards	36,036		—
Other	8,579		8,603
Deferred Tax Assets	168,520		96,628
Less: Valuation allowance	24,691		14,143
Total Deferred Tax Assets	143,829		82,485
Deferred Tax Liabilities:
Depreciation and depletion	110,951		73,344
Operating leases (1)	43,593		33,401
Intangibles	755,980		199,242
Pension	2,004		—
Other	3,473		3,833
Total Deferred Tax Liabilities	916,001		309,820
Net Deferred Tax Assets (Liabilities)	$	(772,172)	$	(227,335)

(1) For more information regarding our operating leases, see Note 10 titled, "Commitments and Contingencies."

At March 31, 2022, we had U.S. federal operating loss carryforwards of $9,694, which remain subject to a 20 year carryforward period. Additionally, we had non-U.S. operating loss carry forwards of $71,171. Although the majority of the non-U.S. carryforwards have indefinite expiration periods, those carryforwards that have definite expiration periods will expire if unused between fiscal years 2023 and 2043. In addition, we have recorded pre-valuation allowance tax benefits of $4,199 related to state operating loss carryforwards. If unused, these state operating loss carryforwards will expire between fiscal years 2023 and 2043. At March 31, 2022, we had $37,501 of pre-valuation allowance tax credit carryforwards of which $28,749 relates to offsets of deferred tax liabilities related to German branches of a U.S. subsidiary. These credit carryforwards can be used through fiscal 2032.

We review the need for a valuation allowance against our deferred tax assets. A valuation allowance of $24,691 has been applied to a portion of the net deferred tax assets because we do not believe it is more-likely-than-not that we will receive future benefit. The valuation allowance increased during fiscal 2022 by $10,548.

Other than the tax expense previously recorded for the one-time transition tax on unremitted earnings of non-US subsidiaries, no additional provision has been made for income taxes on undistributed earnings of foreign subsidiaries as the Company’s position is that these amounts continue to be indefinitely reinvested. The amount of undistributed earnings of subsidiaries was approximately $2,000,000 at March 31, 2022. It is not practicable to estimate the additional income taxes and applicable withholding taxes that would be payable on the remittance of such undistributed earnings.

In October 2015, the Organization for Economic Cooperation and Development (OECD), in conjunction with the G20, finalized broad-based international tax policy guidelines that involve transfer pricing and other international tax subjects. While

some member jurisdictions automatically adopt the new OECD guidelines, most member countries can adopt the guidelines only by new law or regulations. We are currently adopting processes to comply with the reporting requirements specified by the guidelines and are evaluating the other parts of the guidelines.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI https://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Benefit Plans

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Benefit Plans

9. BENEFIT PLANS

In the United States, we sponsor an unfunded post-retirement welfare benefits plan for two groups of United States retirees. Benefits under this plan include retiree life insurance and retiree medical insurance, including prescription drug coverage.

During the second quarter of fiscal 2009, we amended our United States post-retirement welfare benefits plan, reducing the benefits to be provided to retirees under the plan and increasing their share of the costs. The amendments resulted in a decrease of $46,001 in the accumulated post-retirement benefit obligation. The impact of this change was recognized in our Consolidated Balance Sheets in fiscal 2009 and is being amortized as a component of the annual net periodic benefit cost over a period of approximately thirteen years.

We sponsor several defined benefit pension schemes outside the United States: two in the UK, one in the Netherlands, two in Germany, and one in Switzerland. The Synergy Health plc Retirement Benefit Scheme is a defined benefit (final salary) funded pension scheme. In previous years, Synergy sponsored a funded defined benefit arrangement in the Netherlands. This was a separate fund holding the pension scheme assets to meet long-term pension liabilities for past and present employees. Accrual of benefits ceased under the scheme effective January 1, 2013. The Synergy Radeberg and Synergy Allershausen Schemes are unfunded defined pension schemes and are closed to new entrants. The Synergy Daniken Scheme is a defined benefit funded pension scheme. As a result of our fiscal 2018 acquisition of Harwell Dosimeters Ltd, we also sponsor in the Harwell Dosimeters Ltd Retirement Benefits Scheme which is a defined benefit funded pension scheme.

We recognize the funded status of our defined benefit pension and post-retirement benefit plans in our Consolidated Balance Sheets, with a corresponding adjustment to accumulated other comprehensive income, net of tax. The funded status is measured as of March 31 each year and is calculated as the difference between the fair value of plan assets and the benefit obligation (which is the projected benefit obligation for pension plans and the accumulated post-retirement benefit obligation for post-retirement benefit plans). Accumulated comprehensive income (loss) represents the net unrecognized actuarial losses and unrecognized prior service cost. These amounts will be recognized in net periodic benefit cost as they are amortized. We will recognize future changes to the funded status of these plans in the year the change occurs, through other comprehensive income.

Obligations and Funded Status. The following table reconciles the funded status of the defined benefit pension plans and the other post-retirement benefits plan to the amounts recorded on our Consolidated Balance Sheets at March 31, 2022 and 2021, respectively. Benefit obligation balances presented in the following table reflect the projected benefit obligations for our defined benefit pension plans and the accumulated other post-retirement benefit obligation for our post-retirement benefits plan. The measurement date of our defined benefit pension plans and other post-retirement benefits plan is March 31, for both periods presented.


	Defined Benefit Pension Plans				Other Post-Retirement Benefits Plan
	2022		2021		2022		2021
Change in Benefit Obligations:
Benefit Obligations at Beginning of Year	$	149,200	$	123,190	$	10,016	$	11,368

Service cost	1,616		1,357		—		—

Interest cost	2,820		2,816		232		317
Actuarial loss (gain)	(12,177)		12,622		(640)		(114)
Benefits and expenses	(5,375)		(4,714)		(1,083)		(1,555)
Employee contributions	897		1,031		—		—
Curtailments/settlements	(1,334)		—		—		—
Impact of foreign currency exchange rate changes	(5,875)		12,898		—		—
Benefit Obligations at End of Year	129,772		149,200		8,525		10,016
Change in Plan Assets:
Fair Value of Plan Assets at Beginning of Year	145,452		112,203		—		—

Actual return on plan assets	3,421		19,252		—		—
Employer contributions	5,533		5,329		1,083		1,555
Employee contributions	897		1,031		—		—
Benefits and expenses paid	(5,325)		(4,714)		(1,083)		(1,555)
Curtailments/settlements	(1,334)		—		—		—
Impact of foreign currency exchange rate changes	(6,472)		12,351		—		—
Fair Value of Plan Assets at End of Year	142,172		145,452		—		—
Funded Status of the Plans	$	12,400	$	(3,748)	$	(8,525)	$	(10,016)

Amounts recognized in the consolidated balance sheets consist of the following:


	Defined Benefit Pension Plans				Other Post-Retirement Benefits Plan
	2022		2021		2022		2021

Non-current assets	$	14,172	$	—	$	—	$	—
Current liabilities	—		—		(1,190)		(1,326)
Non-current liabilities	(1,772)		(3,748)		(7,335)		(8,690)
Net assets (liabilities)	$	12,400	$	(3,748)	$	(8,525)	$	(10,016)

The pre-tax amount of unrecognized actuarial net loss and unamortized prior service cost included in accumulated other comprehensive (loss) at March 31, 2022, was approximately $(2,914) and $(6,767), respectively.

Defined benefit plans with an accumulated benefit obligation and projected benefit obligation exceeding the fair value of plan assets had the following plan assets and obligations at March 31, 2022 and 2021:


	Defined Benefit Pension Plans
		2022		2021
Aggregate fair value of plan assets		$	142,172	$	145,452
Aggregate accumulated benefit obligations		129,772		149,200
Aggregate projected benefit obligations		129,772		149,200

Components of Net Periodic Benefit Cost and Other Amounts Recognized in Other Comprehensive Income. Components of the annual net periodic benefit cost of our defined benefit pension plans and our other post-retirement benefits plan were as follows:


	Defined Benefit Pension Plans						Other Post-Retirement Benefits Plan
	2022		2021		2020		2022		2021		2020
Service cost	$	1,616	$	1,357	$	1,380	$	—	$	—	$	—
Interest cost	2,699		2,628		2,876		232		317		409
Expected return on plan assets	(4,412)		(3,463)		(4,735)		—		—		—
Prior service cost recognition	61		71		69		(267)		(3,263)		(3,263)
Net amortization and deferral	18		21		9		444		439		482
Curtailments/settlements	(31)		—		—
Net periodic benefit (credit) cost	$	(49)	$	614	$	(401)	$	409	$	(2,507)	$	(2,372)
Recognized in other comprehensive loss (income) before tax:
Net loss (gain) occurring during year	$	(11,028)	$	(1,635)	$	890	$	640	$	114	$	(181)
Amortization of prior service credit	(222)		(85)		(78)		267		3,263		3,263
Amortization of net loss	—		7		—		(444)		(439)		(482)

Total recognized in other comprehensive loss (income)	(11,250)		(1,713)		812		463		2,938		2,600
Total recognized in total benefits cost and other comprehensive loss (income)	$	(11,299)	$	(1,099)	$	411	$	872	$	431	$	228

Assumptions Used in Calculating Benefit Obligations and Net Periodic Benefit Cost. The following table presents significant assumptions used to determine the projected benefit obligations at March 31:


	2022		2021
Discount Rate:

Synergy Health plc Retirement Benefits Scheme	2.80	%	2.10	%

Isotron BV Pension Plan	1.80	%	0.90	%
Synergy Health Daniken AG	0.90	%	0.35	%
Synergy Health Radeberg	1.60	%	1.60	%
Synergy Health Allershausen	1.50	%	0.80	%
Harwell Dosimeters Ltd Retirement Benefits Scheme	2.85	%	2.15	%
Other post-retirement plan	3.25	%	2.50	%

The following table presents significant assumptions used to determine the net periodic benefit costs for the years ended March 31:


	2022		2021		2020
Discount Rate:
Synergy Health plc Retirement Benefits Scheme	2.10	%	2.40	%	2.50	%
Isotron BV Pension Plan	0.90	%	1.60	%	1.20	%
Synergy Health Daniken AG	1.00	%	0.70	%	0.20	%
Synergy Health Radeberg	1.50	%	1.50	%	1.60	%
Synergy Health Allershausen	2.00	%	1.75	%	1.75	%
Harwell Dosimeters Ltd Retirement Benefits Scheme	2.85	%	2.15	%	2.45	%
Other post-retirement plan	2.50	%	3.00	%	3.50	%
Expected Return on Plan Assets:
Synergy Health plc Retirement Benefits Scheme	3.60	%	3.50	%	4.80	%
Isotron BV Pension Plan	0.90	%	1.60	%	1.20	%
Synergy Health Daniken AG	1.00	%	0.70	%	0.65	%

The net periodic benefit cost and the actuarial present value of projected benefit obligations are based upon assumptions that we review on an annual basis. These assumptions may be revised annually based upon an evaluation of long-term trends, as well as market conditions that may have an impact on the cost of providing benefits.

We develop our expected long-term rate of return on plan assets assumptions by evaluating input from third-party professional advisers, taking into consideration the asset allocation of the portfolios and the long-term asset class return expectations.

We develop our discount rate assumptions by evaluating input from third-party professional advisers, taking into consideration the current yield on country specific investment grade long-term bonds which provide for similar cash flow streams as our projected obligations.

We have made assumptions regarding healthcare costs in computing our other post-retirement benefit obligation. The assumed rates of increase generally decline ratably over a five-year period from the assumed current year healthcare cost trend rate to the assumed long-term healthcare cost trend rate noted below.


	2022		2021		2020
Healthcare cost trend rate – medical	7.00	%	7.00	%	6.75	%
Healthcare cost trend rate – prescription drug	7.00	%	7.00	%	6.75	%
Long-term healthcare cost trend rate	4.50	%	4.50	%	4.50	%

assumptions of other plan sponsors and national health trends, and adjustments for plan design changes, workforce changes, and changes in plan participant behavior.

Plan Assets. The investment policies for our plans are generally established by the local pension plan trustees and seek to maintain the plans' ability to meet liabilities and to comply with local minimum funding requirements. Plan assets are invested in diversified portfolios that provide adequate levels of return at an acceptable level of risk. The investment policies are reviewed at least annually and revised, as deemed appropriate to ensure that the objectives are being met. At March 31, 2022, the targeted allocation for the plans were approximately 75% equity investments and 25% fixed income investments.

Financial instruments included in pension plan assets are categorized into three tiers. These tiers include a fair value hierarchy of three levels, based on the degree of subjectivity inherent in the valuation methodology as follows:

Level 1 - Quoted prices for identical assets in active markets.

Level 2 - Quoted prices for similar assets in active markets with inputs that are observable, either directly or indirectly.

Level 3 - Unobservable prices or inputs in which little or no market data exists.

The fair value of our pension benefits plan assets at March 31, 2022 and 2021 by asset category is as follows:


	Fair Value Measurements at March 31, 2022
(In thousands)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Cash	$	559	$	559			$	—
Insured annuities	14,231		—		14,231		—
Insurance contracts	5,383		—		—		5,383
Common and collective trusts valued at net asset value:
Equity security trusts	66,416		—		—		—
Debt security trusts	55,583		—		—		—
Total Plan Assets	$	142,172	$	559	$	14,231	$	5,383


	Fair Value Measurements at March 31, 2021
(In thousands)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Cash	$	657	$	657	$	—	$	—
Insured annuities	17,950		—		17,950		—
Insurance contracts	5,555		—		—		5,555
Common and collective trusts valued at net asset value:
Equity security trusts	60,960		—		—		—
Debt security trusts	60,330		—		—		—

Total Plan Assets	$	145,452	$	657	$	17,950	$	5,555

Collective investment trusts are measured at fair value using the net asset value per share practical expedient. These trusts have not been categorized in the fair value hierarchy and are being presented in the tables above to permit a reconciliation of the fair value hierarchy to the total plan assets.

The fair value measurement of plan assets using significant unobservable inputs (Level 3) changed during fiscal year 2022 due to the following:


	Insurance contracts
Balance at March 31, 2020	$	4,345
Gains (losses) related to assets still held at year-end	197
Transfers out of Level 3	853
Foreign currency	160
Balance at March 31, 2021	$	5,555
Gains (losses) related to assets still held at year-end	(115)
Transfers out of Level 3	(210)
Foreign currency	153
Balance at March 31, 2022	$	5,383

Cash Flows. We contribute amounts to our defined benefit pension plans at least equal to the minimum amounts required by applicable employee benefit laws and local tax laws. We expect to make contributions of approximately $4,103 during fiscal 2023.

Based upon the actuarial assumptions utilized to develop our benefit obligations at March 31, 2022, the following benefit payments are expected to be made to plan participants:


	Other Defined Benefit Pension Plans		Other Post-Retirement Benefits Plan
2023	$	5,560	$	1,190
2024	5,542		1,067
2025	5,721		966
2026	5,882		880
2027	6,060		788
2028-2033	33,250		2,871

The Medicare Prescription Drug, Improvement and Modernization Act of 2003 (the “Act”) provides a prescription drug benefit for Medicare beneficiaries, a benefit we provide to Medicare eligible retirees covered by our post-retirement benefits plan. We have concluded that the prescription drug benefit provided in our post-retirement benefit plan is considered to be actuarially equivalent to the benefit provided under the Act and thus qualifies for the subsidy under the Act. Benefits are subject to a per capita per month cost cap and any costs above the cap become the responsibility of the retiree. Under the plan, the subsidy is applied to reduce the retiree responsibility. As a result, the expected future subsidy no longer reduces our accumulated post-retirement benefit obligation and net periodic benefit cost. We collected subsidies totaling approximately $660 and $899, during fiscal 2022 and fiscal 2021, respectively, which reduced the retiree responsibility for costs in excess of the caps established in the post-retirement benefit plan.

Defined Contribution Plans. We maintain 401(k) defined contribution plans for eligible U.S. employees, a 401(k) defined contribution plan for eligible Puerto Rico employees and similar savings plans for certain employees in Canada, United Kingdom, Ireland, and Finland. We provide a match on a specified portion of an employee’s contribution. The U.S. plan assets are held in trust and invested as directed by the plan participants. The Canadian plan assets are held by insurance companies. The aggregate fair value of the U.S. plan assets was $1,271,941 at March 31, 2022. At March 31, 2022, the U.S. plan held 496,661 STERIS ordinary shares with a fair value of $120,078. We paid dividends of $852, $839, and $855 to the plan and participants on STERIS shares held by the plan for the years ended March 31, 2022, 2021, and 2020, respectively. We contributed approximately $38,600, $29,853, and $27,818, to the defined contribution plans for the years ended March 31, 2022, 2021, and 2020, respectively.

We also maintain a domestic non-qualified deferred compensation plan covering certain employees, which formerly allowed for the deferral of compensation for an employee-specified term or until retirement or termination. There have been no employee contributions made to this plan since fiscal 2012. The Plan was amended in fiscal 2012 to disallow deferrals of salary payable in 2012 and subsequent calendar years and of commissions and other incentive compensation payable in respect of the 2013 and subsequent fiscal years. We hold investments in mutual funds to satisfy future obligations of the plan. We account for these assets as available-for-sale securities and they are included in “Other assets” on our accompanying Consolidated Balance Sheets, with a corresponding liability for the plan’s obligation recorded in “Accrued expenses and other.” The aggregate value of the assets was $1,061 and $1,682 at March 31, 2022 and March 31, 2021, respectively. Realized gains and losses on these investments are recorded in “Interest and miscellaneous income” within “Non-operating expenses” on our accompanying Consolidated Statements of Income. Changes in the fair value of the assets are recorded in other comprehensive income on our accompanying balance sheets.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI https://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Contingencies

12 Months Ended

Mar. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Schedule of Loss Contingencies by Contingency [Text Block]

10. COMMITMENTS AND CONTINGENCIES

We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief.

We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us.

Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations.

For additional information regarding these matters, see the risks and uncertainties described under the title "product and service related regulations and claims" in Item 1A. of this Annual Report on Form 10-K.

From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized.

We are subject to taxation from United States federal, state and local, and foreign jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 8 to our consolidated financial statements titled, “Income Taxes” in this Annual Report on Form 10-K.

As of March 31, 2022 and 2021, our commercial commitments totaled $98,675 and $79,122, respectively. Commercial commitments include standby letters of credit, letters of credit required as security under our self-insured risk retention policies, and other potential cash outflows resulting from an event that requires payment by us. Approximately $13,900 and $11,807 of the March 31, 2022 and 2021 totals, respectively, relate to letters of credit required as security under our self-insured risk retention policies.

As of March 31, 2022, we had minimum purchase commitments with suppliers for raw material purchases totaling $59,869. As of March 31, 2022, we also had commitments of $171,619 for long term construction contracts.

Leases

We lease manufacturing, warehouse and office space, service facilities, vehicles, equipment and communication systems. Certain leases contain options that provide us with the ability to extend the lease term. Such options are included in the lease term when it is reasonably certain that the option will be exercised. We made an accounting policy election to not recognize lease assets or lease liabilities for leases with a lease term of twelve months or less.

We determine if an agreement contains a lease and classify our leases as operating or finance at the lease commencement date. Finance leases are generally those leases for which we will pay substantially all the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. Lease assets arising from finance leases are included in property, plant and equipment, net and the liabilities are included in other liabilities. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the lease asset over the shorter of the lease term or the useful life of the asset. Our finance leases are not material as of March 31, 2022 and for the twelve month period then ended.

Operating lease assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. As most leases do not provide an implicit interest rate, we estimate an incremental borrowing rate to determine the present value of lease payments. Our estimated incremental borrowing rate reflects a secured rate based on recent debt issuances, our estimated credit rating, lease term, as well as publicly available data for instruments with similar characteristics. For operating leases, we recognize lease cost on a straight-line basis over the term of the lease. When accounting for leases, we combine payments for leased assets, related services and other components of a lease.

The components of operating lease expense are as follows:


	Year Ended March 31, 2022		Year Ended March 31, 2021
Fixed operating lease expense	$	45,158	$	31,087
Variable operating lease expense	12,659		9,326
Total operating lease expense	$	57,817	$	40,413

Supplemental cash flow information related to operating leases is as follows:


	Year Ended March 31, 2022		Year Ended March 31, 2021
Cash paid for amounts included in the measurement of operating lease liabilities	$	45,144	$	29,808
Right-of-use assets obtained in exchange for operating lease obligations, net	$	79,241	$	30,574

Maturities of lease liabilities at March 31, 2022 are as follows:


	March 31, 2022
2023	$	42,099
2024	34,669
2025	26,914
2026	21,419
2027 and thereafter	104,769
Total operating lease payments	229,870
Less imputed interest	38,342
Total operating lease liabilities	$	191,528

In the preceding table, the future minimum annual rentals payable under noncancelable leases denominated in foreign currencies have been calculated using March 31, 2022 foreign currency exchange rates.

Supplemental information related to operating leases is as follows:


	March 31,		March 31,
	2022		2021
Weighted-average remaining lease term of operating leases	9.6 years		11.6 years

Weighted-average discount rate of operating leases	3.4	%	4.1	%

- Definition

The entire disclosure for loss and gain contingencies. Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or prior to issuance of the financial statements) as to a probable or reasonably possible loss incurred by an entity that will ultimately be resolved when one or more future events occur or fail to occur, and typically discloses the amount of loss recorded or a range of possible loss, or an assertion that no reasonable estimate can be made.

+ References + Details

Business Segment Information

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Business Segment Information

11. BUSINESS SEGMENT INFORMATION

As a result of the acquisition of Cantel, we have reassessed the organization of our business and have added a new segment called Dental. We now operate and report our financial information in four reportable business segments: Healthcare, Applied Sterilization Technologies, Life Sciences and Dental. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income.

Our Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. Our products and services range from infection prevention consumables and capital equipment, as well as services to maintain that equipment; to the repair of re-usable procedural instruments; to outsourced instrument reprocessing services. In addition, our procedural solutions also include single-use devices and capital equipment infrastructure used primarily in operating rooms, ambulatory surgery centers, endoscopy suites, and other procedural areas.

Our Applied Sterilization Technologies ("AST") segment is a third-party service provider for contract sterilization, as well as testing services needed to validate sterility services for medical device and pharmaceutical manufacturers. Our technology-neutral offering supports Customers every step of the way, from testing through sterilization.

Our Life Sciences segment provides a comprehensive offering of products and services that support pharmaceutical manufacturing, primarily for vaccine and other biopharma Customers focused on aseptic manufacturing. These solutions include a full suite of consumable products, equipment maintenance and specialty services, and capital equipment.

Our Dental segment provides a comprehensive offering for dental practitioners and dental schools, offering instruments, infection prevention consumables and instrument management systems.

We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company.

For the year ended March 31, 2022, revenues from a single Customer did not represent ten percent or more of the Healthcare, Applied Sterilization Technologies or Life Sciences segment revenues. Three Customers collectively and consistently account for more than 40.0% of our Dental segment revenue. The percentage associated with these three Customers collectively in any one period may vary due to the buying patterns of these three Customers as well as other Dental Customers. These three Customers collectively accounted for approximately 45.1% of our Dental segment revenues for the year ended March 31, 2022.

Information regarding our segments is presented in the following tables.


Years Ended March 31,	2022		2021		2020
Revenues:
Healthcare	$	2,845,467	$	1,954,055	$	1,986,809
Applied Sterilization Technologies	852,972		685,912		627,147
Life Sciences	524,964		467,552		416,939
Dental	361,661		—		—
Total revenues	$	4,585,064	$	3,107,519	$	3,030,895
Operating income (loss):
Healthcare	626,098		427,089		420,709
Applied Sterilization Technologies	410,101		310,648		270,917
Life Sciences	216,188		180,796		144,088
Dental	84,441		—		—

Corporate	(260,059)		(219,153)		(207,015)
Total operating income before adjustments	$	1,076,769	$	699,380	$	628,699
Less: Adjustments
Amortization of acquired intangible assets (1)	366,434		83,892		71,675
Acquisition and integration related charges (2)	205,788		35,634		8,225
Redomiciliation and tax restructuring costs (3)	301		1,592		3,699
(Gain) on fair value adjustment of acquisition related contingent consideration (1)	(2,350)		(500)		—
Net (gain) loss on divestiture of businesses (1)	(874)		2,030		1,770
Amortization of inventory and property "step up" to fair value (1)	81,804		5,600		2,392
COVID-19 incremental costs (4)	—		25,793		749
Restructuring charges (credit) (5)	48		(3,029)		3,143
Total operating income	$	425,618	$	548,368	$	537,046

(1) For more information regarding our recent acquisitions and divestitures refer to Note 2 titled, "Business Acquisitions and Divestitures."

(2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.

(3) Costs incurred in tax restructuring.

(4) COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available.

(5) For more information regarding our restructuring efforts refer to our Annual Report on Form 10-K for the year ended March 31, 2021, dated May 28, 2021.

Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare Products and Life Sciences segments.

Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare Products and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare Products and Life Sciences segments. Therefore, their respective amounts are reported together.


March 31,	2022		2021
Assets (1)
Healthcare and Life Sciences	$	6,604,893	$	3,600,182
Applied Sterilization Technologies	3,053,116		2,974,289
Dental	1,765,585		—
Total assets	$	11,423,594	$	6,574,471


Years Ended March 31,	2022		2021		2020
Capital Expenditures
Healthcare and Life Sciences	$	84,487	$	74,446	$	84,648
Applied Sterilization Technologies	198,350		164,816		129,868
Dental	4,726		—		—
Total Capital Expenditures	$	287,563	$	239,262	$	214,516
Depreciation, Depletion, and Amortization (2)
Healthcare and Life Sciences	$	316,222	$	106,266	$	92,193
Applied Sterilization Technologies	115,925		112,971		105,042
Dental	120,957		—		—
Total Depreciation, Depletion, and Amortization	$	553,104	$	219,237	$	197,235

(1) Amounts are still preliminary, as Cantel acquisition valuations have not been finalized.

(2) Fiscal 2022 totals include approximately $229,052, $35,531 and $113,099 for Healthcare and Life Sciences, Applied Sterilization Technologies, and Dental, respectively, of amortization of acquired intangible assets and amortization of property "step-up" to fair value. For more information regarding our recent acquisitions and divestitures see Note 2 titled, "Business Acquisitions and Divestitures."

Financial information for each of our United States and international geographic areas is presented in the following table. Revenues are based on the location of these operations and their Customers. Property, plant and equipment, net are those assets that are identified within the operations in each geographic area.


March 31,	2022		2021
Property, Plant, and Equipment, Net (1)
Ireland	$	60,275	$	52,140
United States	881,057		673,784
Other locations	611,244		509,476
Property, Plant, and Equipment, Net	$	1,552,576	$	1,235,400

(1) Amounts are still preliminary, as Cantel acquisition valuations have not been finalized.


Years Ended March 31,	2022		2021		2020
Revenues:
Ireland	$	82,011	$	71,905	$	63,821
United States	3,228,864		2,227,038		2,211,722
Other locations	1,274,189		808,576		755,352
Total Revenues	$	4,585,064	$	3,107,519	$	3,030,895


Years Ended March 31,	2022		2021		2020
Healthcare:
Capital equipment	$	782,505	$	588,864	$	617,712
Consumables	1,004,605		510,946		486,425
Service	1,058,357		854,245		882,672
Total Healthcare Revenues	$	2,845,467	$	1,954,055	$	1,986,809



Total Applied Sterilization Technologies Service Revenues	$	852,972	$	685,912	$	627,147
Life Sciences:
Capital equipment	$	142,281	$	128,356	$	112,747
Consumables	239,365		215,005		185,904
Service	143,318		124,191		118,288
Total Life Sciences Revenues	$	524,964	467,552		416,939
Dental Revenues	$	361,661	$	—	$	—
Total Revenues	$	4,585,064	$	3,107,519	$	3,030,895

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI https://asc.fasb.org/topic&trid=2134510

+ Details

Common Shares

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Earnings Per Share [Text Block]

12. SHARES AND PREFERRED SHARES

Ordinary Shares

We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share:


Years ended March 31,	2022	2021	2020
Denominator (shares in thousands):
Weighted average shares outstanding—basic	97,535	85,203	84,778
Dilutive effect of share equivalents	791	695	863
Weighted average shares outstanding and share equivalents—diluted	98,326	85,898	85,641

Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive:


Years ended March 31,	2022	2021	2020
Number of ordinary share options (shares in thousands)	243	348	285

Additional Authorized Shares

The Company has an additional authorized share capital of 50,000,000 preferred shares of $0.001 par value each, plus 25,000 deferred ordinary shares of €1.00 par value each, in order to satisfy minimum statutory capital requirements for all Irish public limited companies.

Repurchases of Common Shares	12 Months Ended
Repurchases of Common Shares	Mar. 31, 2022
Repurchases of Common Shares [Abstract]
Schedule of Treasury Stock by Class [Text Block]	13. REPURCHASES OF ORDINARY SHARES On May 7, 2019, our Board of Directors authorized a share repurchase program resulting in a share repurchase authorization of approximately $78,979 (net of taxes, fees and commissions). On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300,000 (net of taxes, fees and commissions). As of March 31, 2022, there was approximately $308,932 (net of taxes, fees and commissions) of remaining availability under the Board authorized share repurchase program. The share repurchase program has no specified expiration date. Under the authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020. The suspension was lifted effective February 10, 2022, enabling the Company to resume stock repurchases pursuant to the prior authorizations. From February 14, 2022, through March 31, 2022, we repurchased 108,368 of our ordinary shares for the aggregate amount of $25,000 (net of fees and commissions) pursuant to the authorizations. During fiscal 2021, we repurchased 35,000 of our ordinary shares for the aggregate amount of $5,047 (net of fees and commissions) pursuant to the authorizations. During fiscal 2020, we repurchased 273,259 of our ordinary shares for the aggregate amount of $40,000 (net of fees and commissions) pursuant to the authorizations. During fiscal 2022, we obtained 244,395 of our ordinary shares in the aggregate amount of $30,775 in connection with share based compensation award programs. During fiscal 2021, we obtained 91,567 of our ordinary shares in the aggregate amount of $9,599 in connection with share based compensation award programs. During fiscal 2020, we obtained 122,884 of our ordinary shares in the aggregate amount of $11,235 in connection with share based compensation award programs.

Share-Based Compensation

12 Months Ended

Mar. 31, 2022

Share-Based Payment Arrangement [Abstract]

Share-Based Compensation

14. SHARE-BASED COMPENSATION

We maintain a long-term incentive plan that makes available shares for grants, at the discretion of the Board of Directors or Compensation and Organizational Development Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. We satisfy share award incentives through the issuance of new ordinary shares.

Stock options provide the right to purchase our shares at the market price on the date of grant, or for options granted to employees in fiscal 2019 and thereafter, 110% of the market price on the date of grant, subject to the terms of the plan and agreements. Generally, one-fourth of the stock options granted to employees become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each year of employment after the grant date. As of March 31, 2022, 3,146,465 shares remained available for grant under the long-term incentive plan.

The fair value of share-based stock option compensation awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits.

The following weighted-average assumptions were used for options granted during fiscal 2022, fiscal 2021 and fiscal 2020:


	Fiscal 2022		Fiscal 2021		Fiscal 2020
Risk-free interest rate	1.10	%	0.46	%	2.26	%
Expected life of options	5.9 years		6.0 years		6.2 years
Expected dividend yield of stock	0.95	%	0.96	%	1.22	%
Expected volatility of stock	24.27	%	23.04	%	20.27	%

The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.85%, 2.78% and 2.77% was applied in fiscal 2022, 2021 and 2020 respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually.

A summary of share option activity is as follows:


	Number of Options	Weighted Average Exercise Price		Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at March 31, 2021	1,637,047	$	112.03
Granted	284,566	215.10
Exercised	(354,252)	77.79
Forfeited	(6,407)	165.10

Outstanding at March 31, 2022	1,560,954	$	138.37	6.7 years	$	161,397
Exercisable at March 31, 2022	854,998	$	104.64	5.5 years	$	117,243

We estimate that 692,204 of the non-vested stock options outstanding at March 31, 2022 will ultimately vest.

The aggregate intrinsic value in the table above represents the total pre-tax difference between the $241.77 closing price of our ordinary shares on March 31, 2022 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of our ordinary shares.

The total intrinsic value of stock options exercised during the years ended March 31, 2022, 2021 and 2020 was $52,952, $39,055 and $57,683, respectively. Net cash proceeds from the exercise of stock options were $10,071, $26,726 and $34,731 for the years ended March 31, 2022, 2021 and 2020, respectively. The tax benefit from stock option exercises was $18,143, $11,559 and $16,440 for the years ended March 31, 2022, 2021 and 2020, respectively.

The weighted average grant date fair value of stock option grants was $37.52, $27.66 and $23.52 for the years ended March 31, 2022, 2021 and 2020, respectively.

Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. As of May 24, 2021, we no longer have outstanding SARS. The fair value of the outstanding SARS as of March 31, 2021 and 2020 was $494, and $544, respectively. The fair value of outstanding SARS is revalued at each reporting date and the related liability and expense were adjusted appropriately.

A summary of the non-vested restricted share and restricted share unit activity is presented below:


	Number of Restricted Shares	Number of Restricted Share Units	Weighted-Average Grant Date Fair Value
Non-vested at March 31, 2021	533,323	29,500	$	121.35
Granted	165,376	21,759	198.14
Vested	(192,633)	(15,621)	95.71
Forfeited	(20,556)	(1,961)	167.88
Non-vested at March 31, 2022	485,510	33,677	$	157.37

Restricted shares and restricted share unit grants are valued based on the closing stock price at the grant date. The value of restricted shares and units that vested during fiscal 2022 was $19,890.

As of March 31, 2022, there was a total of $59,392 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plans. We expect to recognize the cost over a weighted average period of 2.1 years.

Cantel Share Based Compensation Plan

In connection with the June 2, 2021 acquisition of Cantel, outstanding, non-vested Cantel restricted share units were replaced with STERIS restricted share units.

A total 280,402 STERIS restricted share units replaced Cantel awards based on a ratio of one Cantel restricted share unit to 0.4262 STERIS restricted share units. These Cantel awards consisted of time and performance based awards. Cantel time based restricted share units were replaced with STERIS restricted share units with the same three-year pro-rata vesting terms based on the original award date. Performance based Cantel restricted share units were replaced with time based STERIS restricted share units that vest pro rata over the remaining one, two or three anniversaries from the original Cantel award date. The number of performance restricted share units was replaced based on the original target achievement level. All replacement restricted share units retained dividend accumulation rights.

The fair value of each STERIS restricted share unit awarded on June 2, 2021 to replace outstanding non-vested Cantel restricted share units was $191.18 based on the closing price of STERIS ordinary shares on June 2, 2021. Approximately $18,173 of the total $53,607 grant date fair value was attributable to pre-acquisition services provided and was recorded as a component of purchase consideration in connection with the acquisition of Cantel.

During fiscal 2022, recognition of unamortized share-based compensation expense totaling $20,200 was accelerated in connection with the termination of certain Cantel employees in fiscal 2022. As a result of the formal notices provided and the terms of the Cantel share based compensation plans and Cantel Executive Severance and Change of Control Plan, the restricted share units vested requiring acceleration of the remaining related compensation cost.

As of March 31, 2022, there was a total of $6,101 in unrecognized compensation cost related to non-vested STERIS restricted share units awarded to replace Cantel restricted share units. We expect to recognize the cost over a weighted average period of 1.1 years.

A summary of the non-vested restricted share units activity associated with the Cantel share-based compensation plans is presented below:


	Number of Restricted Share Units	Weighted-Average Grant Date Fair Value
Non-vested at March 31, 2021	—	$	—
Granted	280,402	191.18
Vested	(223,267)	191.18
Forfeited	(11,413)	191.18


Non-vested at March 31, 2022	45,722	$	191.18

Financial and Other Guarantees

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Product Warranty Disclosure [Text Block]

15. FINANCIAL AND OTHER GUARANTEES

We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary.

Changes in our warranty liability during the periods presented are as follows:


Years Ended March 31,	2022		2021		2020
Balance, Beginning of Year	$	9,406	$	7,381	$	7,194
Liabilities assumed in acquisition of Cantel	4,769		—		—
Warranties issued during the period	12,571		10,574		12,311
Settlements made during the period	(12,638)		(8,549)		(12,124)
Balance, End of Year	$	14,108	$	9,406	$	7,381

Forward and Swap Contracts

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Derivative Instruments and Hedging Activities Disclosure [Text Block]

16. DERIVATIVES AND HEDGING

From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. Further, we may hold forward foreign exchange contracts to hedge a portion of our expected non-U.S. dollar denominated earnings against our reporting currency, the U.S dollar. We do not use derivative financial instruments for speculative purposes. These contracts are not designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At March 31, 2022, we held a foreign currency forward contract to sell 11.0 million euros. At March 31, 2022, we held commodity swap contracts to buy 801.6 thousand pounds of nickel.


	Asset Derivatives				Liability Derivatives
	Fair Value at		Fair Value at		Fair Value at		Fair Value at
Balance Sheet Location	March 31, 2022		March 31, 2021		March 31, 2022		March 31, 2021
Prepaid & Other	$	2,780	$	57	$	—	$	—
Accrued expenses and other	—		—		198		367

The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:


	Location of (loss) gain recognized in income	Amount of (loss) gain recognized in income
		Years Ended March 31,
		2022		2021		2020
Foreign currency forward contracts	Selling, general and administrative	$	4,379	$	1,178	$	798
Commodity swap contracts	Cost of revenues	3,921		771		(660)

Fair Value Measurements

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Fair Value Disclosures [Text Block]

17. FAIR VALUE MEASUREMENTS

Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at March 31, 2022 and March 31, 2021:


						Fair Value Measurements
At March 31,	Carrying Value				Quoted Prices in Active Markets for Identical Assets					Significant Other Observable Inputs					Significant Unobservable Inputs
						Level 1					Level 2					Level 3
	2022		2021			2022		2021			2022		2021			2022		2021
Assets:
Cash and cash equivalents	$	348,320	$	220,531		$	348,320	$	220,531		$	—	$	—		$	—	$	—
Forward and swap contracts (1)	2,780		57			—		—			2,780		57			—		—
Equity investments (2)	8,520		10,301			8,520		10,301			—		—			—		—
Other investments	2,272		2,665			2,272		2,665			—		—			—		—
Liabilities:
Forward and swap contracts (1)	$	198	$	367		$	—	$	—		$	198	$	367		$	—	$	—
Deferred compensation plans (2)	1,240		1,715			1,240		1,715			—		—			—		—
Total debt (3)	3,088,356		1,650,540			—		—			2,991,680		1,722,459			—		—
Contingent consideration obligations (4)	10,550		19,642			—		—			—		—			10,550		19,642

(1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.

(2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allowed for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During fiscal 2022 and fiscal 2021, we recorded (losses) gains of $(775) and $594, respectively, related to these investments.

(3) We estimate the fair value of our debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. The fair values of our Senior Public Notes are estimated using quoted market prices for the publicly registered Senior Notes.

(4) Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

The changes in Level 3 assets and liabilities measured at fair value on a recurring basis are summarized as follows:


	Contingent Consideration
Balance at March 31, 2020	$	15,988
Additions	3,486
Payments	(984)
Reductions and adjustments	1,175
Foreign currency translation adjustments	(23)
Balance at March 31, 2021	$	19,642
Liabilities assumed in acquisition of Cantel	25,000
Additions	601
Payments	(32,336)
Adjustments	(2,350)
Foreign currency translation adjustments	(7)
Balance at March 31, 2022	$	10,550

Additions and payments of contingent consideration obligations during fiscal year 2022 and 2021 were primarily related to our fiscal year 2022 and 2021 acquisitions. Adjustments are recorded in the selling, general and administrative line of the Consolidated Statements of Income. Refer to Note 2, "Business Acquisitions and Divestitures" for more information.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Reclassifications out of AOCI (Notes)

12 Months Ended

Mar. 31, 2022

Reclassifications out of AOCI Equity [Abstract]

Reclassifications Out of AOCI [Text Block]

18. RECLASSIFICATIONS OUT OF ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Foreign Currency Translation is not adjusted for income taxes. Accumulated other comprehensive income (loss) shown in our Consolidated Statements of Shareholders' Equity and changes in our balances, net of tax, for the years ended March 31, 2022, 2021 and 2020 were as follows:


	Defined Benefit Plans (1)						Foreign Currency Translation (2)						Total Accumulated Other Comprehensive Income (Loss)
	2022		2021		2020		2022		2021		2020		2022		2021		2020
Beginning Balance	$	(5,519)	$	(6,813)	$	(4,204)	$	(55,724)	$	(228,650)	$	(155,574)	$	(61,243)	$	(235,463)	$	(159,778)
Other Comprehensive Income (Loss) before reclassifications	11,148		4,622		1,505		(155,360)		172,926		(73,076)		(144,212)		177,548		(71,571)
Reclassified from Accumulated Other Comprehensive Income (Loss)	(4,353)		(3,328)		(4,114)		—		—		—		(4,353)		(3,328)		(4,114)
Net current-period Other Comprehensive Income (Loss)	6,795		1,294		(2,609)		(155,360)		172,926		(73,076)		(148,565)		174,220		(75,685)
Ending Balance	$	1,276	$	(5,519)	$	(6,813)	$	(211,084)	$	(55,724)	$	(228,650)	$	(209,808)	$	(61,243)	$	(235,463)

(1) Amortization (gain) of defined benefit plan items are reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.

(2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.

Quarterly Results (Unaudited)

12 Months Ended

Mar. 31, 2022

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information [Text Block]

19. QUARTERLY RESULTS (UNAUDITED)


Quarters Ended	March 31,			December 31,			September 30,			June 30,
Fiscal 2022
Revenues:
Product	$	684,508		$	697,256		$	685,238		$	489,279
Service	526,178			511,715			511,747			479,143
Total Revenues	1,210,686			1,208,971			1,196,985			968,422
Cost of Revenues:
Product	347,242			373,793			427,484			271,406
Service	291,822			297,064			289,157			270,734
Total Cost of Revenues	639,064			670,857			716,641			542,140
Gross Profit	571,622			538,114			480,344			426,282
Percentage of Revenues	47.2		%	44.5		%	40.1		%	44.0		%

Net Income Attributable to Shareholders	$	52,261		$	143,623		$	69,811		$	(21,807)
Basic Income Per Ordinary Share Attributable to Shareholders:
Net income	$	0.52		$	1.44		$	0.70		$	(0.24)
Diluted Income Per Ordinary Share Attributable to Shareholders:
Net income	$	0.52		$	1.42		$	0.69		$	(0.24)

Fiscal 2021
Revenues:
Product	$	427,614		$	375,314		$	339,504		$	301,108
Service	445,917			433,610			416,628			367,824
Total Revenues	873,531			808,924			756,132			668,932
Cost of Revenues:
Product	231,658			202,881			175,798			154,739
Service	262,055			260,182			250,297			226,809
Total Cost of Revenues	493,713			463,063			426,095			381,548
Gross Profit	379,818			345,861			330,037			287,384
Percentage of Revenues	43.5		%	42.8		%	43.6		%	43.0		%

Net Income Attributable to Shareholders	$	87,443		$	114,501		$	105,858		$	89,598
Basic Income Per Ordinary Share Attributable to Shareholders:
Net income	$	1.02		$	1.34		$	1.24		$	1.05
Diluted Income Per Ordinary Share Attributable to Shareholders:
Net income	$	1.02		$	1.33		$	1.23		$	1.05

Schedule II - Valuation and Qualifying Accounts

12 Months Ended

Mar. 31, 2022

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure

SCHEDULE II – VALUATION AND QUALIFYING ACCOUNTS


Description	Balance at Beginning of Period		Charges to Costs and Expenses			Charges to Other Accounts			Deductions			Balance at End of Period
(in thousands)
Year ended March 31, 2022
Deducted from asset accounts:
Allowance for trade accounts receivable (1)	$	11,355	$	16,442		$	1,840	(3)	$	(5,266)	(4)	$	24,371
Inventory valuation reserve	19,778		10,931		(2)	228		(3)	—			30,937
Deferred tax asset valuation allowance	14,143		2,888			8,906		(3)	(1,246)			24,691
Recorded within liabilities:
Casualty loss reserves	$	23,283	$	7,069		$	44		$	(4,270)		$	26,126
Year ended March 31, 2021
Deducted from asset accounts:
Allowance for trade accounts receivable (1)	$	12,051	$	3,097		$	349	(3)	$	(4,142)	(4)	$	11,355
Inventory valuation reserve	16,149		4,423		(2)	(794)		(3)	—			19,778
Deferred tax asset valuation allowance	13,891		2,684			277		(3)	(2,709)			14,143
Recorded within liabilities:
Casualty loss reserves	$	23,228	$	5,550		$	2,542		$	(8,037)		$	23,283
Year ended March 31, 2020
Deducted from asset accounts:
Allowance for trade accounts receivable (1)	$	9,645	$	6,760		$	(247)	(3)	$	(4,107)	(4)	$	12,051
Inventory valuation reserve	19,754		(4,105)		(2)	500		(3)	—			16,149
Deferred tax asset valuation allowance	13,478		3,327			(1,927)		(3)	(987)			13,891
Recorded within liabilities:
Casualty loss reserves	$	19,742	$	6,000		$	3,007		$	(5,521)		$	23,228

(1) Net allowance for doubtful accounts and allowance for sales and returns.

(2) Provision for excess and obsolete inventory, net of inventory written off.

(3) Change in foreign currency exchange rates and acquired reserves.

(4) Uncollectible accounts written off, net of recoveries.

Nature of Operations and Summary of Significant Accounting Policies (Policies)

12 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Property, Plant and Equipment, Impairment [Policy Text Block]

Revenue from Contract with Customer [Policy Text Block]

We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less.

Refer to Note 11, titled "Business Segment Information" for disaggregation of revenue.

Product Revenues

Service Revenues

Contract Liabilities

Refer to Note 7, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances.

Service Liabilities

Refer to Note 7, titled "Additional Consolidated Balance Sheet Information" for Service liability balances.

Remaining Performance Obligations

Consolidation, Policy

Use of Estimates, Policy

Cash and Cash Equivalents, Policy

Trade and Other Accounts Receivable, Policy

Inventory, Policy

Property, Plant and Equipment, Policy

We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table:


Asset Type						Useful Life (years)
Land improvements						3-40
Buildings and leasehold improvements						2-50
Machinery and equipment						2-20
Information Systems						2-20
Radioisotope (cobalt-60)						20

Investment, Policy

Asset Retirement Obligation [Policy Text Block]

Business Combinations Policy

Foreign Currency Transactions and Translations Policy

Derivatives, Policy

Standard Product Warranty, Policy

Shipping and Handling Cost, Policy

Advertising Costs, Policy

Accounting Standards Update and Change in Accounting Principle

Recently Issued Accounting Standards Impacting the Company are presented in the following table:

Standard

Date of Issuance

Description

Date of Adoption

Effect on the financial statements or other significant matters

Standards that have been adopted in fiscal 2022

ASU 2019-12 "Income Taxes (Topic 740)"

December 2019

First Quarter Fiscal 2022

We adopted this standard effective April 1, 2021 with no material impact to our consolidated financial statements.

ASU 2020-06 "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)"

August 2020

First Quarter Fiscal 2022

We adopted this standard effective April 1, 2021 and applied it to our accounting for the convertible debt assumed in the acquisition of Cantel Medical LLC ("Cantel").

Standards that have not yet been adopted.

ASU 2021-08 "Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.

October 2021

We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.

Intangible Assets, Finite-Lived, Policy

Goodwill and Intangible Assets, Goodwill, Policy

Self Insurance Liabilities, Policy

Postemployment Benefit Plans, Policy

Fair Value Measurement, Policy

Research and Development Expense, Policy

Income Tax, Policy

Share-based Compensation, Option and Incentive Plans Policy

Costs Associated with Exit or Disposal Activity or Restructuring

Interest Expense, Policy

Contingencies Lease Policy (Policies)	12 Months Ended
Contingencies Lease Policy (Policies)	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Lessee, Leases [Policy Text Block]	Leases We lease manufacturing, warehouse and office space, service facilities, vehicles, equipment and communication systems. Certain leases contain options that provide us with the ability to extend the lease term. Such options are included in the lease term when it is reasonably certain that the option will be exercised. We made an accounting policy election to not recognize lease assets or lease liabilities for leases with a lease term of twelve months or less. We determine if an agreement contains a lease and classify our leases as operating or finance at the lease commencement date. Finance leases are generally those leases for which we will pay substantially all the underlying asset’s fair value or will use the asset for all or a major part of its economic life, including circumstances in which we will ultimately own the asset. Lease assets arising from finance leases are included in property, plant and equipment, net and the liabilities are included in other liabilities. For finance leases, we recognize interest expense using the effective interest method and we recognize amortization expense on the lease asset over the shorter of the lease term or the useful life of the asset. Our finance leases are not material as of March 31, 2022 and for the twelve month period then ended. Operating lease assets and liabilities are recognized at the commencement date of the lease based on the present value of lease payments over the lease term. Lease assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. As most leases do not provide an implicit interest rate, we estimate an incremental borrowing rate to determine the present value of lease payments. Our estimated incremental borrowing rate reflects a secured rate based on recent debt issuances, our estimated credit rating, lease term, as well as publicly available data for instruments with similar characteristics. For operating leases, we recognize lease cost on a straight-line basis over the term of the lease. When accounting for leases, we combine payments for leased assets, related services and other components of a lease.

Nature of Operations and Summary of Significant Accounting Policies (Tables)

12 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Cash Flow, Supplemental Disclosures

Information supplementing our Consolidated Statements of Cash Flows is as follows:


Years Ended March 31,	2022		2021		2020
Cash paid during the year for:
Interest	$	84,696	$	36,257	$	38,021
Income taxes	138,382		109,646		92,462
Cash received during the year for income tax refunds	4,605		4,631		4,378

Property, Plant and Equipment

Information related to the major categories of our depreciable assets is as follows:


March 31,	2022		2021
Land and land improvements (1)	$	84,015	$	69,477
Buildings and leasehold improvements	654,851		567,132
Machinery and equipment	903,649		779,044
Information systems	222,620		193,222
Radioisotope	597,641		565,681
Construction in progress (1)	356,013		211,381
Total property, plant, and equipment	2,818,789		2,385,937
Less: accumulated depreciation and depletion	(1,266,213)		(1,150,537)
Property, plant, and equipment, net	$	1,552,576	$	1,235,400

(1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Accounting Standards Update and Change in Accounting Principle

Recently Issued Accounting Standards Impacting the Company are presented in the following table:

Standard

Date of Issuance

Description

Date of Adoption

Effect on the financial statements or other significant matters

Standards that have been adopted in fiscal 2022

ASU 2019-12 "Income Taxes (Topic 740)"

December 2019

First Quarter Fiscal 2022

We adopted this standard effective April 1, 2021 with no material impact to our consolidated financial statements.

ASU 2020-06 "Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40)"

August 2020

First Quarter Fiscal 2022

We adopted this standard effective April 1, 2021 and applied it to our accounting for the convertible debt assumed in the acquisition of Cantel Medical LLC ("Cantel").

Standards that have not yet been adopted.

ASU 2021-08 "Business Combinations (Topic 805) Accounting for Contract Assets and Contract Liabilities from Contracts with Customers.

October 2021

We are in the process of evaluating the impact that the standard will have on our consolidated financial statements.

Useful lives of PPE table text block

We generally depreciate or deplete property, plant, and equipment over the useful lives presented in the following table:


Asset Type						Useful Life (years)
Land improvements						3-40
Buildings and leasehold improvements						2-50
Machinery and equipment						2-20
Information Systems						2-20
Radioisotope (cobalt-60)						20

Business Acquisitions and Divestitures Business Acquisitions and Divestitures (Tables)

12 Months Ended

Mar. 31, 2022

Business Combinations and Divestitures [Abstract]

Schedule of Finite-Lived Intangible Assets

The estimated useful lives are based on the historical experience of STERIS, available similar industry data and assumptions made by management.Values and useful lives are presented in the table below.

Total

Useful Life

Customer relationships

2,278,000

9-10 years

Trade names

422,000

11 years

Developed technology

222,000

9 years

Non-compete agreements

20,000

2 years

Total intangible assets acquired

2,942,000

Cantel Acquisition Consideration Paid

The total consideration for Cantel Common Stock and stock equivalents was $3,599,471. The consideration was comprised of the following:


(shares in thousands)
Cash consideration $16.93 per Cantel share (42,816 shares)	$	716,412
Cash consideration for fractional shares	14
STERIS plc ordinary shares 14,297 shares at ($188.07 per share)	2,689,317
Consideration related to Cantel equity compensation programs	18,173

Consideration related to equity component of Cantel convertible debt	175,555
Total purchase consideration	$	3,599,471

Schedule of Assets Acquired and Liabilities Assumed, Cantel Acquisition


	Cantel (1)
Cash	$	169,073
Accounts receivable	172,226
Inventory	249,221
Property, plant and equipment	267,360
Lease right-of-use assets	59,720
Other assets	72,864
Intangible assets	2,942,000
Goodwill	1,522,381
Total assets acquired	5,454,845
Convertible debt, par value	168,000
Other current liabilities	247,549
Long-term lease obligations	47,856
Deferred income taxes, net	670,685
Long-term indebtedness	721,284
Total liabilities assumed	1,855,374
Net assets acquired	$	3,599,471

(1) Purchase price allocation is preliminary as of March 31, 2022, as valuations have not been finalized.

Business Acquisition, Pro Forma Information [Table Text Block]


	Fiscal Year Ended March 31,
	(unaudited)
	2022		2021
Net revenues	$	4,790,161	$	4,190,244
Net income from continuing operations	449,382		5,849

Business Combination Assets Acquired and Liabilities Assumed

The table below summarizes the allocation of the purchase price to the net assets acquired based on fair values at the acquisition dates for our fiscal 2022, 2021 and 2020 acquisitions.


	Fiscal Year 2022(1)		Fiscal Year 2021				Fiscal Year 2020
(dollars in thousands)	Other Acquisitions (Excluding Cantel)		Key Surgical		Other Acquisitions		All Acquisitions
Cash	$	—	$	12,615	$	9,159	$	8,811
Accounts receivable	—		13,967		9,621		10,331
Inventory	—		21,414		22,123		8,999
Property, plant and equipment	—		6,030		26,363		9,241
Lease right-of-use assets, net	—		4,907		4,420		4,462
Other assets	—		6,680		3,378		1,133
Intangible assets (2)	1,578		356,999		28,188		36,500
Goodwill	1,602		527,675		42,808		74,531
Total assets	3,180		950,287		146,060		154,008
Current liabilities	(34)		(21,599)		(28,245)		(20,659)
Non-current liabilities	—		(62,870)		(9,704)		(4,000)
Total liabilities	(34)		(84,469)		(37,949)		(24,659)
Net assets	$	3,146	$	865,818	$	108,111	$	129,349

(1) Purchase price allocation is still preliminary as of March 31, 2022, as valuations have not been finalized, pending further analyses of the significant drivers of fair value.

Goodwill and Intangible Assets (Tables)

12 Months Ended

Mar. 31, 2022

Goodwill and Intangible Assets Disclosure [Abstract]

Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Table Text Block]

Information regarding our intangible assets is as follows:


	2022				2021
March 31,	Gross Carrying Amount (1)		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Customer relationships	$	3,117,314	$	539,845	$	968,040	$	291,802
Non-compete agreements	23,571		12,392		5,401		4,169
Patents and technology	518,714		211,822		318,424		171,952
Trademarks and tradenames	470,919		74,455		78,058		42,867
Supplier relationships	54,800		18,267		54,800		15,527

Total	$	4,185,318	$	856,781	$	1,424,723	$	526,317

Schedule of Goodwill [Table Text Block]

Changes to the carrying amount of goodwill for the years ended March 31, 2022 and 2021 were as follows:


	Healthcare Segment		Applied Sterilization Technologies Segment		Life Sciences Segment		Dental		Total
Balance at March 31, 2020	827,266		1,380,262		148,557		—		2,356,085
Goodwill acquired or allocated	536,713		33,770		—		—		570,483

Foreign currency translation adjustments and other	20,784		78,207		490		—		99,481
Balance at March 31, 2021	$	1,384,763	$	1,492,239	$	149,047	$	—	$	3,026,049
Cantel goodwill acquired (1)	1,019,332		—		30,356		472,693		1,522,381
Measurement period adjustments to acquired goodwill	(6,533)		(9,286)		—		—		(15,819)

Divestitures	(7,000)		—		—		—		(7,000)
Foreign currency translation adjustments and other	(63,732)		(50,095)		(115)		(7,326)		(121,268)
Balance at March 31, 2022	$	2,326,830	$	1,432,858	$	179,288	$	465,367	$	4,404,343

(1) Amounts are still preliminary, as Cantel acquisition valuations have not been finalized.

Schedule of Expected Amortization Expense

Based upon the current amount of intangible assets subject to amortization, the amortization expense for each of the five succeeding fiscal years is estimated to be as follows:


	2023		2024		2025		2026		2027
Estimated amortization expense	$	384,258	$	370,549	$	364,488	$	355,475	$	349,116

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (e)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1A
-URI https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 2
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267

Reference 11: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 55
-Paragraph 24
-URI https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267

+ Details

Inventories, Net (Tables)

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Schedule of Inventory, Current

Components of our inventories are presented in the following table.


March 31,	2022		2021

Raw materials	$	195,035	$	103,939
Work in process	76,021		54,283
Finished goods	334,880		176,623

Reserve for excess and obsolete inventory	(30,937)		(19,778)
Inventories, net	$	574,999	$	315,067

Property, Plant and Equipment (Tables)

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Schedule of Change in Asset Retirement Obligation [Table Text Block]

The following table summarizes the activity in the liability for asset retirement obligations.


	Asset Retirement Obligations
Balance at March 31, 2020	$	12,514
Liabilities incurred during the period	859
Liabilities settled during the period	(251)
Accretion expense and change in estimate	137
Foreign currency and other	71
Balance at March 31, 2021	$	13,330
Liabilities incurred during the period	86
Liabilities settled during the period	(3)
Accretion expense and change in estimate	146
Foreign currency and other	(16)
Balance at March 31, 2022	$	13,543

Property, Plant and Equipment

Information related to the major categories of our depreciable assets is as follows:


March 31,	2022		2021
Land and land improvements (1)	$	84,015	$	69,477
Buildings and leasehold improvements	654,851		567,132
Machinery and equipment	903,649		779,044
Information systems	222,620		193,222
Radioisotope	597,641		565,681
Construction in progress (1)	356,013		211,381
Total property, plant, and equipment	2,818,789		2,385,937
Less: accumulated depreciation and depletion	(1,266,213)		(1,150,537)
Property, plant, and equipment, net	$	1,552,576	$	1,235,400

(1) Land is not depreciated. Construction in progress is not depreciated until placed in service.

Debt (Tables)

12 Months Ended

Mar. 31, 2022

Debt Disclosure [Abstract]

Senior Notes in Private Placement [Table Text Block]


	Applicable Note Purchase Agreement	Maturity Date	U.S. Dollar Value at March 31, 2022		U.S. Dollar Value at March 31, 2021
$91,000 Senior notes at 3.20%	2012 Private Placement	December 2022	91,000		91,000
$80,000 Senior notes at 3.35%	2012 Private Placement	December 2024	80,000		80,000
$25,000 Senior notes at 3.55%	2012 Private Placement	December 2027	25,000		25,000
$125,000 Senior notes at 3.45%	2015 Private Placement	May 2025	125,000		125,000
$125,000 Senior notes at 3.55%	2015 Private Placement	May 2027	125,000		125,000
$100,000 Senior notes at 3.70%	2015 Private Placement	May 2030	100,000		100,000
$50,000 Senior notes at 3.93%	2017 Private Placement	February 2027	50,000		50,000
€60,000 Senior notes at 1.86%	2017 Private Placement	February 2027	66,815		70,426
$45,000 Senior notes at 4.03%	2017 Private Placement	February 2029	45,000		45,000
€20,000 Senior notes at 2.04%	2017 Private Placement	February 2029	22,271		23,475
£45,000 Senior notes at 3.04%	2017 Private Placement	February 2029	59,089		61,863
€19,000 Senior notes at 2.30%	2017 Private Placement	February 2032	21,158		22,302
£30,000 Senior notes at 3.17%	2017 Private Placement	February 2032	39,393		41,242
Total Senior Notes			$	849,726	$	860,308

Schedule of Maturities of Long-term Debt [Table Text Block]

The combined annual aggregate amount of maturities of our outstanding debt by fiscal year is as follows:


2023	$	142,875
2024	60,000
2025	165,937
2026	341,408
2027 and thereafter	2,403,414
Total	$	3,113,634

Schedule of Debt

Indebtedness as of March 31, 2022 and 2021 was as follows:


	March 31, 2022		March 31, 2021



Short-term debt
Term loan, current portion	$	27,500	$	—
Delayed draw term loan, current portion	24,375		—
Private Placement Senior Notes	91,000		—
Total short-term debt	$	142,875	$	—


Long-term debt
Private Placement Senior Notes	$	758,726	$	860,308
Revolving Credit Facility	58,908		247,423
Deferred financing costs	(25,278)		(7,191)
Term loan	177,500		550,000
Delayed draw term loan	625,625		—
Senior Public Notes	1,350,000		—
Total long-term debt	$	2,945,481	$	1,650,540
Total debt	$	3,088,356	$	1,650,540

Additional Consolidated Balance Sheets Information (Tables)

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Schedule of Accrued Liabilities

Additional information related to our Consolidated Balance Sheet is as follows:


March 31,	2022		2021
Accrued payroll and other related liabilities:
Compensation and related items	$	71,878	$	47,157
Accrued vacation/paid time off	13,669		12,389
Accrued bonuses	64,702		62,530
Accrued employee commissions	30,171		24,022
Other post-retirement benefits obligations-current portion	1,190		1,326
Other employee benefit plans' obligations-current portion	2,111		2,654
Total accrued payroll and other related liabilities	$	183,721	$	150,078
Accrued expenses and other:
Deferred revenues	$	110,791	$	62,492
Service liabilities	51,365		46,720
Self-insured and related risk reserves-current portion	8,995		8,095
Accrued dealer commissions	31,700		27,348
Accrued warranty	14,108		9,406
Asset retirement obligation-current portion	1,181		1,193

Other	88,404		65,303
Total accrued expenses and other	$	306,544	$	220,557
Other liabilities:
Self-insured risk reserves-long-term portion	$	19,213	$	17,295
Other post-retirement benefits obligations-long-term portion	7,335		8,690
Defined benefit pension plans obligations-long-term portion	1,772		3,748
Other employee benefit plans obligations-long-term portion	1,360		2,353
Accrued long-term income taxes	12,225		13,241
Asset retirement obligation-long-term portion	12,362		12,137
Other	21,312		30,546
Total other liabilities	$	75,579	$	88,010

Income Tax Expense (Tables)

12 Months Ended

Mar. 31, 2022

Income Tax Expense [Abstract]

Schedule of Deferred Tax Assets and Liabilities

The significant components of the deferred tax assets and liabilities recorded in our accompanying balance sheets at March 31, 2022 and 2021 were as follows:


March 31,	2022		2021

Deferred Tax Assets:
Post-retirement benefit accrual	$	2,086	$	2,422
Compensation	14,340		13,208
Net operating loss carryforwards	25,550		15,151
Accrued expenses	12,092		6,360
Insurance	2,561		3,348
Deferred income	20,688		10,281
Bad debt	2,187		1,661
Pension	—		1,574
Operating leases (1)	44,401		34,020
Foreign tax credit carryforwards	36,036		—
Other	8,579		8,603
Deferred Tax Assets	168,520		96,628
Less: Valuation allowance	24,691		14,143
Total Deferred Tax Assets	143,829		82,485
Deferred Tax Liabilities:
Depreciation and depletion	110,951		73,344
Operating leases (1)	43,593		33,401
Intangibles	755,980		199,242
Pension	2,004		—
Other	3,473		3,833
Total Deferred Tax Liabilities	916,001		309,820
Net Deferred Tax Assets (Liabilities)	$	(772,172)	$	(227,335)

Schedule of Income before Income Tax, Domestic and Foreign

Income from continuing operations before income taxes was as follows:


Years Ended March 31,	2022		2021		2020

United States operations	$	79,662	$	326,991	$	325,595
Ireland operations	88,078		73,442		29,543
Other locations operations	146,763		117,100		143,616
	$	314,503	$	517,533	$	498,754

Schedule of Components of Income Tax Expense (Benefit)

The components of the provision for income taxes related to income from continuing operations consisted of the following:


Years Ended March 31,	2022		2021		2020

Current:
United States federal	$	88,158	$	57,550	$	42,032
United States state and local	21,438		16,272		9,971
Ireland	12,002		9,244		5,036
Other locations	53,354		36,699		24,600
	174,952		119,765		81,639
Deferred:
United States federal	(73,833)		7,523		10,089
United States state and local	(17,124)		(550)		2,366
Ireland	(739)		(787)		(899)
Other locations	(11,623)		(5,288)		(2,300)
	(103,319)		898		9,256
Total Provision for Income Taxes	$	71,633	$	120,663	$	90,895

provision for taxes rate reconciliation

The total provision for income taxes can be reconciled to the tax computed at the Ireland statutory tax rate as follows:


Years Ended March 31,	2022		2021		2020
National statutory tax rate	12.5	%	12.5	%	12.5	%
Increase (decrease) in accruals for uncertain tax positions	0.2	%	(0.1)	%	(0.3)	%
U.S. state and local taxes, net of federal income tax benefit	1.4	%	2.4	%	2.0	%
Increase in valuation allowances	0.9	%	0.3	%	0.5	%
U.S. research and development credit	(0.8)	%	(0.5)	%	(0.5)	%
U.S. foreign income tax credit	(1.1)	%	(0.3)	%	(0.6)	%
Difference in non-Ireland tax rates	12.6	%	8.3	%	6.9	%
U.S. federal audit adjustments	—	%	2.1	%	—	%
Excess tax benefit for equity compensation	(5.1)	%	(1.9)	%	(2.8)	%
Tax rate changes on deferred tax assets and liabilities	2.3	%	0.4	%	0.1	%
U.S. tax reform impact, GILTI and FDII	(0.9)	%	(0.6)	%	0.1	%

Capitalized acquisition, redomiciliation costs	1.8	%	0.6	%	0.1	%
All other, net	(1.0)	%	0.1	%	0.2	%
Total Provision for Income Taxes	22.8	%	23.3	%	18.2	%

Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible

A reconciliation of the beginning and ending balances of the total amounts of unrecognized tax benefits is as follows:


	2022		2021
Unrecognized Tax Benefits Balance at April 1	$	2,295	$	875
Increases for tax provisions of current year	—		655
Decreases for tax provisions of prior year	(135)		(896)
Balances related to acquired/disposed businesses	746		1,640
Other, including currency translation	—		21


Unrecognized Tax Benefits Balance at March 31	$	2,906	$	2,295

Benefit Plans (Tables)

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Schedule of Expected Benefit Payments

Based upon the actuarial assumptions utilized to develop our benefit obligations at March 31, 2022, the following benefit payments are expected to be made to plan participants:


	Other Defined Benefit Pension Plans		Other Post-Retirement Benefits Plan
2023	$	5,560	$	1,190
2024	5,542		1,067
2025	5,721		966
2026	5,882		880
2027	6,060		788
2028-2033	33,250		2,871

Schedule of Accrued Liabilities

Amounts recognized in the consolidated balance sheets consist of the following:


	Defined Benefit Pension Plans				Other Post-Retirement Benefits Plan
	2022		2021		2022		2021

Non-current assets	$	14,172	$	—	$	—	$	—
Current liabilities	—		—		(1,190)		(1,326)
Non-current liabilities	(1,772)		(3,748)		(7,335)		(8,690)
Net assets (liabilities)	$	12,400	$	(3,748)	$	(8,525)	$	(10,016)

Schedule of Accumulated and Projected Benefit Obligations


	Defined Benefit Pension Plans
		2022		2021
Aggregate fair value of plan assets		$	142,172	$	145,452
Aggregate accumulated benefit obligations		129,772		149,200
Aggregate projected benefit obligations		129,772		149,200

Components of Net Periodic Benefits Cost and Other Amounts Recognized in Other Comprehensive Income [Table Text Block]

Components of the annual net periodic benefit cost of our defined benefit pension plans and our other post-retirement benefits plan were as follows:


	Defined Benefit Pension Plans						Other Post-Retirement Benefits Plan
	2022		2021		2020		2022		2021		2020
Service cost	$	1,616	$	1,357	$	1,380	$	—	$	—	$	—
Interest cost	2,699		2,628		2,876		232		317		409
Expected return on plan assets	(4,412)		(3,463)		(4,735)		—		—		—
Prior service cost recognition	61		71		69		(267)		(3,263)		(3,263)
Net amortization and deferral	18		21		9		444		439		482
Curtailments/settlements	(31)		—		—
Net periodic benefit (credit) cost	$	(49)	$	614	$	(401)	$	409	$	(2,507)	$	(2,372)
Recognized in other comprehensive loss (income) before tax:
Net loss (gain) occurring during year	$	(11,028)	$	(1,635)	$	890	$	640	$	114	$	(181)
Amortization of prior service credit	(222)		(85)		(78)		267		3,263		3,263
Amortization of net loss	—		7		—		(444)		(439)		(482)

Total recognized in other comprehensive loss (income)	(11,250)		(1,713)		812		463		2,938		2,600
Total recognized in total benefits cost and other comprehensive loss (income)	$	(11,299)	$	(1,099)	$	411	$	872	$	431	$	228

Schedule of Net Benefit Costs

The following table presents significant assumptions used to determine the net periodic benefit costs for the years ended March 31:


	2022		2021		2020
Discount Rate:
Synergy Health plc Retirement Benefits Scheme	2.10	%	2.40	%	2.50	%
Isotron BV Pension Plan	0.90	%	1.60	%	1.20	%
Synergy Health Daniken AG	1.00	%	0.70	%	0.20	%
Synergy Health Radeberg	1.50	%	1.50	%	1.60	%
Synergy Health Allershausen	2.00	%	1.75	%	1.75	%
Harwell Dosimeters Ltd Retirement Benefits Scheme	2.85	%	2.15	%	2.45	%
Other post-retirement plan	2.50	%	3.00	%	3.50	%
Expected Return on Plan Assets:
Synergy Health plc Retirement Benefits Scheme	3.60	%	3.50	%	4.80	%
Isotron BV Pension Plan	0.90	%	1.60	%	1.20	%
Synergy Health Daniken AG	1.00	%	0.70	%	0.65	%

Schedule of Assumptions Used

The following table presents significant assumptions used to determine the projected benefit obligations at March 31:


	2022		2021
Discount Rate:

Synergy Health plc Retirement Benefits Scheme	2.80	%	2.10	%

Isotron BV Pension Plan	1.80	%	0.90	%
Synergy Health Daniken AG	0.90	%	0.35	%
Synergy Health Radeberg	1.60	%	1.60	%
Synergy Health Allershausen	1.50	%	0.80	%
Harwell Dosimeters Ltd Retirement Benefits Scheme	2.85	%	2.15	%
Other post-retirement plan	3.25	%	2.50	%

Schedule of Health Care Cost Trend Rates

The assumed rates of increase generally decline ratably over a five-year period from the assumed current year healthcare cost trend rate to the assumed long-term healthcare cost trend rate noted below.


	2022		2021		2020
Healthcare cost trend rate – medical	7.00	%	7.00	%	6.75	%
Healthcare cost trend rate – prescription drug	7.00	%	7.00	%	6.75	%
Long-term healthcare cost trend rate	4.50	%	4.50	%	4.50	%

To determine the healthcare cost trend rates, we evaluate a combination of information, including ongoing claims cost monitoring, annual statistical analyses of claims data, reconciliation of forecasted claims against actual claims, review of trend assumptions of other plan sponsors and national health trends, and adjustments for plan design changes, workforce changes, and changes in plan participant behavior.

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The fair value of our pension benefits plan assets at March 31, 2022 and 2021 by asset category is as follows:


	Fair Value Measurements at March 31, 2022
(In thousands)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Cash	$	559	$	559			$	—
Insured annuities	14,231		—		14,231		—
Insurance contracts	5,383		—		—		5,383
Common and collective trusts valued at net asset value:
Equity security trusts	66,416		—		—		—
Debt security trusts	55,583		—		—		—
Total Plan Assets	$	142,172	$	559	$	14,231	$	5,383


	Fair Value Measurements at March 31, 2021
(In thousands)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Other Unobservable Inputs (Level 3)
Cash	$	657	$	657	$	—	$	—
Insured annuities	17,950		—		17,950		—
Insurance contracts	5,555		—		—		5,555
Common and collective trusts valued at net asset value:
Equity security trusts	60,960		—		—		—
Debt security trusts	60,330		—		—		—

Total Plan Assets	$	145,452	$	657	$	17,950	$	5,555

Schedule of Defined Benefit Plans Disclosures


	Defined Benefit Pension Plans				Other Post-Retirement Benefits Plan
	2022		2021		2022		2021
Change in Benefit Obligations:
Benefit Obligations at Beginning of Year	$	149,200	$	123,190	$	10,016	$	11,368

Service cost	1,616		1,357		—		—

Interest cost	2,820		2,816		232		317
Actuarial loss (gain)	(12,177)		12,622		(640)		(114)
Benefits and expenses	(5,375)		(4,714)		(1,083)		(1,555)
Employee contributions	897		1,031		—		—
Curtailments/settlements	(1,334)		—		—		—
Impact of foreign currency exchange rate changes	(5,875)		12,898		—		—
Benefit Obligations at End of Year	129,772		149,200		8,525		10,016
Change in Plan Assets:
Fair Value of Plan Assets at Beginning of Year	145,452		112,203		—		—

Actual return on plan assets	3,421		19,252		—		—
Employer contributions	5,533		5,329		1,083		1,555
Employee contributions	897		1,031		—		—
Benefits and expenses paid	(5,325)		(4,714)		(1,083)		(1,555)
Curtailments/settlements	(1,334)		—		—		—
Impact of foreign currency exchange rate changes	(6,472)		12,351		—		—
Fair Value of Plan Assets at End of Year	142,172		145,452		—		—
Funded Status of the Plans	$	12,400	$	(3,748)	$	(8,525)	$	(10,016)

Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]

The fair value measurement of plan assets using significant unobservable inputs (Level 3) changed during fiscal year 2022 due to the following:


	Insurance contracts
Balance at March 31, 2020	$	4,345
Gains (losses) related to assets still held at year-end	197
Transfers out of Level 3	853
Foreign currency	160
Balance at March 31, 2021	$	5,555
Gains (losses) related to assets still held at year-end	(115)
Transfers out of Level 3	(210)
Foreign currency	153
Balance at March 31, 2022	$	5,383

Contingencies lease tables (Tables)

12 Months Ended

Mar. 31, 2022

Leases [Abstract]

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

Maturities of lease liabilities at March 31, 2022 are as follows:


	March 31, 2022
2023	$	42,099
2024	34,669
2025	26,914
2026	21,419
2027 and thereafter	104,769
Total operating lease payments	229,870
Less imputed interest	38,342
Total operating lease liabilities	$	191,528

Supplemental information related to operating leases is as follows:


	March 31,		March 31,
	2022		2021
Weighted-average remaining lease term of operating leases	9.6 years		11.6 years

Weighted-average discount rate of operating leases	3.4	%	4.1	%

Lessee, Supplemental Cash Flow Information

Supplemental cash flow information related to operating leases is as follows:


	Year Ended March 31, 2022		Year Ended March 31, 2021
Cash paid for amounts included in the measurement of operating lease liabilities	$	45,144	$	29,808
Right-of-use assets obtained in exchange for operating lease obligations, net	$	79,241	$	30,574

Lease, Cost

The components of operating lease expense are as follows:


	Year Ended March 31, 2022		Year Ended March 31, 2021
Fixed operating lease expense	$	45,158	$	31,087
Variable operating lease expense	12,659		9,326
Total operating lease expense	$	57,817	$	40,413

Business Segment Information (Tables)

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Schedule of Segment Reporting Information, by Segment


Years Ended March 31,	2022		2021		2020
Revenues:
Healthcare	$	2,845,467	$	1,954,055	$	1,986,809
Applied Sterilization Technologies	852,972		685,912		627,147
Life Sciences	524,964		467,552		416,939
Dental	361,661		—		—
Total revenues	$	4,585,064	$	3,107,519	$	3,030,895
Operating income (loss):
Healthcare	626,098		427,089		420,709
Applied Sterilization Technologies	410,101		310,648		270,917
Life Sciences	216,188		180,796		144,088
Dental	84,441		—		—

Corporate	(260,059)		(219,153)		(207,015)
Total operating income before adjustments	$	1,076,769	$	699,380	$	628,699
Less: Adjustments
Amortization of acquired intangible assets (1)	366,434		83,892		71,675
Acquisition and integration related charges (2)	205,788		35,634		8,225
Redomiciliation and tax restructuring costs (3)	301		1,592		3,699
(Gain) on fair value adjustment of acquisition related contingent consideration (1)	(2,350)		(500)		—
Net (gain) loss on divestiture of businesses (1)	(874)		2,030		1,770
Amortization of inventory and property "step up" to fair value (1)	81,804		5,600		2,392
COVID-19 incremental costs (4)	—		25,793		749
Restructuring charges (credit) (5)	48		(3,029)		3,143
Total operating income	$	425,618	$	548,368	$	537,046

(1) For more information regarding our recent acquisitions and divestitures refer to Note 2 titled, "Business Acquisitions and Divestitures."

(2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions.

(3) Costs incurred in tax restructuring.

(5) For more information regarding our restructuring efforts refer to our Annual Report on Form 10-K for the year ended March 31, 2021, dated May 28, 2021.


March 31,	2022		2021
Assets (1)
Healthcare and Life Sciences	$	6,604,893	$	3,600,182
Applied Sterilization Technologies	3,053,116		2,974,289
Dental	1,765,585		—
Total assets	$	11,423,594	$	6,574,471


Years Ended March 31,	2022		2021		2020
Capital Expenditures
Healthcare and Life Sciences	$	84,487	$	74,446	$	84,648
Applied Sterilization Technologies	198,350		164,816		129,868
Dental	4,726		—		—
Total Capital Expenditures	$	287,563	$	239,262	$	214,516
Depreciation, Depletion, and Amortization (2)
Healthcare and Life Sciences	$	316,222	$	106,266	$	92,193
Applied Sterilization Technologies	115,925		112,971		105,042
Dental	120,957		—		—
Total Depreciation, Depletion, and Amortization	$	553,104	$	219,237	$	197,235

(1) Amounts are still preliminary, as Cantel acquisition valuations have not been finalized.

Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area


March 31,	2022		2021
Property, Plant, and Equipment, Net (1)
Ireland	$	60,275	$	52,140
United States	881,057		673,784
Other locations	611,244		509,476
Property, Plant, and Equipment, Net	$	1,552,576	$	1,235,400

(1) Amounts are still preliminary, as Cantel acquisition valuations have not been finalized.

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]


Years Ended March 31,	2022		2021		2020
Revenues:
Ireland	$	82,011	$	71,905	$	63,821
United States	3,228,864		2,227,038		2,211,722
Other locations	1,274,189		808,576		755,352
Total Revenues	$	4,585,064	$	3,107,519	$	3,030,895

Revenue from External Customers by Products and Services [Table Text Block]


Years Ended March 31,	2022		2021		2020
Healthcare:
Capital equipment	$	782,505	$	588,864	$	617,712
Consumables	1,004,605		510,946		486,425
Service	1,058,357		854,245		882,672
Total Healthcare Revenues	$	2,845,467	$	1,954,055	$	1,986,809



Total Applied Sterilization Technologies Service Revenues	$	852,972	$	685,912	$	627,147
Life Sciences:
Capital equipment	$	142,281	$	128,356	$	112,747
Consumables	239,365		215,005		185,904
Service	143,318		124,191		118,288
Total Life Sciences Revenues	$	524,964	467,552		416,939
Dental Revenues	$	361,661	$	—	$	—
Total Revenues	$	4,585,064	$	3,107,519	$	3,030,895

Common Shares (Tables)

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Schedule of Weighted Average Number of Shares [Table Text Block]


Years ended March 31,	2022	2021	2020
Denominator (shares in thousands):
Weighted average shares outstanding—basic	97,535	85,203	84,778
Dilutive effect of share equivalents	791	695	863
Weighted average shares outstanding and share equivalents—diluted	98,326	85,898	85,641

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]


Years ended March 31,	2022	2021	2020
Number of ordinary share options (shares in thousands)	243	348	285

Share-Based Compensation (Tables)

12 Months Ended

Mar. 31, 2022

Share-Based Payment Arrangement [Abstract]

Schedule of Assumptions Used

The following weighted-average assumptions were used for options granted during fiscal 2022, fiscal 2021 and fiscal 2020:


	Fiscal 2022		Fiscal 2021		Fiscal 2020
Risk-free interest rate	1.10	%	0.46	%	2.26	%
Expected life of options	5.9 years		6.0 years		6.2 years
Expected dividend yield of stock	0.95	%	0.96	%	1.22	%
Expected volatility of stock	24.27	%	23.04	%	20.27	%

Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding

A summary of share option activity is as follows:


	Number of Options	Weighted Average Exercise Price		Average Remaining Contractual Term	Aggregate Intrinsic Value
Outstanding at March 31, 2021	1,637,047	$	112.03
Granted	284,566	215.10
Exercised	(354,252)	77.79
Forfeited	(6,407)	165.10

Outstanding at March 31, 2022	1,560,954	$	138.37	6.7 years	$	161,397
Exercisable at March 31, 2022	854,998	$	104.64	5.5 years	$	117,243

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

A summary of the non-vested restricted share and restricted share unit activity is presented below:


	Number of Restricted Shares	Number of Restricted Share Units	Weighted-Average Grant Date Fair Value
Non-vested at March 31, 2021	533,323	29,500	$	121.35
Granted	165,376	21,759	198.14
Vested	(192,633)	(15,621)	95.71
Forfeited	(20,556)	(1,961)	167.88
Non-vested at March 31, 2022	485,510	33,677	$	157.37

Share-Based Payment Arrangement, Activity

A summary of the non-vested restricted share units activity associated with the Cantel share-based compensation plans is presented below:


	Number of Restricted Share Units	Weighted-Average Grant Date Fair Value
Non-vested at March 31, 2021	—	$	—
Granted	280,402	191.18
Vested	(223,267)	191.18
Forfeited	(11,413)	191.18


Non-vested at March 31, 2022	45,722	$	191.18

Financial and Other Guarantees (Tables)

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Schedule of Guarantor Obligations

Changes in our warranty liability during the periods presented are as follows:


Years Ended March 31,	2022		2021		2020
Balance, Beginning of Year	$	9,406	$	7,381	$	7,194
Liabilities assumed in acquisition of Cantel	4,769		—		—
Warranties issued during the period	12,571		10,574		12,311
Settlements made during the period	(12,638)		(8,549)		(12,124)
Balance, End of Year	$	14,108	$	9,406	$	7,381

Forward and Swap Contracts (Tables)

12 Months Ended

Mar. 31, 2022

Notes To Financial Statements [Abstract]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value


	Asset Derivatives				Liability Derivatives
	Fair Value at		Fair Value at		Fair Value at		Fair Value at
Balance Sheet Location	March 31, 2022		March 31, 2021		March 31, 2022		March 31, 2021
Prepaid & Other	$	2,780	$	57	$	—	$	—
Accrued expenses and other	—		—		198		367

Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance

The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:


	Location of (loss) gain recognized in income	Amount of (loss) gain recognized in income
		Years Ended March 31,
		2022		2021		2020
Foreign currency forward contracts	Selling, general and administrative	$	4,379	$	1,178	$	798
Commodity swap contracts	Cost of revenues	3,921		771		(660)

Fair Value Measurements (Tables)

12 Months Ended

Mar. 31, 2022

Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Fair Value, Measurement Inputs, Disclosure [Table Text Block]

The following table shows the fair value of our financial assets and liabilities at March 31, 2022 and March 31, 2021:


						Fair Value Measurements
At March 31,	Carrying Value				Quoted Prices in Active Markets for Identical Assets					Significant Other Observable Inputs					Significant Unobservable Inputs
						Level 1					Level 2					Level 3
	2022		2021			2022		2021			2022		2021			2022		2021
Assets:
Cash and cash equivalents	$	348,320	$	220,531		$	348,320	$	220,531		$	—	$	—		$	—	$	—
Forward and swap contracts (1)	2,780		57			—		—			2,780		57			—		—
Equity investments (2)	8,520		10,301			8,520		10,301			—		—			—		—
Other investments	2,272		2,665			2,272		2,665			—		—			—		—
Liabilities:
Forward and swap contracts (1)	$	198	$	367		$	—	$	—		$	198	$	367		$	—	$	—
Deferred compensation plans (2)	1,240		1,715			1,240		1,715			—		—			—		—
Total debt (3)	3,088,356		1,650,540			—		—			2,991,680		1,722,459			—		—
Contingent consideration obligations (4)	10,550		19,642			—		—			—		—			10,550		19,642

Fair Value, by Balance Sheet Grouping [Table Text Block]

The changes in Level 3 assets and liabilities measured at fair value on a recurring basis are summarized as follows:


	Contingent Consideration
Balance at March 31, 2020	$	15,988
Additions	3,486
Payments	(984)
Reductions and adjustments	1,175
Foreign currency translation adjustments	(23)
Balance at March 31, 2021	$	19,642
Liabilities assumed in acquisition of Cantel	25,000
Additions	601
Payments	(32,336)
Adjustments	(2,350)
Foreign currency translation adjustments	(7)
Balance at March 31, 2022	$	10,550

- Definition

Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.

+ References + Details

Reclassifications out of AOCI (Tables)

12 Months Ended

Mar. 31, 2022

Reclassifications out of AOCI Equity [Abstract]

Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]


	Defined Benefit Plans (1)						Foreign Currency Translation (2)						Total Accumulated Other Comprehensive Income (Loss)
	2022		2021		2020		2022		2021		2020		2022		2021		2020
Beginning Balance	$	(5,519)	$	(6,813)	$	(4,204)	$	(55,724)	$	(228,650)	$	(155,574)	$	(61,243)	$	(235,463)	$	(159,778)
Other Comprehensive Income (Loss) before reclassifications	11,148		4,622		1,505		(155,360)		172,926		(73,076)		(144,212)		177,548		(71,571)
Reclassified from Accumulated Other Comprehensive Income (Loss)	(4,353)		(3,328)		(4,114)		—		—		—		(4,353)		(3,328)		(4,114)
Net current-period Other Comprehensive Income (Loss)	6,795		1,294		(2,609)		(155,360)		172,926		(73,076)		(148,565)		174,220		(75,685)
Ending Balance	$	1,276	$	(5,519)	$	(6,813)	$	(211,084)	$	(55,724)	$	(228,650)	$	(209,808)	$	(61,243)	$	(235,463)

(1) Amortization (gain) of defined benefit plan items are reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income.

Quarterly Results (Unaudited) (Tables)

12 Months Ended

Mar. 31, 2022

Quarterly Financial Information Disclosure [Abstract]

Effect of Fourth Quarter Events [Table Text Block]


Quarters Ended	March 31,			December 31,			September 30,			June 30,
Fiscal 2022
Revenues:
Product	$	684,508		$	697,256		$	685,238		$	489,279
Service	526,178			511,715			511,747			479,143
Total Revenues	1,210,686			1,208,971			1,196,985			968,422
Cost of Revenues:
Product	347,242			373,793			427,484			271,406
Service	291,822			297,064			289,157			270,734
Total Cost of Revenues	639,064			670,857			716,641			542,140
Gross Profit	571,622			538,114			480,344			426,282
Percentage of Revenues	47.2		%	44.5		%	40.1		%	44.0		%

Net Income Attributable to Shareholders	$	52,261		$	143,623		$	69,811		$	(21,807)
Basic Income Per Ordinary Share Attributable to Shareholders:
Net income	$	0.52		$	1.44		$	0.70		$	(0.24)
Diluted Income Per Ordinary Share Attributable to Shareholders:
Net income	$	0.52		$	1.42		$	0.69		$	(0.24)

Fiscal 2021
Revenues:
Product	$	427,614		$	375,314		$	339,504		$	301,108
Service	445,917			433,610			416,628			367,824
Total Revenues	873,531			808,924			756,132			668,932
Cost of Revenues:
Product	231,658			202,881			175,798			154,739
Service	262,055			260,182			250,297			226,809
Total Cost of Revenues	493,713			463,063			426,095			381,548
Gross Profit	379,818			345,861			330,037			287,384
Percentage of Revenues	43.5		%	42.8		%	43.6		%	43.0		%

Net Income Attributable to Shareholders	$	87,443		$	114,501		$	105,858		$	89,598
Basic Income Per Ordinary Share Attributable to Shareholders:
Net income	$	1.02		$	1.34		$	1.24		$	1.05
Diluted Income Per Ordinary Share Attributable to Shareholders:
Net income	$	1.02		$	1.33		$	1.23		$	1.05

Nature of Operations and Summary of Siginificant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Loss Contingencies [Line Items]
Deferred Revenue, Revenue Recognized									$ 46,760	$ 42,618
Interest Costs, Capitalized During Period									3,886	1,998
Interest Costs Incurred									89,593	37,180	$ 40,279
Interest Paid, Including Capitalized Interest, Operating and Investing Activities									84,696	36,257	38,021
Income Taxes Paid, Net									138,382	109,646	92,462
Advertising Expense									15,599	6,795	12,652
Proceeds from Income Tax Refunds									4,605	4,631	4,378
Revenue, Remaining Performance Obligation, Amount	$ 1,546,000								1,546,000
Cost of Goods and Services Sold									2,568,702	1,764,419	1,710,899
Gross Profit	571,622	$ 538,114	$ 480,344	$ 426,282	$ 379,818	$ 345,861	$ 330,037	$ 287,384	2,016,362	1,343,100	1,319,996
Operating Income (Loss)									425,618	548,368	537,046
Income Tax Expense (Benefit)									71,633	120,663	90,895
Net income									242,870	396,870	407,859
Net Income (Loss) Attributable to Parent	$ 52,261	$ 143,623	$ 69,811	$ (21,807)	$ 87,443	$ 114,501	$ 105,858	$ 89,598	$ 243,888	$ 397,400	$ 407,659
Earnings Per Share, Basic	$ 0.52	$ 1.44	$ 0.70	$ (0.24)	$ 1.02	$ 1.34	$ 1.24	$ 1.05	$ 2.50	$ 4.66	$ 4.81
Earnings Per Share, Diluted	$ 0.52	$ 1.42	$ 0.69	$ (0.24)	$ 1.02	$ 1.33	$ 1.23	$ 1.05	$ 2.48	$ 4.63	$ 4.76
Comprehensive Income (Loss), Net of Tax, Attributable to Parent									$ 95,323	$ 571,620	$ 331,974
Inventory, Net	$ 574,999				$ 315,067				574,999	315,067
Retained earnings	1,999,244				1,939,408				1,999,244	1,939,408
Increase (Decrease) in Inventories									102,922	(3,769)	39,140
Accruals and other, net									(16,398)	9,916	6,191
Deferred income taxes									(106,620)	4,240	9,442
Deferred Revenues, Amount recognized in period from certain capital contracts				$ 14,609
Deferred Cost of Revenues, Amount recognized in period from certain capital contracts				7,560
Product [Member]
Loss Contingencies [Line Items]
Cost of Goods and Services Sold	$ 347,242	$ 373,793	$ 427,484	$ 271,406	$ 231,658	$ 202,881	$ 175,798	$ 154,739	$ 1,419,925	$ 765,076	$ 750,129
Property, Plant and Equipment, Other Types [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life									20 years
Minimum [Member]
Loss Contingencies [Line Items]
Finite-Lived Intangible Assets, Useful Life, Minimum									5 years
Minimum [Member] \| Land Improvements [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life									3 years
Minimum [Member] \| Building [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life									2 years
Minimum [Member] \| Machinery and Equipment [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life									2 years
Minimum [Member] \| Computer Equipment [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life									2 years
Maximum [Member]
Loss Contingencies [Line Items]
Finite-Lived Intangible Assets, Useful Life, Minimum									20 years
Maximum [Member] \| Land Improvements [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life									40 years
Maximum [Member] \| Building [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life									50 years
Maximum [Member] \| Machinery and Equipment [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life									20 years
Maximum [Member] \| Computer Equipment [Member]
Loss Contingencies [Line Items]
Property, Plant and Equipment, Useful Life									20 years
Expected recognition within the next year [Member]
Loss Contingencies [Line Items]
Revenue, Remaining Performance Obligation, Percentage	54.00%								54.00%
Expected recognition beyond the next year [Member] [Member]
Loss Contingencies [Line Items]
Revenue, Remaining Performance Obligation, Percentage	37.00%								37.00%

Nature of Operations and Summary of Significant Accounting Policies - Change in Accounting Principle (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Loss Contingencies [Line Items]
Cost of Goods and Services Sold									$ 2,568,702	$ 1,764,419	$ 1,710,899
Gross Profit	$ 571,622	$ 538,114	$ 480,344	$ 426,282	$ 379,818	$ 345,861	$ 330,037	$ 287,384	2,016,362	1,343,100	1,319,996
Operating Income (Loss)									425,618	548,368	537,046
Income Tax Expense (Benefit)									71,633	120,663	90,895
Net income									242,870	396,870	407,859
Net Income (Loss) Attributable to Parent	$ 52,261	$ 143,623	$ 69,811	$ (21,807)	$ 87,443	$ 114,501	$ 105,858	$ 89,598	$ 243,888	$ 397,400	$ 407,659
Earnings Per Share, Basic	$ 0.52	$ 1.44	$ 0.70	$ (0.24)	$ 1.02	$ 1.34	$ 1.24	$ 1.05	$ 2.50	$ 4.66	$ 4.81
Earnings Per Share, Diluted	$ 0.52	$ 1.42	$ 0.69	$ (0.24)	$ 1.02	$ 1.33	$ 1.23	$ 1.05	$ 2.48	$ 4.63	$ 4.76
Comprehensive Income (Loss), Net of Tax, Attributable to Parent									$ 95,323	$ 571,620	$ 331,974
Inventory, Net	$ 574,999				$ 315,067				574,999	315,067
Retained earnings	1,999,244				1,939,408				1,999,244	1,939,408
Increase (Decrease) in Inventories									(102,922)	3,769	(39,140)
Accruals and other, net									(16,398)	9,916	6,191
Deferred income taxes									(106,620)	4,240	9,442
Product [Member]
Loss Contingencies [Line Items]
Cost of Goods and Services Sold	$ 347,242	$ 373,793	$ 427,484	$ 271,406	$ 231,658	$ 202,881	$ 175,798	$ 154,739	$ 1,419,925	$ 765,076	$ 750,129

Business Acquisitions and Divestitures Business Acquisitions and Divestitures Narrative (Details) € in Thousands, $ in Thousands			3 Months Ended								12 Months Ended
	Jan. 03, 2022 USD ($)	Jan. 04, 2021 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Sep. 30, 2020 USD ($)	Jun. 30, 2020 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Mar. 31, 2022 EUR (€)	Jun. 02, 2021 USD ($)	Mar. 31, 2021 EUR (€)	Oct. 31, 2019 EUR (€)	Mar. 31, 2017 EUR (€)
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability			$ 10,550				$ 19,642				$ 10,550	$ 19,642	$ 15,988
Revenues			1,210,686	$ 1,208,971	$ 1,196,985	$ 968,422	873,531	$ 808,924	$ 756,132	$ 668,932	4,585,064	3,107,519	3,030,895
Business Combination, Acquisition Related Costs											205,788	35,634	8,225
Proceeds from Divestiture of Businesses											169,712	518	439
Gain (Loss) on Disposition of Business											(874)	2,030	1,770
Investment Owned, at Cost										$ 4,955
Line of Credit Provided to Investee			11,606								11,606
Payments to Acquire Businesses, Net of Cash Acquired											550,449	909,192	109,814
Deferred consideration			50				1,194				50	1,194
Subsequent event- Forgiveness of Loan Receivable			11,708								11,708
Business Acquisition, Goodwill, Expected Tax Deductible Amount			$ 427,035				197,344				$ 427,035	197,344
Entity Number of Employees			3,700								3,700			3,700
Cantel Acquisition Assumed Debt Obligations			$ 721,284								$ 721,284
Contingent Consideration Liability Assumed in Cantel Combination			25,000								25,000				$ 25,000
Business Acquisition, Pro Forma Revenue											4,790,161	4,190,244
Business Acquisition, Pro Forma Net Income (Loss)											449,382	5,849
Net sales attributable to Cantel											974,408
Operating (loss) income attributable to Cantel											$ 41,757
Minimum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life											5 years
Minimum [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life											9 years
Maximum [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life											20 years
Maximum [Member] \| Customer Relationships [Member]
Business Acquisition [Line Items]
Finite-Lived Intangible Asset, Useful Life											10 years
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired		$ 78,045									$ 3,146	20,909	128,860
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			3,146				108,111				3,146	108,111	129,349
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			0				26,363				0	26,363	9,241
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			1,578				28,188				1,578	28,188	36,500
Key Surgical [Domain]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired												853,203
Equity Investments [Domain]
Business Acquisition [Line Items]
Non cash consideration paid in acquisition												41,771
Cantel Medical Corp.
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			3,599,471								3,599,471
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			267,360								267,360
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			2,942,000								2,942,000
Cantel Medical Corp. \| Customer Relationships [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			2,278,000								2,278,000
Cantel Medical Corp. \| Trade Names [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			422,000								$ 422,000
Finite-Lived Intangible Asset, Useful Life											11 years
Cantel Medical Corp. \| Developed Technology Rights
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			222,000								$ 222,000
Finite-Lived Intangible Asset, Useful Life											9 years
Cantel Medical Corp. \| Noncompete Agreements [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			20,000								$ 20,000
Finite-Lived Intangible Asset, Useful Life											2 years
Dutch Linen Loan [Member]
Business Acquisition [Line Items]
Other Loan Receivable \| €																		€ 15,000
Financing Receivable, after Allowance for Credit Loss			$ 8,129				8,568				$ 8,129	8,568		€ 7,300		€ 7,300
Other Receivables \| €																	€ 7,300
Equity Investee Loan [Member]
Business Acquisition [Line Items]
Interest Rate First Four Years										7 years
Financing Receivable, after Allowance for Credit Loss							$ 7,084					7,084
Loan Rate 4% [Member] [Domain]
Business Acquisition [Line Items]
Interest rate on loan receivable										4.00%
Years 5-6,8% Int Rate [Member] [Member]
Business Acquisition [Line Items]
Interest rate on loan receivable																	8.00%
Years 1-4, 4% Int Rate [Member]
Business Acquisition [Line Items]
Interest rate on loan receivable																	4.00%	4.00%
Years 5-15, 12% Int Rate [Member]
Business Acquisition [Line Items]
Interest rate on loan receivable																		12.00%
China HCS [Member]
Business Acquisition [Line Items]
Gain (Loss) on Disposition of Business													2,365
AST Lab Divestiture [Domain]
Business Acquisition [Line Items]
Revenues												6,000
Proceeds from Divestiture of Businesses												518
Gain (Loss) on Disposition of Business												$ 2,024
HCS China Divestiture [Domain]
Business Acquisition [Line Items]
Revenues													$ 5,000
Renal Care
Business Acquisition [Line Items]
Revenues	$ 180,000
Proceeds from Divestiture of Businesses	196,000
Gain (Loss) on Disposition of Business	950
Potential Earnout on Divestiture of Business	$ 12,300

Business Acquisitions and Divestitures Synergy Consideration (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands			3 Months Ended	12 Months Ended
	Jun. 02, 2021	Jan. 04, 2021	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired				$ 550,449	$ 909,192	$ 109,814
Consideration related to equity component of convertible debt				175,555
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired		$ 78,045		3,146	$ 20,909	$ 128,860
Cantel Medical Corp.
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross				716,412
Business Combination, Consideration Transferred, Other				14
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable				2,689,317
Consideration Transferred, Equity Awards Issued and Issuable				18,173
Consideration related to equity component of convertible debt				175,555
Business Combination, Consideration Transferred				3,599,471
Business Combination, Long-term Obligations Assumed			$ 721,284	$ 721,284
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	42,816		14,297
Business Acquisition, Share Price	$ 16.93		$ 188,070.00	$ 188,070.00

Business Acquisitions and Divestitures Synergy Acquisition (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Business Acquisition [Line Items]
Operating Lease, Right-of-Use Asset	$ 188,480	$ 150,142
Goodwill	4,404,343	$ 3,026,049	$ 2,356,085
Cantel Medical Corp.
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	169,073
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables	172,226
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory	249,221
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment	267,360
Operating Lease, Right-of-Use Asset	59,720
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	72,864
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	2,942,000
Goodwill	1,522,381
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	5,454,845
Business combination, Convertible Debt, Par Value Assumed	168,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities	(247,549)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	(1,855,374)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	3,599,471
Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Lease Obligation	47,856
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities	$ 670,685

Business Acquisitions and Divestitures Synergy Finite-Lived Intangibles (Details) - Cantel Medical Corp. $ in Thousands	12 Months Ended
	Mar. 31, 2022 USD ($)
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 2,942,000
Developed Technology Rights
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 222,000
Finite-Lived Intangible Asset, Useful Life	9 years
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 20,000
Finite-Lived Intangible Asset, Useful Life	2 years

Business Acquisitions and Divestitures Business Acquisition Summary (Details) - USD ($) $ in Thousands		12 Months Ended
	Oct. 31, 2019	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2018
Business Acquisition [Line Items]
Proceeds from Divestiture of Businesses		$ 169,712	$ 518	$ 439
Business Combination, Acquisition Related Costs		205,788	35,634	8,225
Gain (Loss) on Disposition of Business		874	(2,030)	(1,770)
Operating Lease, Right-of-Use Asset		188,480	150,142
Goodwill		4,404,343	3,026,049	2,356,085
Business Acquisition, Goodwill, Expected Tax Deductible Amount		427,035	197,344
Dutch Linen Loan [Member]
Business Acquisition [Line Items]
Interest Rate Period	4 years				15 years
Series of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents		0	9,159	8,811
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables		0	9,621	10,331
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory		0	22,123	8,999
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment		0	26,363	9,241
Operating Lease, Right-of-Use Asset		0	4,420	4,462
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other		0	3,378	1,133
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill		1,578	28,188	36,500
Goodwill		1,602	42,808	74,531
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets		3,180	146,060	154,008
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities		(34)	(28,245)	(20,659)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities		0	(9,704)	(4,000)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		(34)	(37,949)	(24,659)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net		$ 3,146	108,111	$ 129,349
Key Surgical
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents			12,615
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables			13,967
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory			21,414
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			6,030
Operating Lease, Right-of-Use Asset			4,907
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other			6,680
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill			356,999
Goodwill			527,675
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets			950,287
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities			(21,599)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities			(62,870)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities			(84,469)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			865,818
Finite-Lived Customer Relationships, Gross			$ 315,575

Goodwill and Intangible Assets Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Goodwill [Line Items]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 14,250
Goodwill	4,404,343	$ 3,026,049	$ 2,356,085
Goodwill, Acquired During Period		570,483
Finite-Lived Intangible Assets, Amortization Expense	368,698	86,512	$ 74,528
Finite-Lived Intangible Assets, Gross	4,185,318	1,424,723
Finite-Lived Intangible Assets, Accumulated Amortization	856,781	526,317
Trademarks and Trade Names [Member]
Goodwill [Line Items]
Finite-Lived Intangible Assets, Gross	470,919	78,058
Finite-Lived Intangible Assets, Accumulated Amortization	$ 74,455	$ 42,867

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Goodwill and Intangible Assets Goodwill Rollforward (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Goodwill [Line Items]
Goodwill	$ 4,404,343	$ 3,026,049	$ 2,356,085
Goodwill, Purchase Accounting Adjustments	(15,819)	1,522,381
Goodwill, Acquired During Period		570,483
Goodwill, Written off Related to Sale of Business Unit	(7,000)
Goodwill, Foreign Currency Translation Gain (Loss)	(121,268)	99,481
Healthcare [Member]
Goodwill [Line Items]
Goodwill	2,326,830	1,384,763	827,266
Goodwill, Purchase Accounting Adjustments	(6,533)	1,019,332
Goodwill, Acquired During Period		536,713
Goodwill, Written off Related to Sale of Business Unit	(7,000)
Goodwill, Foreign Currency Translation Gain (Loss)	(63,732)	20,784
Applied Sterilization Technologies [Member]
Goodwill [Line Items]
Goodwill	1,432,858	1,492,239	1,380,262
Goodwill, Purchase Accounting Adjustments	(9,286)	0
Goodwill, Acquired During Period		33,770
Goodwill, Written off Related to Sale of Business Unit	0
Goodwill, Foreign Currency Translation Gain (Loss)	(50,095)	78,207
Life Sciences
Goodwill [Line Items]
Goodwill	179,288	149,047	148,557
Goodwill, Purchase Accounting Adjustments	0	30,356
Goodwill, Acquired During Period		0
Goodwill, Written off Related to Sale of Business Unit	0
Goodwill, Foreign Currency Translation Gain (Loss)	(115)	490
Dental
Goodwill [Line Items]
Goodwill	465,367	0	$ 0
Goodwill, Purchase Accounting Adjustments	0	472,693
Goodwill, Acquired During Period		0
Goodwill, Written off Related to Sale of Business Unit	0
Goodwill, Foreign Currency Translation Gain (Loss)	$ (7,326)	$ 0

Goodwill and Intangible Assets Other Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 4,185,318	$ 1,424,723
Finite-Lived Intangible Assets, Accumulated Amortization	856,781	526,317
Indefinite-lived Intangible Assets (Excluding Goodwill)	14,250
Customer Relationships [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	3,117,314	968,040
Finite-Lived Intangible Assets, Accumulated Amortization	539,845	291,802
Noncompete Agreements [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	23,571	5,401
Finite-Lived Intangible Assets, Accumulated Amortization	12,392	4,169
Patented Technology [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	518,714	318,424
Finite-Lived Intangible Assets, Accumulated Amortization	211,822	171,952
Trademarks and Trade Names [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	470,919	78,058
Finite-Lived Intangible Assets, Accumulated Amortization	74,455	42,867
supplier relationships [Member]
Summary of Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	54,800	54,800
Finite-Lived Intangible Assets, Accumulated Amortization	$ 18,267	$ 15,527

Goodwill and Intangible Assets Future Amortization of Intangible Assets (Details) $ in Thousands	Mar. 31, 2022 USD ($)
Other Intangible Assets [Abstract]
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 384,258
Finite-Lived Intangible Assets, Amortization Expense, Year Two	370,549
Finite-Lived Intangible Assets, Amortization Expense, Year Three	364,488
Finite-Lived Intangible Assets, Amortization Expense, Year Four	355,475
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$ 349,116

Inventories, Net (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Notes To Financial Statements [Abstract]
Inventory, Raw Materials	$ 195,035	$ 103,939
Inventory, Work in Process	76,021	54,283
Inventory, Finished Goods	334,880	176,623
Inventory Valuation Reserves	(30,937)	(19,778)
Inventories, net	$ 574,999	$ 315,067

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Property, Plant and Equipment [Line Items]
Document Period End Date	Mar. 31, 2022
Asset Retirement Obligation	$ 13,543	$ 13,330	$ 12,514
Asset Retirement Obligation, Liabilities Incurred	86	859
Asset Retirement Obligation, Liabilities Settled	(3)	(251)
Asset Retirement Obligation, Accretion Expense	146	137
Asset Retirement Obligation, Foreign Currency Translation Gain (Loss)	(16)	71
Land	84,015	69,477
Buildings and Improvements, Gross	654,851	567,132
Machinery and Equipment, Gross	903,649	779,044
Capitalized Computer Software, Gross	222,620	193,222
Materials, Supplies, and Other	597,641	565,681
Construction in Progress, Gross	356,013	211,381
Property, Plant and Equipment, Gross	2,818,789	2,385,937
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment	(1,266,213)	(1,150,537)
Property, Plant and Equipment, Net	1,552,576	1,235,400
Depreciation	$ 184,406	$ 132,725	$ 122,707

Debt (Details) $ / shares in Units, € in Thousands, £ in Thousands			12 Months Ended
	May 15, 2020 USD ($) $ / shares	May 15, 2015 USD ($)	Mar. 31, 2022 USD ($) $ / shares	Mar. 31, 2019	Mar. 31, 2022 EUR (€)	Mar. 31, 2022 GBP (£)	Jun. 30, 2021 USD ($)	Jun. 02, 2021 $ / shares shares	Apr. 01, 2021 USD ($)	Mar. 31, 2021 USD ($)	Mar. 19, 2021 USD ($)	Feb. 27, 2017 USD ($)	Feb. 27, 2017 EUR (€)	Feb. 27, 2017 GBP (£)	Dec. 31, 2012 USD ($)
Debt Instrument [Line Items]
Long-term Debt, Current Maturities			$ 142,875,000
Line of Credit Facility, Amount Outstanding			58,908,000							$ 247,423,000
Long-term Debt			3,113,634,000
Long-term Debt			2,945,481,000							1,650,540,000
Long-term Debt, Maturities, Repayments of Principal in Year Two			60,000,000
Long-term Debt, Maturities, Repayments of Principal in Year Three			165,937,000
Long-term Debt, Maturities, Repayments of Principal in Year Four			341,408,000
Long-term Debt, Maturities, Repayments of Principal after Year Five			2,403,414,000
Term loan, current portion			27,500,000							0
Delayed draw term loan, current portion			24,375,000							0
Senior Notes, Current			91,000,000							0
Short-term Debt			142,875,000							0
Senior Notes, Noncurrent			758,726,000							860,308,000
Debt Issuance Costs, Net			(25,278,000)							(7,191,000)
Term Loan, long term portion			177,500,000							550,000,000
Delayed Draw Term Loan, long term portion			625,625,000				$ 650,000,000			0
Debt, Long-Term and Short-Term, Combined Amount			$ 3,088,356,000							1,650,540,000
Business Acquisition, Shares Received Per Ordinary Share \| shares								0.33787
Common Stock, Par or Stated Value Per Share \| $ / shares			$ 0.001					$ 0.001
Debt Instrument, Convertible, Units of Property Reference								25.0843
Debt Instrument, Convertible, Parent Shares \| shares								8.4752
Debt Instrument, Convertible, Cash Per One Thousand Dollars Ratio								424.68
Debt Instrument, Convertible, Increase in Conversion Rate, Shares \| shares								0.9931
Debt Instrument, Convertible, Stock Price \| $ / shares								$ 81.3520
Consideration related to equity component of convertible debt			$ 175,555,000
Convertible debt premium liability			$ 203,361,000
Cantel Medical Corp.
Debt Instrument [Line Items]
Business Acquisition, Share Price \| $ / shares			$ 188,070.00					$ 16.93
Consideration related to equity component of convertible debt			$ 175,555,000
10 year maturity
Debt Instrument [Line Items]
Debt Instrument, Term		10 years		10 years
15 year maturity
Debt Instrument [Line Items]
Debt Instrument, Term		15 years
Debt Instrument, Maturity Date, Description				15 years
Senior Notes
Debt Instrument [Line Items]
Senior Notes		$ 350,000,000													$ 200,000,000
Long-term Debt			849,726,000							860,308,000
Debt Instrument, Face Amount			1,350,000,000						$ 1,350,000,000	0
Long-term Debt, Cash Settlement Value			$ 371,361,000
Convertible Debt
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 168,000,000
STE 3.70% due 2022 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.20%		3.20%	3.20%
Debt Instrument, Face Amount			$ 91,000,000							91,000,000
STE 3.85% due 2024 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.35%		3.35%	3.35%
Debt Instrument, Face Amount			$ 80,000,000							80,000,000
STE 4.05% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.55%		3.55%	3.55%
Debt Instrument, Face Amount			$ 25,000,000							25,000,000
STE 3.45% due 2025 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.45%		3.45%	3.45%
Debt Instrument, Face Amount			$ 125,000,000							125,000,000
STE 3.55% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.55%		3.55%	3.55%
Debt Instrument, Face Amount			$ 125,000,000							125,000,000
STE 3.70% due 2030 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.70%		3.70%	3.70%
Debt Instrument, Face Amount			$ 100,000,000							100,000,000
STE 3.93% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.93%		3.93%	3.93%
Debt Instrument, Face Amount			$ 50,000,000							50,000,000
STE 1.86% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			1.86%		1.86%	1.86%
Debt Instrument, Face Amount			$ 66,815,000		€ 60,000					70,426,000
STE 4.03% due 2029 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			4.03%		4.03%	4.03%
Debt Instrument, Face Amount			$ 45,000,000							45,000,000
STE 2.04% due 2029 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			2.04%		2.04%	2.04%
Debt Instrument, Face Amount			$ 22,271,000		€ 20,000					23,475,000
STE 3.04% due 2029 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.04%		3.04%	3.04%
Debt Instrument, Face Amount			$ 59,089,000			£ 45,000				61,863,000
STE 2.30% due 2032 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			2.30%		2.30%	2.30%
Debt Instrument, Face Amount			$ 21,158,000		€ 19,000					22,302,000
STE 3.17% due 2032 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.17%		3.17%	3.17%
Debt Instrument, Face Amount			$ 39,393,000			£ 30,000				$ 41,242,000
United States of America, Dollars
Debt Instrument [Line Items]
Senior Notes												$ 95,000,000
United Kingdom, Pounds
Debt Instrument [Line Items]
Senior Notes \| £														£ 75,000
Euro Member Countries, Euro
Debt Instrument [Line Items]
Senior Notes \| €													€ 99,000
2031 Notes \| Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage									2.70%
Debt Instrument, Face Amount									$ 675,000,000
2051 Notes \| Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage									3.75%
Debt Instrument, Face Amount									$ 675,000,000
Cantel Convertible Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	3.25%
Debt Instrument, Convertible, Conversion Price \| $ / shares	$ 41.51
Debt Instrument, Convertible, Conversion Ratio	24.0912
Term Loan Facility \| Line of Credit
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity											$ 550,000,000
Debt Instrument, Interest Rate, Stated Percentage			1.875%		1.875%	1.875%					1.25%
Revolving Credit Facility [Member] \| Line of Credit
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity											$ 1,250,000,000
Bridge Loan \| Line of Credit
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity											625,000,000
Delayed Draw Term Loan \| Line of Credit
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity											$ 750,000,000
Debt Instrument, Interest Rate, Stated Percentage			1.875%		1.875%	1.875%					1.25%

Debt 2017 Senior Notes (Details) € in Thousands, £ in Thousands	Mar. 31, 2022 USD ($)	Mar. 31, 2022 EUR (€)	Mar. 31, 2022 GBP (£)	Apr. 01, 2021 USD ($)	Mar. 31, 2021 USD ($)
Debt Instrument [Line Items]
Long-term Debt	$ 2,945,481,000				$ 1,650,540,000
Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	1,350,000,000			$ 1,350,000,000	0
Long-term Debt	849,726,000				860,308,000
STE 3.70% due 2022 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 91,000,000				91,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.20%	3.20%	3.20%
STE 3.85% due 2024 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 80,000,000				80,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.35%	3.35%	3.35%
STE 4.05% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 25,000,000				25,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.55%	3.55%	3.55%
STE 3.45% due 2025 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 125,000,000				125,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.45%	3.45%	3.45%
STE 3.55% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 125,000,000				125,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.55%	3.55%	3.55%
STE 3.70% due 2030 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 100,000,000				100,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.70%	3.70%	3.70%
STE 3.93% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 50,000,000				50,000,000
Debt Instrument, Interest Rate, Stated Percentage	3.93%	3.93%	3.93%
STE 1.86% due 2027 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 66,815,000	€ 60,000			70,426,000
Debt Instrument, Interest Rate, Stated Percentage	1.86%	1.86%	1.86%
STE 4.03% due 2029 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 45,000,000				45,000,000
Debt Instrument, Interest Rate, Stated Percentage	4.03%	4.03%	4.03%
STE 2.04% due 2029 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 22,271,000	€ 20,000			23,475,000
Debt Instrument, Interest Rate, Stated Percentage	2.04%	2.04%	2.04%
STE 3.04% due 2029 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 59,089,000		£ 45,000		61,863,000
Debt Instrument, Interest Rate, Stated Percentage	3.04%	3.04%	3.04%
STE 2.30% due 2032 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 21,158,000	€ 19,000			22,302,000
Debt Instrument, Interest Rate, Stated Percentage	2.30%	2.30%	2.30%
STE 3.17% due 2032 Senior Notes
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 39,393,000		£ 30,000		$ 41,242,000
Debt Instrument, Interest Rate, Stated Percentage	3.17%	3.17%	3.17%

Additional Consolidated Balance Sheets Information (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Notes To Financial Statements [Abstract]
Employee-related Liabilities	$ 71,878	$ 47,157
Accrued Vacation	13,669	12,389
Accrued Bonuses	64,702	62,530
Accrued Liabilities for Commissions, Expense and Taxes	30,171	24,022
Liability, Other Retirement Benefits	1,190	1,326
Liability, Retirement and Postemployment Benefits	2,111	2,654
Employee-related Liabilities, Current	183,721	150,078
Deferred Revenue	110,791	62,492
Service liabilities	51,365	46,720
Self Insurance Reserve, Current	8,995	8,095
Accrued Sales Commission	31,700	27,348
Standard and Extended Product Warranty Accrual	14,108	9,406	$ 7,381	$ 7,194
Asset Retirement Obligation, Current	1,181	1,193
Other Accrued Liabilities	88,404	65,303
Accrued Liabilities	306,544	220,557
Self Insurance Reserve, Noncurrent	19,213	17,295
Liability, Other Retirement Benefits, Noncurrent	7,335	8,690
Liability, Defined Benefit Pension Plan, Noncurrent	1,772	3,748
Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent	1,360	2,353
Accrued Income Taxes, Noncurrent	12,225	13,241
Asset Retirement Obligations, Noncurrent	12,362	12,137
Other Liabilities	21,312	30,546
Other Liabilities, Noncurrent	$ 75,579	$ 88,010

Income Tax Expense (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	May 21, 2021
Operating Loss Carryforwards [Line Items]
Income Tax Examination, Penalties and Interest Accrued	$ 152	$ 106
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	3,058
Uncertain Tax Liability Resulting From IRS Notice	12,000			$ 50,000
Deferred Tax Assets, Tax Credit Carryforwards	37,501
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Postretirement Benefits	$ 2,086	$ 2,422
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate	12.50%	12.50%	12.50%
Current Federal Tax Expense (Benefit)	$ 12,002	$ 9,244	$ 5,036
Effective Income Tax Rate, Continuing Operations	22.80%	23.30%	18.20%
Unrecognized Tax Benefits	$ 2,906	$ 2,295	$ 875
Current State and Local Tax Expense (Benefit)	21,438	16,272	9,971
Current Income Tax Expense (Benefit)	174,952	119,765	81,639
Deferred Federal Income Tax Expense (Benefit)	(739)	(787)	(899)
Deferred State and Local Income Tax Expense (Benefit)	(17,124)	(550)	2,366
Increase (Decrease) in Deferred Income Taxes	(103,319)	898	9,256
Income Tax Expense (Benefit)	$ 71,633	$ 120,663	$ 90,895
Effective Income Tax Rate Reconciliation, State and Local Income Taxes	1.40%	2.40%	2.00%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	0.90%	0.30%	0.50%
Effective Tax Rate Reconciliation, Increase (decrease) in Valuation Allowances	0.20%	(0.10%)	(0.30%)
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent	(0.80%)	(0.50%)	(0.50%)
Effective Income Tax Rate Reconciliation, Tax Credits, Foreign	(1.10%)	(0.30%)	(0.60%)
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential	12.60%	8.30%	6.90%
Effective Tax Rate Reconciliation, UK Tax Rate Differential	0.00%	2.10%	0.00%
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent	(5.10%)	(1.90%)	(2.80%)
Effective Tax Reconciliation, deferred tax assets and liabilities	2.30%	0.40%	0.10%
U.S. tax reform impact GILTI and FDII	(0.90%)	(0.60%)	0.10%
Capitalized Interest Costs- Effective tax rate	1.80%	0.60%	0.10%
Effective Income Tax Rate Reconciliation, Other Adjustments	(1.00%)	0.10%	0.20%
Unrecognized Tax Benefits, Increases Resulting from Current Period Tax Positions	$ 0	$ 655
Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions	(135)	(896)
Unrecognized Tax Benefits, Increase Resulting from Acquisition	(746)	(1,640)
Unrecognized Tax Benefits, Increase Resulting from Foreign Currency Translation	0	21
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits	14,340	13,208
Deferred Tax Assets, Operating Loss Carryforwards	9,694
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities	12,092	6,360
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance	2,561	3,348
Deferred Tax Assets, Deferred Income	20,688	10,281
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Allowance for Doubtful Accounts	2,187	1,661
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Pensions	0	1,574
Deferred Tax Assets, Operating leases	44,401	34,020
Deferred Tax Assets, Tax Credit Carryforwards, Foreign	36,036	0
Deferred Tax Liabilities, Leasing Arrangements	43,593	33,401
Deferred Tax Assets, Other	8,579	8,603
Deferred Tax Assets, Gross, Current	168,520	96,628
Deferred Tax Assets, Valuation Allowance	24,691	14,143
Deferred Tax Assets, Net of Valuation Allowance	143,829	82,485
Deferred Tax Liabilities, Property, Plant and Equipment	110,951	73,344
Deferred Tax Liabilities, Goodwill and Intangible Assets, Intangible Assets	755,980	199,242
Deferred Tax Liabilities, Pension	2,004	0
Deferred Tax and Other Liabilities, Noncurrent	3,473	3,833
Deferred tax liabilities, net of deferred tax assets	916,001	309,820
Deferred Tax Liabilities	(772,172)	(227,335)
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	71,171
Deferred Tax Assets, Operating Loss Carryforwards, State and Local	4,199
Valuation Allowance, Deferred Tax Asset, Change in Amount	10,548
Deferred Tax Assets, Operating Loss Carryforwards	25,550	15,151
Undistributed Earnings of Foreign Subsidiaries	2,000,000
IRS settlement paid	7,300
Deferred tax Asset Credit Carryforward, German Branches	28,749
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	314,503	517,533	$ 498,754
Costa Rica Exempt thorugh 2025 and partially exempt through 2029 [Member]
Operating Loss Carryforwards [Line Items]
Income Tax Holiday, Aggregate Dollar Amount	$ 2,600
Income Tax Holiday, Income Tax Benefits Per Share	$ 0.03
UNITED STATES
Operating Loss Carryforwards [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Foreign	$ 79,662	326,991	325,595
Current Foreign Tax Expense (Benefit)	88,158	57,550	42,032
Deferred Foreign Income Tax Expense (Benefit)	(73,833)	7,523	10,089
Other Foreign Entities [Member]
Operating Loss Carryforwards [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Foreign	146,763	117,100	143,616
Current Foreign Tax Expense (Benefit)	53,354	36,699	24,600
Deferred Foreign Income Tax Expense (Benefit)	(11,623)	(5,288)	(2,300)
IRELAND
Operating Loss Carryforwards [Line Items]
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ 88,078	$ 73,442	$ 29,543

Benefit Plans (Change in benefit obligations funded status) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	$ 153	$ 160
Defined benefit plan repayment of obligation [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	4,103
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	1,190
Defined Benefit Plan, Benefit Obligation	8,525	10,016	$ 11,368
Defined Benefit Plan, Service Cost	0	0	0
Defined benefit plan, change in benefit obligation, interest cost	232	317
Defined Benefit Plan, Actuarial Net (Gains) Losses	(640)	(114)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	1,083	1,555
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0	0
Defined Benefit Plan, Benefits Paid (Deprecated 2017-01-31)	(1,083)	(1,555)
Defined Benefit Plan, Plan Assets, Payment for Settlement	0	0
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Defined Benefit Plan, Plan Assets, Amount	0	0	0
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	0	0
Defined Benefit Plan, Plan Assets, Contributions by Employer	1,083	1,555
Defined Benefit Plan, Funded (Unfunded) Status of Plan	(8,525)	(10,016)
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	0	0
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	0	0
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	0	0
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	5,560
Defined Benefit Plan, Benefit Obligation	129,772	149,200	123,190
Defined Benefit Plan, Service Cost	1,616	1,357	1,380
Defined benefit plan, change in benefit obligation, interest cost	2,820	2,816
Defined Benefit Plan, Actuarial Net (Gains) Losses	(12,177)	12,622
Defined Benefit Plan, Benefit Obligation, Benefits Paid	5,375	4,714
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	897	1,031
Defined Benefit Plan, Benefits Paid (Deprecated 2017-01-31)	(5,325)	(4,714)
Defined Benefit Plan, Plan Assets, Payment for Settlement	(1,334)	0
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	897	1,031
Defined Benefit Plan, Plan Assets, Amount	142,172	145,452	$ 112,203
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	3,421	19,252
Defined Benefit Plan, Plan Assets, Contributions by Employer	5,533	5,329
Defined Benefit Plan, Funded (Unfunded) Status of Plan	12,400	(3,748)
Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment	(1,334)	0
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	(6,472)	12,351
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	$ (5,875)	$ 12,898

Benefit Plans (Amounts recognized in balance sheets) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Liability, Defined Benefit Plan, Current	$ (1,190)	$ (1,326)
Liability, Defined Benefit Plan, Noncurrent	(7,335)	(8,690)
Liability, Defined Benefit Pension Plan	(8,525)	(10,016)
Assets for Plan Benefits, Defined Benefit Plan	0	0
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Liability, Defined Benefit Plan, Current	0	0
Liability, Defined Benefit Plan, Noncurrent	(1,772)	(3,748)
Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position	12,400
Liability, Defined Benefit Pension Plan		(3,748)
Assets for Plan Benefits, Defined Benefit Plan	$ 14,172	$ 0

Benefit Plans (Amortize pre-tax amount AOCI) (Details) $ in Thousands	12 Months Ended
	Mar. 31, 2022 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax	$ (2,914)
Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax	$ (6,767)

Benefit Plans (Accumulated benefit obligation exceeding the fair value of plan assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2008
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Accumulated Benefit Obligation				$ 46,001
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Amount	$ 142,172	$ 145,452	$ 112,203
Defined Benefit Plan, Accumulated Benefit Obligation	129,772	149,200
defined benefit plans, aggregate projected benefit obligation	$ 129,772	$ 149,200

- Definition

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

+ References + Details

Benefit Plans (Projected benefit obligation exceeding the fair value of plan assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Sep. 30, 2008
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Accumulated Benefit Obligation				$ 46,001
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation	$ 129,772	$ 149,200	$ 123,190
Defined Benefit Plan, Plan Assets, Amount	142,172	145,452	112,203
Defined Benefit Plan, Accumulated Benefit Obligation	129,772	149,200
Defined Benefit Plan, Service Cost	1,616	1,357	1,380
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	61	71	69
Defined Benefit Plan, Interest Cost	2,699	2,628	2,876
Defined Benefit Plan, Actuarial Net (Gains) Losses	(12,177)	12,622
Defined Benefit Plan, Benefit Obligation, Benefits Paid	5,375	4,714
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	897	1,031
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	(5,875)	12,898
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	3,421	19,252
Defined Benefit Plan, Plan Assets, Contributions by Employer	5,533	5,329
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	897	1,031
Defined Benefit Plan, Plan Assets, Benefits Paid	5,325	4,714
Defined Benefit Plan, Funded (Unfunded) Status of Plan	12,400	(3,748)
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation	8,525	10,016	11,368
Defined Benefit Plan, Plan Assets, Amount	0	0	0
Defined Benefit Plan, Service Cost	0	0	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	(267)	(3,263)	(3,263)
Defined Benefit Plan, Interest Cost	232	317	$ 409
Defined Benefit Plan, Actuarial Net (Gains) Losses	(640)	(114)
Defined Benefit Plan, Benefit Obligation, Benefits Paid	1,083	1,555
Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant	0	0
Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)	0	0
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)	0	0
Defined Benefit Plan, Plan Assets, Contributions by Employer	1,083	1,555
Defined Benefit Plan, Plan Assets, Contributions by Plan Participant	0	0
Defined Benefit Plan, Plan Assets, Benefits Paid	1,083	1,555
Defined Benefit Plan, Funded (Unfunded) Status of Plan	$ (8,525)	$ (10,016)

Benefit Plans (Components of the annual net periodic benefit cost) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax	$ (2,914)
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(640)	$ (114)
Defined Benefit Plan, Service Cost	0	0	$ 0
Defined Benefit Plan, Interest Cost	232	317	409
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	0	0	0
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	(267)	(3,263)	(3,263)
Net amortization and deferral	444	439	482
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	409	(2,507)	(2,372)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax	640	114	(181)
Defined Benefit Plan, Amortization of Net Prior Service Cost (Credit)	267	3,263	3,263
Defined Benefit Plan, Amortization of Net Gains (Losses)	(444)	(439)	(482)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax	463	2,938	2,600
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	872	431	228
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(12,177)	12,622
Defined Benefit Plan, Service Cost	1,616	1,357	1,380
Defined Benefit Plan, Interest Cost	2,699	2,628	2,876
Defined Benefit Plan, Expected Return (Loss) on Plan Assets	(4,412)	(3,463)	(4,735)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	61	71	69
Net amortization and deferral	18	21	9
Defined Benefit Plan, Net Periodic Benefit Cost (Credit)	(49)	614	(401)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment	(31)	0	0
Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax	(11,028)	(1,635)	890
Defined Benefit Plan, Amortization of Net Prior Service Cost (Credit)	(222)	(85)	(78)
Defined Benefit Plan, Amortization of Net Gains (Losses)	0	7	0
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, before Tax	(11,250)	(1,713)	812
Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Gain (Loss), before Tax	$ (11,299)	$ (1,099)	$ 411

Benefit Plans (Assumptions used in calculating benefit obligations and net periodic benefit cost) (Details)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Synergy Health PLC Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	2.80%	2.10%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	3.60%	3.50%	4.80%
Isotron [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	1.80%	0.90%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	0.90%	1.60%	1.20%
Daniken [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	0.90%	0.35%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.00%	0.70%	0.65%
Radeberg [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	1.60%	1.60%
Allershausen [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	1.50%	0.80%
Harwell Dosimeters [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	2.85%	2.15%
Other Pension Plans, Defined Benefit [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate	3.25%	2.50%

Benefit Plans (Significant assumptions used to determine the net periodic benefit costs) (Details)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Synergy Health PLC Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	2.10%	2.40%	2.50%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	3.60%	3.50%	4.80%
Isotron [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	0.90%	1.60%	1.20%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	0.90%	1.60%	1.20%
Daniken [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	1.00%	0.70%	0.20%
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets	1.00%	0.70%	0.65%
Radeberg [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	1.50%	1.50%	1.60%
Allershausen [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	2.00%	1.75%	1.75%
Harwell Dosimeters [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	2.85%	2.15%	2.45%
Other Post-Retirement Benefit Plans, Net
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate	2.50%	3.00%	3.50%

Benefit Plans (Assumed long-term healthcare cost trend rate) (Details)	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Postemployment Benefits [Abstract]
Healthcare cost trend rate medical	7.00%	7.00%	6.75%
Healthcare prescription drug	7.00%	7.00%	6.75%
Defined Benefit Plan, Ultimate Health Care Cost Trend Rate	4.50%	4.50%	4.50%

Benefit Plans (Targeted asset allocation of plan assets and the actual allocation of plan assets) (Details)	Mar. 31, 2022
Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	75.00%
Debt Securities
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	25.00%

Benefit Plans (Fair value of our pension benefits plan assets) (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Other Investments	$ 5,383	$ 5,555	$ 4,345
Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	348,320	220,531
Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Fair Value, Inputs, Level 3
Defined Benefit Plan Disclosure [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Insurance Contract	5,383	5,555
Trading Securities, Cost	66,416	60,960
Cash and Cash Equivalents, Fair Value Disclosure	559	657
Other Investments	14,231	17,950
Defined Benefit Plan, Plan Assets, Amount	142,172	145,452	$ 112,203
Debt Securities, Trading	55,583	60,330
Other Defined Benefit Pension Plans [Member] \| Fair Value, Inputs, Level 1
Defined Benefit Plan Disclosure [Line Items]
Insurance Contract	0	0
Cash and Cash Equivalents, Fair Value Disclosure	559	657
Other Investments	0	0
Defined Benefit Plan, Plan Assets, Amount	559	657
Other Defined Benefit Pension Plans [Member] \| Fair Value, Inputs, Level 2
Defined Benefit Plan Disclosure [Line Items]
Insurance Contract	0	0
Cash and Cash Equivalents, Fair Value Disclosure		0
Other Investments	14,231	17,950
Defined Benefit Plan, Plan Assets, Amount	14,231	17,950
Other Defined Benefit Pension Plans [Member] \| Fair Value, Inputs, Level 3
Defined Benefit Plan Disclosure [Line Items]
Insurance Contract	5,383	5,555
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Other Investments	0	0
Defined Benefit Plan, Plan Assets, Amount	$ 5,383	$ 5,555

Benefit Plans (Expected payments to be made to plan participants) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Gross Prescription Drug Subsidy Receipts Received (Deprecated 2017-01-31)	$ 660	$ 899
Other Defined Benefit Pension Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(12,177)	12,622
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	5,560
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	5,542
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	5,721
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	5,882
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	6,060
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	33,250
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	61	71	$ 69
Other Postretirement Benefit Plans, Defined Benefit
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)	(640)	(114)
Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months	1,190
Defined Benefit Plan, Expected Future Benefit Payments in Year Two	1,067
Defined Benefit Plan, Expected Future Benefit Payments in Year Three	966
Defined Benefit Plan, Expected Future Benefit Payments in Year Four	880
Defined Benefit Plan, Expected Future Benefit Payments in Year Five	788
Defined Benefit Plan, Expected Future Benefit Payments in Five Fiscal Years Thereafter	2,871
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	$ (267)	$ (3,263)	$ (3,263)

Benefit Plans (Details Textual) - USD ($) $ in Thousands	12 Months Ended
Benefit Plans (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 38,600	$ 29,853	$ 27,818
Defined Contribution Plan, Fair Value of Plan Assets	$ 1,271,941
STERIS Corporation shares held in defined contribution plan	496,661
Fair value of STERIS Corporatio stock held in defined contribution plan	$ 120,078
Defined Contribution Plan, Dividends Paid	852	839	$ 855
Deferred Compensation Plan Assets	$ 1,061	$ 1,682
Equity Securities [Member]
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	75.00%
Debt Securities
Defined Benefit Plan, Plan Assets, Target Allocation, Percentage	25.00%

Benefit Plans Benefit Plans (Rollforward of Level 3 assets) (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Other Investments	$ 5,383	$ 5,555	$ 4,345
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Period Increase (Decrease)	(115)	197
Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)	153	160
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3	$ (210)	$ 853

Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
Contingencies (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Loss Contingencies [Line Items]
Operating Lease, Weighted Average Remaining Lease Term	9 years 7 months 6 days	11 years 7 months 6 days
Operating Lease, Payments	$ 45,144	$ 29,808
Fixed Operating Lease Expense	45,158	31,087
Commitments and Contingencies
Letters of credit as security for self insurance risk and retention policies	13,900	11,807
Purchase Commitment, Remaining Minimum Amount Committed	59,869
Variable Operating Lease Expense	12,659	9,326
Operating Lease, Expense	57,817	40,413
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	79,241	$ 30,574
Lessee, Operating Lease, Liability, Payments, Due Year Two	34,669
Lessee, Operating Lease, Liability, Payments, Due Year Three	26,914
Lessee, Operating Lease, Liability, Payments, Due Year Five	21,419
Lessee, Operating Lease, Liability, Payments, Due after Year Five	104,769
Lessee, Operating Lease, Liability, Payments, Due	229,870
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	$ 38,342
Operating Lease, Weighted Average Discount Rate, Percent	3.40%	4.10%
Operating Lease, Liability	$ 191,528
Lessee, Operating Lease, Liability, to be Paid, Year One	42,099
Commercial commitments [Member]
Loss Contingencies [Line Items]
Commitments and Contingencies	98,675	$ 79,122
Long term Construction Contracts [Member] [Member]
Loss Contingencies [Line Items]
Commitments and Contingencies	$ 171,619

Business Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Jun. 02, 2021
Segment Reporting Information [Line Items]
amortization of inventory and property step up to fair value									$ 81,804	$ 5,600	$ 2,392
amortization and impairment of acquired intangible assets									366,434	83,892	71,675
Business Combination, Acquisition Related Costs									205,788	35,634	8,225
loss (gain) on fair value contingent consideration adjustments									(2,350)	(500)	0
Gain (Loss) on Disposition of Business									(874)	2,030	1,770
COVID-19 incremental costs									0	25,793	749
redomiciliation costs									301	1,592	3,699
Restructuring expenses									48	(3,029)	3,143
Assets	$ 11,423,594				$ 6,574,471				11,423,594	6,574,471
Payments to Acquire Productive Assets									287,563	239,262	214,516
Depreciation, Depletion and Amortization									553,104	219,237	197,235
Property, Plant and Equipment, Net	1,552,576				1,235,400				1,552,576	1,235,400
Revenues	1,210,686	$ 1,208,971	$ 1,196,985	$ 968,422	873,531	$ 808,924	$ 756,132	$ 668,932	4,585,064	3,107,519	3,030,895
Operating Income (Loss)									425,618	548,368	537,046
Contingent Consideration Liability Assumed in Cantel Combination	25,000								25,000			$ 25,000
Healthcare and Life Sciences [Member]
Segment Reporting Information [Line Items]
Assets	6,604,893				3,600,182				6,604,893	3,600,182
Payments to Acquire Productive Assets									84,487	74,446	84,648
Depreciation, Depletion and Amortization									316,222	106,266	92,193
Amortization of Acquired Intangibles and PPE Step Up									229,052
Applied Sterilization Technologies [Member]
Segment Reporting Information [Line Items]
Assets	3,053,116				2,974,289				3,053,116	2,974,289
Payments to Acquire Productive Assets									198,350	164,816	129,868
Depreciation, Depletion and Amortization									115,925	112,971	105,042
Revenues									852,972	685,912	627,147
Operating Income (Loss)									410,101	310,648	270,917
Amortization of Acquired Intangibles and PPE Step Up									35,531
Dental
Segment Reporting Information [Line Items]
Assets	$ 1,765,585				0				1,765,585	0
Payments to Acquire Productive Assets									4,726	0	0
Depreciation, Depletion and Amortization									120,957	0	0
Revenues									361,661	0	0
Operating Income (Loss)									84,441	0	0
Amortization of Acquired Intangibles and PPE Step Up									$ 113,099
Dental \| Revenue Benchmark \| Customer Concentration Risk
Segment Reporting Information [Line Items]
Concentration Risk, Percentage									45.10%
Historical Average Percentage of Concentration Risk	40.00%
OperatingSegmentAllExceptCorpandOther [Member]
Segment Reporting Information [Line Items]
Revenues									$ 4,585,064	3,107,519	3,030,895
Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues									2,845,467	1,954,055	1,986,809
Operating Income (Loss)									626,098	427,089	420,709
Life Science Member [Member]
Segment Reporting Information [Line Items]
Revenues									524,964	467,552	416,939
Operating Income (Loss)									216,188	180,796	144,088
OperatingSegmentCorpandOther [Member]
Segment Reporting Information [Line Items]
Operating Income (Loss)									(260,059)	(219,153)	(207,015)
OperatingSegmentAll [Member]
Segment Reporting Information [Line Items]
Revenues									4,585,064	3,107,519	3,030,895
Operating Income (Loss)									1,076,769	699,380	628,699
Adjustments to Liability
Segment Reporting Information [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability									(2,350)
Additions [Member]
Segment Reporting Information [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability									601	3,486
Reductions and Payout
Segment Reporting Information [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability									(32,336)	(984)
Consumable revenues [Member] \| Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues									1,004,605	510,946	486,425
Consumable revenues [Member] \| Life Science Member [Member]
Segment Reporting Information [Line Items]
Revenues									239,365	215,005	185,904
Capital equipment revenues [Member] \| Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues									782,505	588,864	617,712
Capital equipment revenues [Member] \| Life Science Member [Member]
Segment Reporting Information [Line Items]
Revenues									142,281	128,356	112,747
Service revenues [Member] \| Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues									1,058,357	854,245	882,672
Service revenues [Member] \| Life Science Member [Member]
Segment Reporting Information [Line Items]
Revenues									143,318	124,191	118,288
IRELAND
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net	$ 60,275				52,140				60,275	52,140
Revenues									82,011	71,905	63,821
UNITED STATES
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net	881,057				673,784				881,057	673,784
Revenues									3,228,864	2,227,038	2,211,722
Other foreign locations [Member]
Segment Reporting Information [Line Items]
Revenues									1,274,189	808,576	$ 755,352
Other Foreign Entities [Member]
Segment Reporting Information [Line Items]
Property, Plant and Equipment, Net	$ 611,244				$ 509,476				$ 611,244	$ 509,476

Common Shares (Details) - $ / shares	12 Months Ended
Common Shares (Details) - $ / shares	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Jun. 02, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Common Stock, Par or Stated Value Per Share	$ 0.001			$ 0.001
Preferred Stock, Par or Stated Value Per Share	$ 0.001
Value (EUROS) Ordinary Shares Deferred	25,000
Weighted Average Number of Shares Outstanding, Basic	97,535,000	85,203,000	84,778,000
Weighted Average Number Diluted Shares Outstanding Adjustment	791,000	695,000	863,000
Weighted Average Number of Shares Outstanding, Diluted	98,326,000	85,898,000	85,641,000
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	243,000	348,000	285,000

Repurchases of Common Shares (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Mar. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) shares	Mar. 31, 2020 USD ($) shares	Mar. 31, 2022 EUR (€) shares	Jun. 02, 2021 $ / shares	Jul. 30, 2019 USD ($)	May 07, 2019 USD ($)
Debt Securities, Available-for-sale [Line Items]
Preferred Stock, Shares Authorized	50,000,000			50,000,000
Preferred Stock, Par or Stated Value Per Share \| $ / shares	$ 0.001
Stock Repurchase Program, Authorized Amount \| $	$ 308,932					$ 300,000	$ 78,979
Stock Repurchased During Period, Shares	108,368	35,000	273,259
Stock Repurchased and Retired During Period, Value \| $	$ 25,000	$ 5,047	$ 40,000
Common Stock, Par or Stated Value Per Share \| $ / shares	$ 0.001				$ 0.001
Deferred Ordinary Shares	25,000			25,000
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation	244,395	91,567	122,884
Payment, Tax Withholding, Share-based Payment Arrangement \| $	$ 30,775	$ 9,599	$ 11,235
Euro Member Countries, Euro
Debt Securities, Available-for-sale [Line Items]
Par Value (Euros) of Deferred Ordinary Shares \| €				€ 1.00

Share-Based Compensation (Details) - USD ($)	12 Months Ended
Share-Based Compensation (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Item]
Remaining shares available for grant	3,146,465
Weighted-average assumptions used for options granted:
Risk-free interest rate	1.10%	0.46%	2.26%
Expected life of options	5 years 10 months 24 days	6 years	6 years 2 months 12 days
Exptected dividend yield of stock	0.95%	0.96%	1.22%
Expected volatility of stock	24.27%	23.04%	20.27%
Estimated forfeiture rate	2.85%	2.78%	2.77%
Summary of share option activity:
Number of Options, Outstanding, Beginning of Period	1,637,047
Weighted Average Exercise Price, Outstanding, Beginning of Period	$ 112.03
Number of Options, Granted	284,566
Weighted Average Exercise Price, Granted	$ 215.10
Number of Options, Exercised	(354,252)
Weighted Average Exercise Price, Exercised	$ 77.79
Number of Options, Forfeited	(6,407)
Weighted Average Exercise Price, Forfeited	$ 165.10
Number of Options, Outstanding, End of Period	1,560,954	1,637,047
Weighted Average Exercise Price, Outstanding, End of Period	$ 138.37	$ 112.03
Average Remaining Contractual Term, Outstanding	6 years 8 months 12 days
Aggregate Intrinsic Value, Outstanding	$ 161,397,000
Number of Options, Exercisable	854,998
Weighted Average Exercise Price, Exercisable	$ 104.64
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 6 months
Aggregate Intrinsic Value, Exercisable	$ 117,243,000
Non-vested stock options outstanding expected to vest	692,204
Common Stock, Fair Market Value Per Share	$ 241.77
Total intrinsic value of stock options exercised	$ 52,952,000	$ 39,055,000	$ 57,683,000
Net cash proceeds from the exercise of stock options	10,071,000	26,726,000	34,731,000
Tax benefit from stock option exercises	$ 18,143,000	$ 11,559,000	$ 16,440,000
Weighted average grant date fair value of stock option grants, per share	$ 37.52	$ 27.66	$ 23.52
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	29,500
Number of Restricted Shares, Granted	21,759
Number of Restricted Shares, Vested	(15,621)
Number of Restricted Shares, Canceled	(1,961)
Number of Restricted Shares, Non-vested at End of Period	33,677	29,500
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 59,392,000
Weighted average period for recognition of unrecognized compensation cost	2 years 1 month 6 days
Stock Appreciation Rights (SARs)
Summary of non-vested restricted share activity:
FairValueOfOutstandingStockAppreciationRights		$ 494,000	$ 544,000
Restricted Stock
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	533,323
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 121.35
Number of Restricted Shares, Granted	165,376
Weighted-Average Grant Date Fair Value, Granted	$ 198.14
Number of Restricted Shares, Vested	(192,633)
Weighted-Average Grant Date Fair Value, Vested	$ 95.71
Number of Restricted Shares, Canceled	(20,556)
Weighted-Average Grant Date Fair Value, Canceled	$ 167.88
Number of Restricted Shares, Non-vested at End of Period	485,510	533,323
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 157.37	$ 121.35
Fair Value, Share-based Payment Awards, Other than Options	$ 19,890,000
RSUs Cantel
Summary of non-vested restricted share activity:
Number of Restricted Shares, Non-vested at Beginning of Period	0
Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period	$ 0
Number of Restricted Shares, Granted	280,402
Weighted-Average Grant Date Fair Value, Granted	$ 191.18
Number of Restricted Shares, Vested	(223,267)
Weighted-Average Grant Date Fair Value, Vested	$ 191.18
Number of Restricted Shares, Canceled	(11,413)
Weighted-Average Grant Date Fair Value, Canceled	$ 191.18
Number of Restricted Shares, Non-vested at End of Period	45,722	0
Weighted-Average Grant Date Fair Value, Non-vested at End of Period	$ 191.18	$ 0
Unrecognized compensation cost related to nonvested share-based compensation granted	$ 6,101,000
Weighted average period for recognition of unrecognized compensation cost	1 year 1 month 6 days
Restricted Stock Units (RSUs)
Summary of share option activity:
Weighted average grant date fair value of stock option grants, per share	$ 191.18
Summary of non-vested restricted share activity:
Share-based Compensation Arrangement by Share-based Payment Award, Conversion Ratio	0.4262
Share-Based Payment Arrangement, Expense	$ 20,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Weighted Average Grant Date Fair Value	53,607,000
Restricted Stock or Unit Expense	280,402
Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period, Weighted Average Grant Date Fair Value Attributable to Pre-Acquisition Services	$ 18,173,000

Financial and Other Guarantees (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Standard and Extended Product Warranty Accrual	$ 14,108	$ 9,406	$ 7,381	$ 7,194
Standard and Extended Product Warranty Accrual, Increase for Warranties Issued	12,571	10,574	12,311
Standard Product Warranty Accrual, Decrease for Payments	(12,638)	(8,549)	(12,124)
Standard Product Warranty Accrual, Additions from Business Acquisition	$ 4,769	$ 0	$ 0

Forward and Swap Contracts (Details) € in Thousands, $ in Thousands	12 Months Ended
	Mar. 31, 2022 USD ($) lb	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Mar. 31, 2022 EUR (€)
Other Assets
Derivative [Line Items]
Derivative Assets	$ 2,780	$ 57
Derivative Liabilities	0	0
Accrued Liabilities
Derivative [Line Items]
Derivative Assets	0	0
Derivative Liabilities	198	367
Selling, General and Administrative Expenses
Derivative [Line Items]
Gain (Loss) on Foreign Currency Derivatives Recorded in Earnings, Net	4,379	1,178	$ 798
Cost of Sales
Derivative [Line Items]
Gain (Loss) on Sale of Commodity Contracts	$ 3,921	$ 771	$ (660)
212230 Copper, Nickel, Lead, and Zinc Mining [Member]
Derivative [Line Items]
Derivative, Nonmonetary Notional Amount, Mass \| lb	801,600
Euro Member Countries, Euro
Derivative [Line Items]
Notional Amount of Foreign Currency Derivative Purchase Contracts (Deprecated 2013-01-31) \| €				€ 11,000

Fair Value Measurements (Details) - USD ($)
$ in Thousands

12 Months Ended

Mar. 31, 2022

Mar. 31, 2021

Mar. 31, 2020

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Document Period End Date

Mar. 31, 2022

Equity Securities, FV-NI, Gain (Loss)

$ (775)

$ 594

Business Acquisition, Contingent Consideration, at Fair Value

10,550

19,642

$ 15,988

Fair Value, Inputs, Level 1

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Investments, Fair Value Disclosure

2,272

2,665

Cash and Cash Equivalents, Fair Value Disclosure

348,320

220,531

Foreign Currency Contract, Asset, Fair Value Disclosure

^[1]

Equity Securities, FV-NI

^[2]

8,520

10,301

Foreign Currency Contracts, Liability, Fair Value Disclosure

^[1]

Deferred Compensation Plan Assets

^[2]

1,240

1,715

Long-term Debt, Fair Value

Business Acquisition, Contingent Consideration, at Fair Value

^[3]

Fair Value, Inputs, Level 2

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Investments, Fair Value Disclosure

^[2]

Cash and Cash Equivalents, Fair Value Disclosure

Foreign Currency Contract, Asset, Fair Value Disclosure

^[1]

2,780

Foreign Currency Contracts, Liability, Fair Value Disclosure

^[1]

198

367

Deferred Compensation Plan Assets

^[2]

Long-term Debt, Fair Value

2,991,680

1,722,459

Business Acquisition, Contingent Consideration, at Fair Value

^[3]

Fair Value, Inputs, Level 3

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Investments, Fair Value Disclosure

^[2]

Cash and Cash Equivalents, Fair Value Disclosure

Foreign Currency Contract, Asset, Fair Value Disclosure

^[1]

Foreign Currency Contracts, Liability, Fair Value Disclosure

^[1]

Deferred Compensation Plan Assets

^[2]

Long-term Debt, Fair Value

Business Acquisition, Contingent Consideration, at Fair Value

^[3]

10,550

19,642

Additions [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

601

3,486

Foreign Currency Gain (Loss)

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

(7)

(23)

Reductions and Payout

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

(32,336)

(984)

Reductions [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability

1,175

Cost of Sales

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Gain (Loss) on Sale of Commodity Contracts

3,921

771

$ (660)

Reported Value Measurement [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

Investments, Fair Value Disclosure

2,272

2,665

Cash and Cash Equivalents, Fair Value Disclosure

348,320

220,531

Foreign Currency Contract, Asset, Fair Value Disclosure

^[1]

2,780

Equity Securities, FV-NI

^[2]

8,520

10,301

Foreign Currency Contracts, Liability, Fair Value Disclosure

^[1]

198

367

Deferred Compensation Plan Assets

^[2]

1,240

1,715

Long-term Debt, Fair Value

3,088,356

1,650,540

Business Acquisition, Contingent Consideration, at Fair Value

^[3]

$ 10,550

$ 19,642

[1]	The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates.
[2]	We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allowed for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income
[3]	Contingent consideration obligations arise from prior business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates.

Reclassifications out of AOCI (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (209,808)	$ (61,243)	$ (235,463)	$ (159,778)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	144,212	(177,548)	71,571
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	(4,353)	(3,328)	(4,114)
Total other comprehensive (loss) income attributable to shareholders	148,565	(174,220)	75,685
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax	1,276	(5,519)	(6,813)	(4,204)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	11,148	4,622	1,505
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	4,353	3,328	4,114
Total other comprehensive (loss) income attributable to shareholders	6,795	1,294	(2,609)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	(211,084)	(55,724)	(228,650)	$ (155,574)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	(155,360)	172,926	(73,076)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	0	0	0
Total other comprehensive (loss) income attributable to shareholders	$ (155,360)	$ 172,926	$ (73,076)

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References + Details

Accumulated Other Comprehensive Incom (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Equity [Abstract]
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (209,808)	$ (61,243)	$ (235,463)	$ (159,778)

- Definition

+ References + Details

Quarterly Results (Unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Effect of Fourth Quarter Events [Line Items]
Revenues	$ 1,210,686	$ 1,208,971	$ 1,196,985	$ 968,422	$ 873,531	$ 808,924	$ 756,132	$ 668,932	$ 4,585,064	$ 3,107,519	$ 3,030,895
Cost of revenues:
Cost of Goods and Services Sold									2,568,702	1,764,419	1,710,899
Cost of Revenue	639,064	670,857	716,641	542,140	493,713	463,063	426,095	381,548
Gross Profit	$ 571,622	$ 538,114	$ 480,344	$ 426,282	$ 379,818	$ 345,861	$ 330,037	$ 287,384	2,016,362	1,343,100	1,319,996
Gross Profit Percentage	47.20%	44.50%	40.10%	44.00%	43.50%	42.80%	43.60%	43.00%
Restructuring expenses									48	(3,029)	3,143
Net Income (Loss) Attributable to Parent	$ 52,261	$ 143,623	$ 69,811	$ (21,807)	$ 87,443	$ 114,501	$ 105,858	$ 89,598	$ 243,888	$ 397,400	$ 407,659
Earnings Per Share, Basic	$ 0.52	$ 1.44	$ 0.70	$ (0.24)	$ 1.02	$ 1.34	$ 1.24	$ 1.05	$ 2.50	$ 4.66	$ 4.81
Earnings Per Share, Diluted	$ 0.52	$ 1.42	$ 0.69	$ (0.24)	$ 1.02	$ 1.33	$ 1.23	$ 1.05	$ 2.48	$ 4.63	$ 4.76
Service [Member]
Effect of Fourth Quarter Events [Line Items]
Revenues	$ 526,178	$ 511,715	$ 511,747	$ 479,143	$ 445,917	$ 433,610	$ 416,628	$ 367,824	$ 2,028,783	$ 1,663,979	$ 1,628,107
Cost of revenues:
Cost of Goods and Services Sold	291,822	297,064	289,157	270,734	262,055	260,182	250,297	226,809	1,148,777	999,343	960,770
Product [Member]
Effect of Fourth Quarter Events [Line Items]
Revenues	684,508	697,256	685,238	489,279	427,614	375,314	339,504	301,108	2,556,281	1,443,540	1,402,788
Cost of revenues:
Cost of Goods and Services Sold	$ 347,242	$ 373,793	$ 427,484	$ 271,406	$ 231,658	$ 202,881	$ 175,798	$ 154,739	$ 1,419,925	$ 765,076	$ 750,129

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Beginning Balance	$ 14,143	$ 13,891	$ 13,478
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense	2,888	2,684	3,327
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment	8,906	277	(1,927)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction	(1,246)	(2,709)	(987)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance	24,691	14,143	13,891
SEC Schedule, 12-09, Allowance, Loss on Finance Receivable
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Beginning Balance	11,355	12,051	9,645
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense	16,442	3,097	6,760
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment	1,840	349	(247)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction	(5,266)	(4,142)	(4,107)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance	24,371	11,355	12,051
SEC Schedule, 12-09, Reserve, Inventory
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Beginning Balance	19,778	16,149	19,754
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense	10,931	4,423	(4,105)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment	228	(794)	500
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction	0	0	0
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance	30,937	19,778	16,149
SEC Schedule, 12-09, Reserve, Casualty Loss
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Beginning Balance	23,283	23,228	19,742
SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense	7,069	5,550	6,000
SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment	44	2,542	3,007
SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction	(4,270)	(8,037)	(5,521)
SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount, Ending Balance	$ 26,126	$ 23,283	$ 23,228